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ABSTRACT 
 
 
PED/PEA-15 is a cytosolic protein whose overexpression is a common 
feature of type 2 diabetes. It has been involved in generating insulin resistance 
by blocking insulin-stimulated glucose transport in differentiated L6 skeletal 
muscle cells and 3T3-L1 adipocytes. 
Transgenic mice ubiquitously overexpressing PED/PEA-15 exhibit 
mildly elevated random-fed blood glucose levels and decreased glucose 
tolerance compared to their non transgenic littermates. Furthermore, these mice 
were hyperinsulinemic in the basal state and showed elevated free fatty acids 
(FFAs) and triglyceride blood levels. Consistent with these results, insulin-
stimulated glucose uptake was decreased in fat and muscle tissues of the 
PED/PEA-15 transgenic mice, accompanied by protein kinase C (PKC) alpha 
activation and blockage of insulin-dependent PKC zeta activation. In addition, 
PED/PEA-15 transgenic mice featured whole body insulin resistance and a 
reduction in insulin response to glucose loading. Finally, the treatment with a 
60% fat diet led PED/PEA-15 transgenic mice to develop diabetes.  
Thus, in vivo, overexpression of PED/PEA-15 may lead to diabetes by 
impairing insulin action and insulin secretion. Studies to elucidate the 
molecular mechanism responsible for PED/PEA-15-induced insulin-resistance 
were also performed. Previous investigations evidenced that PED/PEA-15 
binds to phospholipase D (PLD), an enzyme responsible for diacylglycerol 
production, which then mediates activation of classical PKC isoforms 
including PKCα. 
In this work, I sought to test the hypothesis that blocking PED/PEA-
15/PLD1 interaction may improve insulin-sensitivity both in cellular models 
and in vivo. To this aim, I identified a molecule (PLDi peptide) that is able to 
inhibit PED/PEA-15/PLD1 interaction, PLDi corresponds to aminoacids 712-
1074 of PLD1 protein. Therefore, I verified whether the expression of this 
inhibitory peptide rescues normal insulin sensitivity and insulin-stimulated 
glucose transport in HEK293 and L6 cell lines overexpressing PED/PEA-15. 
Based on results obtained from these experiments, I tested the possibility to 
reduce PED/PEA-15-PLD1 interaction by adenoviral-mediated expression of 
D4 in vivo.  
The outcome of these experiments may provide the rationale for 
setting-up high-throughput screening systems to identify additional molecules 
antagonizing PED/PEA-15 action. Such molecules may include novel agents to 
improve beta-cell function and to correct deranged metabolism in fat and 
muscle tissues in type 2 diabetes. 
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BACKGROUND 
 
  
1. Diabetes mellitus 
Diabetes is one of the most common metabolic disorders. There are 200 
million diabetic individuals in the world; this creates a need to understand the 
etiology of the disease and the genetic and environmental factors influencing 
its pathogenesis. Diabetes mellitus is a chronic metabolic syndrome caused by 
insulin deficiency and characterized by elevated glucose level; often it may be 
associated with microvascular, neurological, and macrovascular complications 
including retinopathy, nephropathy, neuropathy, and increased risk of 
cardiovascular disease (Malecki and Klupa 2005).  
According to the classification recommended by the American Diabetes 
Association (2004), diabetes mellitus can be classified as type 1, type 2, other 
specific types, and gestational diabetes mellitus. 
Type 1 diabetes mellitus (T1DM) always occurs in childhood and 
adolescence with an absolute insulin insufficiency caused by autoimmune or 
idiopathic destruction of insulin-producing β-cells in the pancreas by CD4 and 
CD8 T cells and macrophages infiltrating the islets. Insulin injection is always 
necessary for survival in T1DM because of the complete lack of endogenous 
insulin (Gillespie 2006). 
Type 2 diabetes mellitus (T2DM) is more complex in etiology and is 
characterized by a relative insulin deficiency, reduced insulin action, and 
insulin resistance of glucose transport in skeletal muscle and adipose tissue. 
The manifestation of type 2 diabetes is a continuum of insulin resistance 
culminating in the failure of insulin secretion to compensate for insulin 
resistance, and the progression to full diabetes ensues when pancreatic β-cell 
hypersecretion of insulin fails to compensate for insulin resistance (Del Guerra 
et al. 2005). 
 
 
2. Pathophysiology of type 2 diabetes mellitus 
The susceptibility to the development of T2DM is determined by two 
factors: genetics and environment. The pathophysiology of T2DM is very 
complex and has not been completely understood. Any gene mutation or 
metabolic disturbance leading to a defect in insulin secretion, insulin transport, 
insulin action, glucose transport, or enzymes associated with glucose 
metabolism can theoretically result in hyperglycemia or clinical diabetes. Most 
patients with T2DM exhibit two different defects: the impairment of insulin 
secretion and decreased insulin sensitivity (Tseng 2004).  
The substantial contribution of genetic factors to the development of 
diabetes has been known for many years. An example for genetic subtypes of 
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T2DM involves mutations in glucokinase, which phosphorylates glucose to 
glucose-6-phosphate, leading to impaired glycolysis, showing higher 
concordance rate for T2DM among monozygotic twins (between 41% and 
55%) in comparison to dizygotic twins (between 10% and 15%). There are 
populations with extremely high prevalence of T2DM, for example Pima 
Indians that can not be explained solely by environmental factors, but also by 
familial clustering of diabetes-related traits.  
However, it is well known that the incidence of T2DM is also 
associated with environmental factors. The differences in the prevalence of 
T2DM in relative populations living in different geographical and cultural 
regions (for example Asians in Japan and USA) also support the role of non-
genetic factors (Malecki and Klupa 2005).  The relations between genetic and 
environmental factors in the development of T2DM may be complex. 
Environmental factors may be responsible for the initiation of β-cell damage or 
other metabolic abnormalities, while genes may regulate the rate of progression 
to overt diabetes. On the other hand, in some cases genetic factors may be 
necessary for environmental factors even to start processes leading to the 
development of the disease (Zimmet et al. 2001). 
 
 
3. Insulin signaling and pathways in insulin action 
Insulin is the most potent anabolic hormone known and is essential for 
appropriate tissue development, growth, and maintenance of whole-body 
glucose homeostasis. The molecule contains two peptide chains called A chain 
and B chain linked together by two disulfide bonds. This hormone is secreted 
by the β cells of the pancreatic islets of Langerhans in response to increased 
circulating levels of glucose and amino acids after a meal.  
Insulin regulates glucose homeostasis at many sites by reducing hepatic 
glucose output (gluconeogenesis and glycogenolysis) and by increasing the rate 
of glucose uptake in skeletal muscle and fat to regulate blood glucose 
concentration (Figure 1). In liver and fat cells, insulin also promotes the 
synthesis and storage of carbohydrates, lipids, and proteins, inhibits their 
degradation and release into the circulation, and attenuating fatty acid release 
from triglycerides in fat and muscle (Pessin and Saltiel 2000). 
The first step by which insulin increases energy storage or utilization 
involves the regulated transport of glucose into the cell, mediated by the 
glucose transporter GLUT4. Insulin stimulates the translocation of a pool of 
GLUT4 to the plasma membrane, through a process of regulated recycling, in 
which endocytosis, sorting into specialized vesicles, exocytosis, tethering, 
docking, and fusion of the protein are tightly regulated (Chang et al. 2004). 
The precise intracellular events that mediate insulin action are initiated 
through the binding to and activation of its cell-surface receptor, the insulin 
receptor substrates, and the molecules that interact with these substrates. 
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Figure 1: Glucose homeostasis. The balance among gluconeogenesis by liver, insulin-dependent 
utilization of glucose by adipose and muscle tissues is regulated by insulin production from β cells. 
 
 
3.1 The insulin receptor 
The insulin receptor is an heterotetrameric bifunctional transmembrane 
glycoprotein composed of two extracellular α subunits and two transmembrane 
β subunits linked by disulfide bonds. The α subunits contain the insulin-
binding domain while the transmembrane β subunits function as a tyrosine-
specific protein kinase (IRK), resulting in the increased catalytic activity of the 
kinase (Paz et al. 1997). Binding of insulin triggers oligomerization and 
receptor autophosphorylation on tyrosine residues and tyrosine 
phosphorylation of insulin receptor substrates that include the insulin receptor 
substrate family (IRS1 through 4), IRS5, IRS-6, Gab-1, Cbl, APS and Shc 
isoforms, and signal regulatory protein (SIRP) family members 
(Bandyopadhyay et al. 1997). 
 
 
3.2 Insulin-receptor substrates 
The finding that insulin stimulates tyrosine phosphorylation of a 185 
kDa protein in all cell types and tissues led to the hypothesis that substrate 
phosphorylation mediates insulin signal transduction. Four related proteins 
have recently expanded this family, including IRS-2, IRS-3, Gab-1 and p62dok. 
These docking proteins are not related by extensive amino acid sequence 
identities, but are related functionally as insulin receptor substrates.  
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They amplify receptor signals by recruiting SH2-proteins to their 
autophosphorylation sites and dissociate the intracellular signaling complex 
from endocytic pathways of the activated receptor, important for insulin-
stimulated biological effects such as glucose uptake. The IRS family members 
vary in molecular weight between 60 KDa and 180 KDa. Each contains several 
common structures: an NH2-terminal PH and/or PTB domain that mediates 
protein-lipid or protein-protein interactions; multiple COOH-terminal tyrosine 
residues that create SH2-protein binding site; proline rich regions to engage 
SH3 domain; serine/threonine-rich regions which may regulate overall function 
through other protein-protein interactions (White 1998).  
Recent data from knockout mice and cell lines suggest that IRS proteins 
are differentially expressed, may engage different signaling molecules and 
mediate distinct responses (Saltiel and Kahn 2001). One of the major 
mechanisms used by IRS-proteins to generate downstream signals is the direct 
binding to the SH2 domains of various signaling proteins. One pathway 
proceeds through the insulin receptor substrates IRS-1 and IRS-2 and depends 
on the activation of the enzyme phosphatidylinositol-3-kinase (PI-3 kinase). PI-
3 triggers a series of downstream events involving protein kinase C (PKC), 
leading to insulin-stimulated translocation of glucose transporters (GLUTs) to 
the plasma membrane and glucose transport via the transporters (Chang et al. 
2004). Another pathway proceeds through Grb2/Sos and Ras, leading to the 
activation of the MAP kinase isoforms ERK1 and ERK2, that are involved in 
proliferation and differentiation processes. However, in most cases, a specific 
effect of insulin requires the participation of both the pathways in a complex 
interplay which could explain the pleiotropy and the specificity of the insulin 
signal (Cusi et al. 2000). 
 
 
3.3 The PI-3 kinase pathway and Akt/PKB signaling 
PI-3 kinase is the best studied signaling molecule activated by IRS-1. It 
plays an important role in the regulation of biological responses by various 
hormones, growth factors and cytokines, including mitogenesis, differentiation, 
chemotaxis, membrane ruffling, and insulin-stimulated glucose transport. 
Moreover, PI-3 kinase dependent pathway has a pivotal role in many insulin-
regulated metabolic processes, including glucose uptake, GLUT4 translocation, 
general and growth-specific protein synthesis and glycogen synthesis. PI-3 
kinase was originally identified as a dimer composed of a 110 KDa catalytic 
subunit (p110α or p110β) associated with an 85 KDa regulatory subunit (p85α 
or p85β). The latter one possesses two SH2 domains that interact with tyrosine-
phosphorylated pYMXM and pYXXM motifs in IRS proteins, thereby 
activating the associated catalytic domain. This effect is maximal when both 
the SH2 domains are occupied (Le Roith and Zick 2001). 
Following its activation by insulin, PI-3K catalyses the phosphorylation 
of phosphatidylinositol-4,5-diphospate (PIP2) to produce phosphatidylinositol 
3,4,5 triphosphate (PIP3). It binds to the pleckstrin homology (PH) domains of 
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phosphoinositide-dependent kinase (PDK1), which further phosphorylates 
Protein kinase B (PKB/Akt) and atypical Protein Kinase Cs (aPKCs) 
propagating the PI3K signal (Lietzke et al., 2000; Klarlund et al., 1997). 
Moreover, PI-3-kinase possesses serine kinase activity by interacting with 
other signaling proteins involved in insulin action independently from PIP3 
generation (Kessler et al. 2001). 
Akt is a 57 KDa serine/threonine kinase characterized by a pleckstrin 
homology domain (PH) located in its NH2 terminal region and a catalytic 
domain related to protein kinase C (PKC) and protein kinase A (PKA) family 
members. The three Akt isoforms show a broad tissue distribution and can be 
activated by a wide variety of growth stimuli such as growth factors and 
cytokines (Vanhaesebroeck and Alessi 2000). Akt is an important mediator of 
biological functions of insulin, involving membrane translocation and 
phosphorylation 
Several studies recognized that Akt promotes insulin-stimulated 
glucose uptake, mediating translocation of vesicles containing GLUT4 from 
intracellular stores to the plasma membrane. Furthermore, in response to 
insulin, Akt promotes glycogen synthesis through phosphorylation of both 
alpha and beta isoforms glycogen-synthase kinase-3 (GSK-3), resulting in the 
inactivation of the catalytic activity of the enzyme and therefore, activating 
pathways that are normally repressed by GSK3 (Cantley 2002). 
 
 
3.4 The MAPK pathway 
Another pathway for insulin signaling is the MAPK cascade. This 
pathway is initiated by tyrosine phosphorylation of IRS1 or Shc proteins by the 
receptor kinase, inducing their association with the SH2 domain of the adapter 
protein Grb2 (Figure 2). This association with phosphorylated Shc induces 
Grb2 to target the nucleotide exchange factor SOS, which in turn associates 
with and activates the GTP-binding protein p21ras (Skolnik et al. 1993). The 
activation of p21ras leads to the stimulation of Raf and other kinases that can 
phosphorylate MAPK kinase or MEK, a dual specificity kinase that catalyzes 
the phosphorylation of MAPK on threonine and tyrosine residues, causing its 
activation (Crews et al. 1992). Activated ERKs mediate the growth promoting 
effects of insulin; they can translocate into the nucleus, where they catalyze the 
phosphorylation of transcription factors, phospholipase A2 and other kinases, 
such as Elk-1, p62TCF  etc., initiating a transcriptional programme that leads to 
cellular proliferation or differentiation. Increased basal Erk1/2 MAPK activity 
seems to contribute to the development of insulin resistance, on the contrary, 
the p38 MAPK has been proposed as a positive regulator of insulin action for 
its capability to increase the uptake of glucose by plasma membrane- localized 
GLUT4 transporter (Pirola et al. 2004). 
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Figure 2: MAPK pathway. Extracellular stimuli lead to activation of MAP kinase via a signaling 
cascade (MAPK cascade) composed of MAP kinase, MAP kinase kinase (MKK or MAP2K), and MAP 
kinase kinase kinase (MKKK or MAP3K). A MAP3K that is activated by extracellular stimuli phosphorylates 
a MAP2K on its serine and threonine residues, and then this MAP2K activates a MAP kinase through 
phosphorylation on its serine and tyrosine residues. This MAP kinase signaling cascade has been 
evolutionarily well-conserved from yeast to mammals. 
 
 
3.5 The protein kinase C superfamily 
Other signaling proteins that have been proposed to function in parallel 
with Akt include members of the mammalian protein kinase C (PKC) 
superfamily, which are heterogeneous members of phospholipids-dependent 
kinases that can be divided into three categories on the basis of cofactor 
requirements and structure.  
The isoenzymes have been classified into three subclasses as follows: 
the classical isoenzymes (PKC-α, -β, -γ) which are activated by phorbol esters 
and calcium; the novel (PKC-δ, -ε, -η), calcium-independent isoenzymes, 
which can be stimulated by phorbol esters; the atypical isoenzymes (PKC-ζ, -
λ), which do not respond to either phorbol esters or calcium (Jaken 1996). The 
human genes coding for the different PKC isoenzymes have been localized on 
different chromosomes and show different tissue distributions (Farese 1994).  
The isoenzymes consist of a single polypeptide chain that contains 
similarly to other kinases, an amino-terminal regulatory region (of 20-70 KDa) 
and a carboxy-terminal kinase domain (of 45 KDa). The regulatory region 
maintains the catalytic domain in an inactive state because it contains an 
autoinhibitory domain, or pseudosubstrate, and one or two different membrane-
targeting motifs, called C1 domain, which is present in all isoenzymes, and the 
C2 domain, which is present in conventional and novel protein kinase Cs. The 
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C1 domain is a cysteine-rich sequence that binds diacylglycerol and phorbol 
esters, functional analogs of diacylglycerol; the C2 domain binds acidic 
phospholipids and different regulators that participate in protein activation. The 
catalytic domain, instead, is responsible for transferring a phosphate group 
from ATP to appropriate serine or threonine residues in the PKC substrates 
(Newton 1997; Cortright et al. 2000). 
Protein kinase C transduces a myriad of signals and appear to be 
important their role in insulin action. It has been shown that PKCs mediate 
insulin effects in muscle and adipose cells, by phorbol esters activation, an 
analog of DAG (Farese et al. 2005). Nevertheless, PKCα and β have also been 
shown to inhibit insulin signaling. In particular, overexpression of PKCα 
determines an increased serine/threonine phosphorylation of IR and IRS1 with 
a subsequent reduction of IR tyrosine kinase activity and signaling (Chin et al. 
1993). Much more accepted, instead, is the concept that PKCζ and λ are 
relevant molecules in mediating insulin effect on glucose transporters 
translocation and glucose uptake in different cell systems. 
 
3.6 Glucose transport 
Glucose transport in mammalian cells and tissues occurs by facilitated 
diffusion mediated by a family of glucose transporters. Six different transporter 
proteins, encoded by distinct genes, have been characterized in mammalian 
tissues, denoted GLUT1 through GLUT5 and GLUT7, according to their 
chronological identification by molecular cloning. The GLUT1 gene product is 
most abundant in red blood cells and brain microvessels but is present in 
almost every tissue. GLUT2 is found predominantly in liver, enterocyte 
basolateral membranes and pancreatic β cells. GLUT3 is expressed almost 
exclusively in brain neurons and fetal muscle. GLUT4 expression is restricted 
to tissues where glucose transport is insulin sensitive, i.e., skeletal and cardiac 
muscles, brown and white fat. GLUT5 is present in human enterocyte luminal 
membranes, sperm, skeletal muscle and adipocytes. GLUT6 is pseudogene 
with no protein product and GLUT7 is the intracellular glucose transporter of 
liver microsomes (Klip et al. 1994).  
The major GLUT isoforms involved in glucose uptake by cells and 
tissues in response to insulin stimulation are GLUT1 and GLUT4. GLUT1 
contributes to basal glucose uptake because it is localized mostly at the plasma 
membrane in the basal state, whereas GLUT4 is sequestered in intracellular 
organelles and translocates to the cell surface only after insulin stimulation.  
Several studies from L6 muscle cells and 3T3-L1 adipocytes demonstrated the 
mechanism involved in GLUT4 translocation (Condorelli et al. 1998). In 
particular, activation of the insulin receptor induces tyrosine phosphorylation 
of the IRS family of protein substrates that, in turn, engages the SH2 domains 
of the p85 subunit of PI 3-kinase (Figure 3). This activation generates the 
formation of PIP3 that stimulates the kinase activity of PDK, interacts with 
PKB and activates the atypical PKC family members (zeta and lambda), 
responsible for insulin-stimulated glucose transport (Watson and Pessin 2006). 
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Figure 3: Insulin signal transduction. A schematic model for insulin-stimulated glucose 
transport depicting the involvement of the classic PI 3K-dependent pathway and the proposed PI-3K-
independent, alternative pathway. The activated insulin receptor catalyzes IRS tyrosine phosphorylation, 
leading to recruitment of downstream effectors, the most crucial for glucose transport being PI-3K. Akt and 
the atypical PKC isoforms have both been implicated as PtdIns(3,4,5)P3 effectors involved in GLUT4 
translocation, although it has been proposed that these two Ser/Thr kinases target separate GLUT4 
compartments. 
 
 
Moreover, recent observations indicate that high insulin levels and not 
insulin deficiency cause a reduction in GLUT4 mRNA by inhibiting GLUT4 
transcription. This may provide an explanation for the reduction in GLUT4 
mRNA levels observed in adipose cells and skeletal muscle of some animal 
models of non-insulin-dependent diabetes (Flores-Riveros et al. 1993). 
 
 
4. Defects in insulin action  
Many mutations in the insulin receptor gene are known to lead to 
impaired insulin receptor biosynthesis, while others can affect post-
translational modification of the proteins and thus, reduce the transport of the 
receptor to the cell surface and in turn, the ability to phosphorylate substrate 
proteins. Other mutations can impair the binding of insulin to its receptor or the 
activation of the receptor tyrosine kinase. These mutations typically behave in 
recessive manner and can be associated with severe insulin resistance and rare 
syndromes (Stern 2000).  
Several studies have been conducted to investigate this topic, including 
studying rare monogenic forms of insulin resistance, assessing insulin 
resistance in the relatives of diabetic individuals, comparing the differential 
concordance of insulin resistance between monozygotic and dizygotic twins 
and studying nuclear families. The major negative control results from 
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phosphorylation of serine/threonine residues on the receptor and/or IRS 
proteins. A deleterious role for molecules released from the adipose tissue is 
postulated in the insulin-resistance of the liver and muscles present in type 2 
diabetes, obesity and metabolic syndrome. 
 
4.1 Insulin resistance 
Insulin resistance (IR) has emerged as an impaired biological response 
to insulin caused by reduced insulin-stimulated glucose uptake in skeletal 
muscle and by impaired suppression of endogenous glucose production, which 
are critical for maintaining normal glucose homeostasis. Initially, is present a 
compensatory increase in insulin secretion to maintain normal blood glucose 
levels and, if this is insufficient, blood glucose concentration increases in both 
the fasting (impaired fasting glucose) and postprandial (impaired glucose 
tolerance) states. The coexistence of insulin resistance and hyperinsulinaemia 
appears to contribute directly or indirectly to many other disorders, such as 
typical forms of type 2 diabetes mellitus, dyslipidaemia, hypertension, 
atherosclerosis and a pro-coagulant state (Samaras et al. 2006). 
 
4.2 Mechanisms of insulin resistance 
Numerous studies focused on dysregulation of insulin post-receptor 
signaling have established associations between molecular events and insulin 
resistance, with deregulated concentrations of cytokines (TNF-α, IL-6), 
metabolites (glucose, glucosamine, fatty acids) and glycated proteins, which 
often contribute to IR by increasing Ser/Thr phosphorylation of IRS-1 (Figure 
4). TNF-α and IL-6 decrease insulin signaling by impairing the insulin-
stimulated tyrosine phosphorylation of IRS molecules and by inducing the 
suppressors of cytokine signaling, SOCS-1 and -3, which have at least three 
different mechanisms of action: they compete with IRS-1 for association with 
insulin receptor, they inhibit Janus kinase, involved in insulin signaling, and 
they augment proteosomal IRS-1 degradation (Mlinar et al. 2006).  
Hyperglycaemia also has adverse consequences on the efficacy of 
insulin action because severely decreases Akt/PKB activity. Besides 
glucosamine produced from glucose and being the main substrate for cellular 
glycosylation, enhances glycosylation of IRS-1, thereby decreasing its activity 
and glycosylation of glycogen-synthase, which reduces its insulin 
responsiveness. High concentrations of circulating fatty acids contribute to the 
induction of insulin resistance by decreasing insulin-induced PI3K activation 
and inhibit insulin-mediated glucose metabolism by affecting a number of 
protein kinases in rats. Finally, glycated proteins, emerging as a consequence 
of  hyperglycaemia, were shown to diminish intracellular PI3K, PKB and 
GSK-3 activity, thus possibly contributing to IR (Pirola et al. 2004). 
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Figure 4: Mechanisms that can produce insulin resistance. Multiple mechanisms exist for 
down regulation insulin signaling, such as decreased synthesis, increased degradation, inhibitory serine 
phosphorylation, interaction with inhibitory proteins, and alteration of the ratios of different molecules. 
 
 
 
5. PED/PEA-15 protein 
The Phosphoprotein Enriched in Diabetes/ Phosphoprotein Enriched in 
Astrocytes-15 (PED/PEA-15) is a 15 kDa cytosolic protein widely expressed in 
different tissues and highly conserved among mammals, whose gene maps on 
human chromosome 1q21-22 (Estelles et al. 1996). 
The structure of PED/PEA-15 includes a canonical N-terminal Death 
Effector Domain (DED) of 80 aminoacids that regulate apoptotic signaling 
pathways (Figure 5). Within the N-terminus there is a nuclear export sequence 
(NES) that mediate its cytoplasmic localization. In particular, PED/PEA-15 
regulates the actions of ERK-MAP kinase cascade by binding to ERK in the 
nucleus, exporting it into the cytoplasm and preventing the entrance into the 
cell cycle caused by sustained phospho-ERK nuclear accumulation 
(Formstecher et al. 2001; Brunet et al. 1999).  
In the C-terminal domain, PED/PEA-15 protein can be phosphorylated 
on two different residues: the Ser104, identified as a site of regulation for 
protein kinase C (PKC) (Araujo et al. 1993; Estelles et al. 1996), and the 
Ser116 regulated by calcium–calmodulin kinase 2 (CaMKII) (Kubes et al. 
1998) and PKB/Akt (Trencia et al. 2003; see below attached publications).  
PED/PEA-15 can interact with a number of proteins: FADD and FLICE 
through its DED domain; ERKs, whose bindings requires distinct regions in 
both the DED and C-terminal region (Hill et al. 2002); OMI/HtrA2, whose 
binding requires the DED (Trencia et al. 2004); PLD, whose interacting site 
consists of part of the DED plus additional C-terminal flanking sequences 
(Zhang et al. 2000). 
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It has been recently demonstrated that PED/PEA-15 plays an important 
role both as antiapoptotic and as inducer insulin-resistance.  
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Figure 5: Structure of PED/PEA-15 protein. 
 
 
5.1 PED/PEA-15 and its antiapoptotic function 
Several lines of evidence showed that PED/PEA-15 exerts its 
antiapoptotic action through at least three distinct mechanisms. Firstly, the 
DED of PED/PEA-15 binds the DED of both Fas Associated Death Domain 
(FADD) and caspase 8 (FLICE), thereby inhibiting FLICE activation by tumor 
necrosis factor-α and Fas-L, preventing DISC assembly and blocking the 
apoptotic effects of these cytokines (Condorelli et al. 1999). Interestingly, 
PED/PEA-15, also plays a crucial role in the negative regulation of TRAIL, a 
member of the TNF family that triggers rapid apoptosis in different types of 
tumor cells, included malignant glioma cells. This study has demonstrated that 
PED/PEA-15 plays an important role in tumor sensitivity to anti neoplastic 
agents (Hao et. al. 2001). Increased levels of protein confer, indeed greater 
susceptibility to skin carcinogenesis in vivo and may enhance cutaneous tumor 
progression toward malignancy (Formisano et al. 2005).   
Secondly, PED/PEA-15 prevents stress-activated protein kinase 
(SAPK) activation triggered by growth factor deprivation, oxidative stress 
(exposure to H2O2) and anisomycin treatment. The inhibition of apoptosis 
induced by these stimuli is exerted by blocking JNK1/2 and p38 
phosphorylations, and inhibits stress-induced Cdc-42, MKK4 and MKK6 
activation by requiring also the interaction of PED/PEA-15 with ERK1/2 
(Condorelli et al. 2002; see below attached publications). 
Thirdly, it has also been recently shown that PED/PEA-15 also binds to 
Omi/HtrA2, a serine protease and a mitochondrial protein, inhibiting apoptosis 
triggered by stress and physical agents. After UV exposure, Omi/HtrA2 
released into the cytosol binds and displaces the mammalian caspase inhibitor 
XIAP releasing their suppressive effect on caspases activity. Interestingly, this 
mechanism was accompanied by a significant decrease in cellular PED/PEA-
15 levels, due to an increased PED/PEA-15 degradation upon OMI/HtrA2 
release into the cytoplasm (Trencia et al. 2004). 
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5.2 PED/PEA-15 and its role in insulin resistance 
Overexpression of the PED/PEA-15 gene is a common defect in type 2 
diabetes. During a study using a differential display technique to identify genes 
whose expression was altered in type 2 diabetes, it has been demonstrated that 
both PED/PEA-15 mRNA and protein levels were overexpressed in fibroblasts 
from type 2 diabetics compared with non-diabetic individuals (Figure 6). Also 
skeletal muscle and adipose tissues, two major sites of insulin resistance in 
type 2 diabetes, showed the same behaviour (Condorelli et al. 1998).  
Furthermore, a recent study showed that PED/PEA-15 overexpression 
represents a common abnormality in both T2DM and their First Degree 
Relatives (FDR) and can be easily detected in peripheral blood leukocytes. In 
susceptible individuals, this defect associates with the presence of T2DM-
affected subjects in the pedigrees and not with other major T2DM risk factors. 
In euglycemic FDR of T2DM, high PED/PEA-15 levels strongly correlate with 
resistance to insulin action in the lean mass, suggesting that PED/PEA-15 
contributes to early appearance of insulin-resistance in these individuals 
(Valentino et al. 2006). 
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Figure 6: PED/PEA-15 mRNA levels. RNA was extracted from fibroblasts, skeletal muscle, 
adipose tissues and white blood cells from type 2 diabetics and their controls. The quantification by real-
time PCR showed that PED/PEA-15 mRNA was overexpressed both in tissues and in blood cells. 
 
 
 
To investigate the role of ped/pea-15 gene in the insulin resistance, 
several studies have been performed in vitro and in vivo. 
In vitro, Ped/Pea-15 cDNA has been stably transfected in L6 skeletal 
muscle and 3T3-L1 adipose cells to levels comparable to those occurring in 
type 2 diabetes. These cells overexpressing PED/PEA-15 showed an impaired 
glucose uptake with a lack of further insulin-dependent uptake and the use of 
an antisense oligonucleotide to inhibit endogenous PED/PEA-15 expression in 
muscle cells and adipocytes significantly expanded insulin sensitivity of 
glucose uptake. Thus, PED/PEA-15 may represent a physiological regulator of 
glucose transporter trafficking and glucose transport in the major insulin-
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responsive skeletal muscle and adipose tissues (Condorelli et al. 1998). A 
following study has shown that in L6 skeletal muscle cells overexpressing 
PED/PEA-15 (L6PED), PKCα and β are also constitutively activated, while 
PKCζ features no basal change but completely loses insulin sensitivity in 
L6PED. In these cells, blockage of PKCα and β, additively rescues glucose 
uptake to the levels of cells expressing only endogenous PED/PEA-15 (L6), 
restoring most of the defect in both basal and insulin-stimulated glucose 
uptake. Blockage of PKCα and β also restores insulin activation of PKCζ in 
L6PED cells. Similar rescue of normal glucose uptake and PKCζ activation were 
also achieved by overexpression of PKCζ in L6PED cells. Thus, chronic 
activation of PKCα and β caused by the overexpression of PED/PEA-15 
appears to downregulate insulin induction of PKCζ activity (Condorelli et al. 
2001).  
In vivo, we reported that transgenic mice overexpressing PED/PEA-15 
to levels comparable to those occurring in human type 2 diabetes exhibit mildly 
elevated random-fed blood glucose levels and become hyperglycemic after 
glucose loading, indicating that increased expression of this gene is sufficient 
to impair glucose tolerance. Moreover, transgenic mice become diabetic after 
administration of high-fat diets, indicating that, in vivo, the overexpression of 
PED/PEA-15 in conjunction with environmental modifiers may lead to 
diabetes. Based on the insulin tolerance tests, ped/pea-15 transgenic mice were 
less sensitive to insulin as compared with their nontransgenic littermates. 
Furthermore, transgenic mice were markedly hyperinsulinemic in the basal 
state and exhibited increased free fatty acid levels in blood: these findings 
indicate the presence of insulin resistance in PED/PEA-15 mice. This 
abnormality has been associated with a decrease in insulin stimulated glucose 
uptake. GLUT4 membrane translocation in response to insulin was also 
significantly decreased in tibialis muscles and perigonadal adipose tissues from 
PED/PEA-15 transgenic mice, without a significant change in the total GLUT4 
levels in transgenic muscle or adipose tissues.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: GLUT4 membrane translocation. Tissues from insulin-injected animals were frozen 
in liquid nitrogen and harvested for plasma membrane preparation. Total homogenates and plasma 
membrane lysates were then analyzed by Western blotting with GLUT4 antibody. Blots were revealed by 
enhanced chemiluminescence and autoradiography. The autoradiographs shown are representative of four 
independent experiments ( see below attached publications). 
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This defect was accompanied by dysregulation of protein kinase C 
signaling, independently of the phosphatidylinositol 3-kinase/Akt/PKB 
pathway. Indeed, transgenic mice showed an increased PKCα activation and a 
block of insulin induction of protein kinase Cζ. Furthermore, the transgenic 
mice showed reduced insulin response to a glucose challenge, indicating that 
the overexpression of PED/PEA-15 impairs insulin secretion in addition to 
insulin action (Vigliotta et al. 2004; see below attached publications). 
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Figure 8: PKC signaling in ped/pea-15 transgenic mice. The mice were fasted overnight or fed ad 
libitum, followed by intraperitoneal insulin injection (0.75 mU g–1 body weight). The animals were killed, and 
tibialis or perigonadal fat tissue was collected, homogenized, and solubilized. The lysates were Western 
blotted with phospho-PKCα (P-PKCα) and PKCα antibodies (left panel) to analyzing PKCα activation, while 
with phospho-PKCζ (P-PKCζ) and PKCζ antibodies to evaluate PKCζ activation (see below attached 
publications). 
 
 
Thus, these findings identify PED/PEA-15 as a novel gene controlling 
insulin action and insulin secretion contributing, under appropriate 
environmental conditions, to genetic susceptibility to type 2 diabetes in 
humans.  
 
 
6. Phospholipase D protein 
As noted above, PED/PEA-15 interaction with PLD may represent a 
initial major event in dysregulating insulin action (Vigliotta et al. 2003; see 
below attached publications). Classical phospholipase D (PLD) enzymes 
hydrolyze the principal membrane lipid phosphatidylcholine (PC) to generate 
phosphatidic acid (PA) and free choline (Cho) and performs a 
transphosphatidylation reaction using water or primary alcohols (ethanol or 1-
butanol) as the nucleophile to generate PA, phosphatidylethanol or 
phosphatidylbutanol (PBut), respectively (Figure 9) (Jenkins and Frohman 
2005). PLD is a member of a superfamily, which includes phosphoinositide-
specific phospholipase C, phospholipase A2 and sphingomyelinase; all are 
phospholipids-degrading enzymes that generate biologically active products 
which are assumed to play important functions in cell regulation. In the context 
of these specific roles, PLD has been proposed to function in regulated 
secretion, cytoskeletal reorganization, membrane trafficking, transcriptional 
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regulation and cell-cycle control (Liscovitch et al. 2000).  
 
 
 
 
Figure 9: Structure of PLD1 with some notable structural features. Catalysis requires the four 
conserved regions (I - IV), which can even be co-expressed separately. Sites of interaction of two activators 
(PKC and Rho) are indicated. Near the N-terminus of the protein, three potential membrane-targeting 
signals are evident, a PX domain, a PH domain and a dual palmitoylation site (palm; cysteine residues 240 
and 241) within the PH domain. 
 
 
 
PLD superfamily members are found in organisms ranging from viruses to 
bacteria, yeast, plants and animals, where PLD activity is present in a wide 
variety of cell types including blood platelets, hepatocytes, lymphocytes, 
fibroblasts, neuronal cells, muscle cells and endothelial cells. Cloning of the 
plant and yeast PLDs led ultimately to the cloning of two mammalian isoforms: 
PLD1 and PLD2, each of which is expressed as two splice variants and 
localized  the first, on the Golgi or perinuclear vesicular structures, whereas the 
second, appears to be associated with the plasma membrane (Exton et al. 
2002). The defining feature of PLD enzymes is the catalytic motif designated 
HKD, denoting the HxxxxKxD sequence, where the aminoacids are histidine 
(H), any amino acid (x), lysine (K) and aspartic acid (D), which are critical for 
enzymatic catalysis both in vitro and in vivo, as evidenced by the observation 
that point mutations in the motif disrupt PLD activity (Sung et al. 1997). Other 
highly conserved regions the PLD genes are the phox consensus sequence 
(PX), the pleckstrin homology (PH) domain and the PI4,5P2 binding site at 
their N-terminal which are implicated in phospholipids and protein binding 
(Figure 10) (Exton 2002). Further, only in PLD1 is present a conserved loop 
region proposed to function as a possible negative regulatory element (Sung et 
al. 1999). The C-terminal four amino acids of mammalian PLDs are 
completely conserved and any change of these residues causes loss of catalytic 
activity (Xie et al. 2000). 
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Figure 10: Basic Structure of PLD1 and PLD2. Structure showing amino (N) and carboxy (C) 
terminals. Conserved domains are showed as boxes: the catalytic HKD motif, phox consensus sequence 
(PX), pleckstrin homology (PH), phosphatidylinositol bisphosphate (PIP2) and PLD1 loop region. 
 
 
 
 
Mammalian PLD activity is regulated by many factors, including 
phosphoinositides, Protein kinase C-α (PKCα), ADP ribosylation factor 
(ARF), Rho GTPases such as RhoA, Cdc42, Rac1 and non-PKC protein 
phosphorylation. In comparison with PLD1, recombinant PLD2 exhibits high 
basal activity in vitro, so it can be activated mildly by ARF, exhibiting 1,5-2 
fold activation (Sarri et al. 2003). 
 
 
6.1 PLD1 isoform: expression and regulation 
The mammalian PLD1 cDNA was cloned from HeLa cell library and 
found to encode a 1074-amino-acid protein. PLD1 has been renamed PLD1a 
after another splice variant has been identified, PLD1b, that lacks a 38-amino-
acid region. The domain structure contains the four core domains I-IV, a 
putative PX domain, a C-terminal motif which is conserved in all eukaryotic 
PLDs and a 116-amino-acid loop between domains I and II (Sung et al. 1997). 
The phospholipase D1 is highly expressed in kidney and lung, but detectable 
levels were also observed in small intestine, colon, liver, heart and spleen, but 
very low levels were seen in the testis, thymus and muscle (Katayama et al. 
1998). Several studies have showed that PLD activity correlated with 
metabolic regulation, hormone response, mitogenesis, cardiac and brain 
function, immune response, senescence and neoplasia, and is regulated by 
various small GTPases such as Arf1 and its isoforms, RhoA, other Rho family 
members, and RalA (Colley et al. 1997). The members of Rho family G 
proteins activate PLD1 in vitro and in vivo (Chong et al. 1994); all Arf family 
G proteins activate PLD1 in vitro, whereas the evidence for an in vivo role is 
strongest for Arf 6, which is principally localized to the plasma membrane 
(Cavenagh et al. 1996). Ras and Ral appear to play a role in the regulation of 
PLD by tyrosine kinases even if the mechanisms involved are not clear (Jiang 
et al. 1995). Studies with inhibitors of tyrosine kinases suggest a role for 
tyrosine phosphorylation in the activation of PLD by many agonists whose 
receptors couple to heterotrimeric G proteins (Exton 2002). In addition, Protein 
kinase C-α is a major regulator of PLD activity both in vivo and in vitro, 
through a direct non-phosphorylating mechanism (Kim et al. 2000). 
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7. PED/PLD1 interaction: D4 domain 
Recent studies showed that PLD1 associated with GLUT4-containing 
membranes acted in a constitutive manner to promote the mechanisms of 
GLUT4 translocation by insulin (Emoto et al. 2000). Given the proposed roles 
for PLD1 in regulation of GLUT4 translocation, in signal transduction, 
apoptosis and its regulation by PKC, PED/PEA-15 appeared to be an 
interacting partner of potential biological significance.  
Interestingly, observations suggested that PED/PEA-15/PLD1 binding 
resulted in increased PLD1 levels, thus increasing PLD activity both in vitro 
and in vivo. The PLD1 interaction domain of PED/PEA-15 was identified 
based on multiple overlapping clones obtained using a two hybrid screening 
approach. The amplification by polymerase chain reaction to obtain shortest 
overlapping region identified the D4 domain as the minimum interacting 
domain (Figure 11). Then, pull-down experiments using GST-fused proteins 
demonstrated that PED/PEA-15 binds PLD1 and the D4 domain was detected 
using Western blotting visualization. Finally, the interaction PED/PEA-
15/PLD1 has been also examined in extracts from different eukaryotic cells, 
using antibodies anti-PED/PEA-15. The D4 fragment of PLD1 co-
immunoprecipitated efficiently with PED/PEA-15 and vice-versa, 
demonstrating that the interaction was specific (Zhang et al. 2000). 
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Figure 11: Schematic representation of PED/PEA-15/PLD1 minimal interaction domain. 
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AIM OF THE STUDY 
 
Ped/Pea-15 gene is overexpressed in peripheral tissues from type 2 
diabetics. In cultured cells and in transgenic mice, PED/PEA-15 
overexpression impairs insulin-resistance and insulin secretion. 
Recent findings from our own as well as other groups indicated that 
PED/PEA-15 is a phospholipase binding protein. Increased interaction of 
PED/PEA-15 with PLD1 could be a key event in mediating abnormalities in 
insulin action in vitro and in vivo. 
The aim of this work has been to prove the concept that limiting 
PED/PEA-15/PLD1 interaction may improve insulin-sensitivity in vitro and in 
vivo and ameliorate glucose tolerance in PED/PEA-15 overexpressing mice 
and in other animal models of type 2 diabetes.  
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MATHERIALS AND METHODS 
 
Plasmids construction 
The cloning of PED/PEA-15 cDNA in pcDNA3 vector containing the 
Myc-tagged has been previously described (Condorelli et al. 2002; see below 
attached publications). The D4 cDNA fragment has been amplified by PCR by 
HeLa cells in a reaction mixture with Taq-Long Expand PCR System (Roche 
Diagnostics, Mannheim, Germany) and with the following primers: Hind III-
D4 5’-CGATCAAGCTTCGCTGGAACTTCACAAAAAT-3’ and Xba I-D4 
5’-CGATCTCTAGAGGATACGAGAATGCGTCAGG-3’ for cloning in 
pcDNA3-HA vector and with the following primers: Hind III-D4-F 5’-
GCTAGGGTACCGGATACGAGAATGCGTCAGG-3’ and Kpn I-D4-R 3’-
CGATCAAGCTTCCGCTGGAACTTCACAAAAAT-5’ for cloning in 
pEGFP-C2 vector. The fragment D4 in both vectors has been amplified with 
following program: 1 cycle (94°C for 2’), 10 cycles (94°C for 10’’, 58°C for 
30’’, 68°C for 3’), 25 cycles (95°C for 30’’, 58°C for 30’’, 68°C for 3’and 
20’’) plus an increase of 20’’ to each cycle for elongation time, 1 cycle (68°C 
for 7’), stop 4°C. The PCR-derived fragment was sequenced to confirm its 
predicted composition (Primm San Raffaele Biomedical Science Park, Milan 
Italy). The D4 fragment (1,1 kb) has been cloned into pcDNA3-HA vector 
carrying Hind III-XbaI restriction sites and in pEGFP-C2 vector carrying Hind 
III-Kpn I restriction sites. The presence of D4 fragment has been confirmed by 
DNA sequencing (PRIMM). 
Cell culture and Transfections  
The 293 human kidney embryonic cells and L6 rat skeletal muscle cells 
were grown in Dulbecco’s Modified Eagle’s Medium supplemented with 10% 
fetal calf serum, 10,000 U/ml penicillin, 10 mg/ml streptomycin and 2% L-
Glutamine in a 5% humidified CO2 incubator. Transient transfections have 
been performed using the Lipofectamine Plus as according to the 
manufacturer’s instructions (Invitrogen Corporation, Carlsbad, CA) and total of 
4-6 µg plasmid DNA for dish. Stable transfections have been performed by 
selecting positive clones with G418 (Calbiochem, Darmstad, Germany) at the 
effective dose of 0,8 mg/ml. Cellular loading of PED/PEA-15 peptides (1-53, 
53-79, 79-112) has been performed with cationic lipid mixture ProVectinTM 
Protein Delivery Reagent (Imgenex Corporation, San Diego, CA). 
Western Blot Analysis and  Immunoblotting 
Cells grown in a subconfluent culture were lysed in lysis buffer (50 mM 
HEPES, pH 7.5, 150 mM NaCl, 10 mM EDTA, 10 mM Na4P2O7, 2 mM 
Na3VO4, 100 mM NaF, 10% glycerol, 1% Triton X-100, 1 mM PMSF, 10 
mg/ml aprotinin) for 2 h at 4°C and lysates were centrifuged at 14,000 x g for 
15 minutes to remove cellular debris. Protein concentrations were determined 
by Biorad Dc Protein Assay kit and equal amounts of the protein from each 
sample were separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) with 12% gels, as described by Laemmli, 1997. 
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Proteins separated on the gels were electroblotted onto nitrocellulose filters and 
probed with antibodies to PED/PEA-15 antiserum (1:2000), anti-PLD (1:1000 
Cell Signalling Technology, Beverly, MA), p-PKCα and HA (1:2000 Upstate 
Biotechnology, Lake Placid, N.Y.), p-PKCζ, and Tubulin (1:2000 Santa Cruz 
Biotech Inc., CA), GFP-peptide living colors (BD Transduction Laboratories, 
USA). Immunoreactive bands were visualized by enhanced chemiluminescence 
(ECL kit, Amersham Pharmacia Biotech, Piscataway, NJ, USA). 
PLD assay in intact cells 
In vivo PLD activity was performed measuring phosphatidic acid and 
phosphatidyl-butanol. For experiments involving insulin and TPA stimulation, 
the cells were transfected with 6 μg of PED/PEA-15 cDNA. The cells were 
labelled with 5 µCi of [14C] palmitic acid for 60-mm dish, added to the 
starvation medium (DMEM + 0,25%BSA) and incubated over night at 37°C in 
a 5% CO2–enriched, humidified atmosphere. The cells were washed twice in 
HHBG buffer (10 mM HEPES pH 7.4, 1,26 mM CaCl2, 0,5 mM MgCl2, 0,4 
mM MgSO4, 5,37 mM KCl, 137 mM NaCl, 4,2 NaH2PO4, 1% (w/v) BSA, 10 
mM glucose) and incubated in  0,5% butan-1-ol in HHBG buffer for 20 
minutes at 37°C. Subsequently, the cells were treated with or without insulin 
(160 ng/ml) for 30 minutes. After incubation the buffer was aspirated and 0,5 
ml of ice-cold methanol was added to each dish. The cell debris was scraped as 
described by B. and Dyer into a glass vial and kept on ice. Chloroform and 2 N 
HCl were added to give a final chloroform/methanol/HCl ratio of 1:1:0,04 (by 
vol.). After vortex-mixing the vials were centrifuged at 1200 g for 5 minutes 
and the lower phase containing lipids was prelevated and incubated with 500 µl 
of chloroform and 50 μl of 2 N NaCl in other vials. After vortex-mixing the 
vials were centrifuged at 1200 g for 5 minutes and the lower phase was 
prelevated to unite it to previous phase. The organic phase was dried with N2 e 
the lipids were resunspended in 20 μl of chloroform. Then, they were spotted 
on to Wathmann TLC plates. The labelled products were separated by TLC 
using the upper phase of a mixture of ethylacetate/2,2,4-
trimethylpentane/acetic acid/water ratio of 13:2:3:10 (by vol.). The positions of 
the spots corresponding to [14 C] phosphatidyl-butanol were determined by 
autoradiography. The area containing phosphatidylbutanol was scraped and the 
radioactivity was counted. 
Co-immunoprecipitation  
Lysates from HEK293 and L6 transfected and untransfected cells and 
tissues (i.e. brain and skeletal muscle) from Ped/Pea-15 transgenic mice were 
precleared with 20 μl of pre-immune serum at 4°C for 30 minutes. For each 
condition, 2 μg of PED/PEA-15 or PLD 1 antibodies were added to 500 μg of 
cleared lysates and incubate at 4°C for 16 h. After incubation, the mixture was 
incubated with 20 μl of protein A Sepharose resin pre-equilibrated (Sigma-
Alderich Chemie Steinheim, Germany) with HNT buffer (50 mM HEPES, pH 
7.5, 150 mM NaCl, 0,1% Triton X-100) for 2 h at 4°C with vibrant shaking. 
The protein A Sepharose resin were precipitated by centrifugation at 10,000 
rpm for 2 minutes and washed with 500 μl of washing buffer for five times. 
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The bound antibody-antigen complexes were eluted in sample buffer and total 
elute was separated by 12% SDS-PAGE, transferred to nitrocellulose 
membranes and blotted with PLD1 or PED/PEA-15 antibodies. The enhanced 
chemiluminescence was performed as previously described.  
Immunofluorescence microscopy 
Cells were grown onto glass coverslips in six-well multidishes and 
allowed to adhere for 24 hours. Cells were fixed with methanol for 5 minutes at 
-20°C and blocked with PBS containing 3% normal goat serum for 1 hour at 
room temperature. The primary antibody was made in blocking solution and 
incubated for 1 hour at room temperature. The cells were incubated in a 1:1000 
dilution of the appropriate secondary antibody conjugated to fluorescein 
isothiocyanate for 30 minutes at room temperature for GFP detection. After 
washes with TBS-0,1% Tween 20, the coverslips were stained with 4,6-
Diamidio-2-phenylindole (DAPI) to identify the nucleus. Immunostaining and 
DAPI staining were mounted with 50% glycerol in PBS and were examined 
under a fluorescence microscopy (Leica, Exton, PA). 
PLD assay in vitro 
For PLD1 activity assay, brain and muscle tissue from Ped/Pea-15 
transgenic mice were homogenized in T-PERTM extraction reagent (Pierce, 
Rockford, IL). Each homogenate was centrifuged at 10,000 rpm for 5 minutes: 
the pellet was discarded, while the supernatant was designated as crude 
membranes. PLD1 activity was determined under the assay condition by 
measuring the transphosphatidylation activity in the presence of butan-1-ol. 
The standard assay mixture, containing 50 mM HEPES/NaOH, pH 7.5, 200 
mM NaCl, 3 mM MgCl2, 2 mM CaCl2, 3 mM EGTA, 1 mM dithiothreitol, 400 
mM butan-1-ol, 140 µM phosphatidylethanolamine (PE), 12 µM PIP2 and 8,6 
µM 1-palmitoyl-2-[1-14C] palmitoyl-PC (Amersham International) in a total 
volume of 100 µl, was incubated for 60 minutes at 37°C. 1 µM of PC, 1,4 µM 
of PIP2 and 16 µM of PE were added as a mixed micelles. Recombinant 1 µM 
of ARF1 and 0,05 µM of RhoA were added to the mixture and were activated 
using 10 µM of Guanosine 5’-[γ-thio]-triphosphate (GTP[S]). The reaction was 
stopped with 100 µl of 1 M HCl and the lipid product was extracted with 1 ml 
of chloroform/methanol (2:1 by vol.) and washed with 0,5 ml of 170 mM 
NaCl. The lower phase was isolated, concentrated in a centrifugal vaporizer 
and separated on a Silica Gel 60 TLC plate with chloroform/methanol/acetic 
acid (13:3:1 by vol.) as the developing solvent. The positions of the spots 
corresponding to [14C] phosphatidyl-butanol were determined by 
autoradiography. The area containing phosphatidyl-butanol was scraped and 
the radioactivity was counted. 
Flow cytometry 
Six-well multidishes containing 2,5 x 105 L6 and L6PED cells were 
incubated for 24 hours at 37°C in 2 mL complete medium and were infected 
with AdGFP adenovirus for 16 hours. Cells were then detached from the dishes 
by trypsinization, centrifuged, washed twice with 1 mL PBS, and resunspended 
in 500 µl PBS containing 0,25% BSA. Samples were stored in ice-cold before 
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final readings. The cellular green fluorescent protein was detected in a linear 
scale using flow cytometer (Dako Cytomation CyAn ADP). About 20,000 events 
were recorded for each sample and data were analyzed with Software Dako 
associated. 
Intramuscular injection and Tissue collection 
Three-months old transgenic and control mice (25-30 g) were 
anaesthetized intramuscularly with 2,2,2-tribromoethanol (Sigma-Alderich 
Chemie Steinheim, Germany). The legs were shaved and moistened with 70% 
ethanol. AdGFP and AdβGal adenoviruses were injected into tibialis anterior 
muscle with a U-100 insulin syringe in a proximal to distal direction. The 
concentration injected was 2 x 107 pfu in a volume of 200 µl. Mice were fed ad 
libitum and maintained under a 12-h light/dark cycle. Animal procedures were 
performed in accordance with recommendations for the proper care and use of 
laboratory animals. After infection times, tissue samples (brain, tibialis and 
soleus muscles, perigonadal adipose tissues) were collected rapidly after 
transgenic mice were sacrificed by 2,2,2-tribromoethanol overdose. Tissue 
samples were homogenized in a Polytron (Brinkman Instruments, N.Y.) in T-
PERTM extraction reagent (25 mM Bicine, 150 mM Sodium Chloride, pH 7.6) 
with a ratio of 1 g of tissue to 20 ml according to manufacture’s instruction 
(Pierce, Rockford, IL). After centrifugation at 10,000 rpm for 5 minutes, the 
supernatants were performed as cellular lysates. 
β-Galactosidase assay and X-Gal staining 
To analyze total β-Galactosidase expression activity the muscles from 
Ped/Pea-15 transgenic mice and their controls were homogenized in 2 ml of a 
1x reporter lysis buffer from a β-Galactosidase enzyme assay System (Promega 
Corporation, Madison, WI, USA). Following 15 minutes of incubation at room 
temperature, the samples were centrifuged at 14,000 rpm for 5 minutes at 4°C. 
Supernatants were collected and 10 µl were placed into the 96-well plate 
containing assay buffer (50 µl of Galacton and 25 µl of Emerald). All samples 
have been mixed by pipetting the well contents. The absorbance of the samples 
was measured at 420 nm in a luminometer (Centro LB960 Berthold 
Technologies). To perform X-Gal staining with In Situ β-Galactosidase 
Staining Kit (Stratagene, La Jolla, CA) L6 cells were fixed in 20% 
formaldehyde and 2% glutaraldehyde in PBS pH7,4 for 10 minutes at room 
temperature and then washed in PBS. Cells were incubated for 16 hours at 
37°C in staining buffer (5 mM K4Fe(CN)6, 5 mM K3Fe(CN)6, 2 mM MgCl2, 
10% dimethyl sulfoxide (DMSO) in PBS with X-Gal staining solution (100  
mg/ml 5-Bromo-4-chloro-3-indoyl-β-D-galactopyranoside). Staining solution 
was removed and cells were washed two times with PBS. Quantification of 
blue cells to determine the infection efficiency was performed by the manual 
tagging in the total population. 
Adenovirus construction 
The D4 cDNA was excised from the pEGFP-D4 expression construct 
by digestion with Hind III and Kpn I restriction enzymes. The fragment was 
gel-purified and ligated into the Hind III-Kpn I sites of pAdTrack-CMV shuttle 
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vector (containing CMV promoter, a polyadenylation site and GFP fusion 
protein) using a cloning system described in He et al. 1998). The resulting 
plasmid was linearized with Pme I and transformed together with a supercoiled 
adenoviral vector (pAdEasy-E1) into electrocompetent E. coli strain BJ5183. 
Recombinants were selected with kanamycin and screened by restriction 
endonuclease digestion. The positive transformants were linearized with Pac I 
digestion. The resulting recombinant pAdTrack-CMV containing D4 sequences 
were linearized with Pac I digestion and transfected in 1,5 x 106 packaging cell 
lines (HEK293) plated in 25 cm2 flasks using Lipofectamine Plus (Invitrogen 
Corporation, Carlsbad, CA). After 24 hours of transfection, the cells were 
overlaid with agarose to permit isolation of individual virus plaques; visible 
plaques were selected 7-10 days following transfection and expanded. Virus 
was purified from 293 cells by three freeze/thaw cycles using, alternately, 
liquid nitrogen and a 37°C water bath. After three freeze/thaw cycles, the cell 
lysates were centrifuged on cesium chloride step gradients at 60,000 x g for 2 
hours at 20°C to separate viruses from defective particles and empty capsids. 
The purified viral stocks were subjected to dialysis against 1 x TE (10 mM 
Tris-HCl + 1 mM EDTA pH 8.0) containing 17% glycerol for 24 hours at 4°C 
with fresh buffer being added every 12 hours. Aliquots of purified recombinant 
virus were frozen and stored at -80°C until used. 
2-deoxy-D-glucose (2-DG) uptake 
Briefly, confluent cells were infected with AdTrack-CMV-D4 
adenovirus for 16 hours. Following, the cells were incubated in DMEM 
supplemented with 0.25% albumin for 18 h at 37°C. The medium was aspirated 
and cells were further incubated for 30 min in glucose-free HEPES buffer (5 
mmol/l KCl, 120 mmol/l NaCl, 1.2 mmol/l MgSO4, 10 mmol/l NaHCO3, 1.2 
mmol/l KHPO4, and 20 mmol/l HEPES, pH 7.8, 2% albumin). The cells were 
incubated with 100 nmol/l insulin for 30 min, supplemented during the final 10 
min with 0.2 mmol/l [14C]2-DG. Cells were then solubilized and the 2-DG 
uptake was quantitated by liquid scintillation counting.  
Densitometry and statistical analysis  
Densitometric analysis was performed using a Scion Image Analyzer. 
All the data were expressed as mean ± SD. Significance was assessed by 
Student's t test for comparison between two means. Data were analyzed with 
Statview software (Abacusconcepts) by one-factor analysis of variance. P 
values of less than 0.05 were considered statistically significant. 
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RESULTS AND DISCUSSION 
 
 
PED/PEA-15 protein binds PLD1 and enhances PLD1 
activity in HEK293 and L6 cells 
Several studies in vitro have been performed to elucidate the molecular 
mechanisms responsible for insulin-resistance induced by PED/PEA-15 
overexpression. Investigations from our own as well as other groups evidenced 
that PED/PEA-15 is a phospholipase binding protein (Zhang et al. 2000).  
In accordance with previous data that showed PED/PEA-15 as a 
phospholipase D interactor, I verified the association between the two proteins 
in a well characterized cellular system, the HEK293 human embryonic kidney 
cells stably overexpressing PED/PEA-15 (Y1). These cells have been subjected 
to western blot analysis to evaluate PED/PEA-15 and PLD1 protein levels, and 
untransfected 293 cells were used as control cells (293). PED/PEA-15 protein 
was significantly overexpressed in Y1 cells compared to control cells. As 
shown in figure 12 A, PLD1 levels were also higher in Y1 cells compared to 
293 cells. This finding suggested that PED/PEA-15 overexpression was 
correlated with increased levels of PLD1. 
It has been demonstrated that Protein kinase C (PKC)-α is 
constitutively activated in L6 skeletal muscle cells overexpressing PED/PEA-
15 (Condorelli et al. 2001).  
To further investigate this effect in HEK293 cells and to address the 
role of PKCα in PED/PEA-15 function, I evaluated the levels of activation of 
PKCα in 293 overexpressing PED/PEA-15. I observed that in Y1 cells the 
activation of PKCα was increased by three-fold compared to control cells 
(Figure 12 B). 
These findings showed that also in HEK293 cells, PED/PEA-15 
overexpression was associated with increased PLD1 levels and induction of 
PKCα activation. 
To verify the interaction between PED/PEA-15 and PLD1, lysates from 
Y1 and 293 cells were precipitated with anti-PED/PEA-15 antibody and the 
immunoprecipitated proteins were analyzed by western blot with specific 
antiboby against PLD1. The enhanced chemiluminescence (ECL) revealed 
three-fold increased levels of PLD1 associated to PED/PEA-15 in Y1 cells 
compared to 293 cells (Figure 12 B).  
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Figure 12: Effect of PED/PEA-15 expression in 293 and 293Y1 cells. Cellular lysates of control 
(293) and PED/PEA-15 (Y1) cells have been subjected to western blotting analysis to analyze PED/PEA-15, 
PLD1 and PKCα expression levels. The autoradiography shows an increased expression of PED/PEA-15 
and PLD1 proteins in Y1 cells compared to 293 cells. Anti-Tubulin antibody has been used to normalize (A). 
PKCα hyperactivation has been observed also in Y1 cells compared with 293 cells (B). Co-
immunoprecipitation experiments in these cells demonstrated that PED/PEA-15 binds phospholipase D1 at 
higher extent in Y1, compared to 293 cells (B). 
 
 
 
 
In previous studies we have demonstrated that in differentiated L6 
skeletal muscle cells and 3T3-L1 adipocytes, the increased expression of 
PED/PEA-15 blocks insulin-dependent translocation of GLUT4. These 
changes occurred with no detectable alterations in the total content of GLUT4, 
the major insulin-stimulated glucose transporter. Like glucose transport, PKCα 
and PKCβ are also constitutively activated and are not further stimulable by 
insulin in L6PED. PKC-zeta features no basal change but completely loses 
insulin sensitivity in L6PED (Condorelli et al. 2001). However, the impaired 
translocation of GLUT4 is due to the alteration of PKC signalling caused by 
PED/PEA-15/PLD1 interaction (Vigliotta et al. 2003; see below attached 
publications). 
Indeed, by western blot analysis I demonstrated that PLD expression 
was three-fold higher also in L6 skeletal muscle cells stably overexpressing 
PED/PEA-15 (L6PED), as compared to controls (L6) (Figure 13 A).  
Furthermore, as shown by co-immunoprecipitation experiments, 
PED/PEA-15/PLD1 interaction was more evident in L6PED cells than in L6 
control cells (Figure 13 B). Thus, this binding stabilized PLD1, leading to 
enhanced phospholipase activity in the cells overexpressing PED/PEA-15. 
These changes are accompanied by increased diacylglycerol levels, a major 
activator of classical PKCs (Condorelli et al. 2001).  
Consistently, PKCα phosphorylation was also increased in L6 cells. 
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Figure 13: PED/PEA-15 and PLD1 expression. Cell lysates of L6 and L6 cells stably transfected 
with PED/PEA-15 cDNA have been subjected to western blotting analysis to analyze the expression levels 
of PED/PEA-15 and PLD1 proteins (A). An increase of both proteins was shown in L6PED cells to compared 
control cells and also an increase of PKCα activation was present in L6PED. Next, the co-
immunoprecipitation experiment showed that PED/PEA-15/PLD1 interaction was higher in L6PED than L6 
cells (B). 
 
 
As described by Zhang et al. 2000 the binding of PED/PEA-15 to PLD1 
protein induced an increase of phospholipase D cellular activity. To verify if 
the increased amount of PLD1 was paralleled by an increased activity, PLD1 
activity was evaluated by measuring the levels of transphosphatidylbutanol 
generated by the transphosphatidylation reaction. Y1 and 293 cells have been 
treated with TPA (100 nM) for 30 minutes and then, subjected to lipid 
extraction as described in Matherials and Methods. PLD1 activity has been 
measured evaluating the specific reaction of transphosphatidylation catalyzed 
by the enzyme using 1-butanol as a substrate. The chromatography showed that 
TPA stimulates PLD1 activity in 293 cells; in Y1 cells, there was an increase in 
both basal and TPA-stimulated PLD1 activity, compared to 293 cells (Figure 
14 A). Similar results were also obtained in L6 cells. These results indicated 
that the overexpression of PED/PEA-15 causes an increase in the expression 
and activation of PLD1. 
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Figure 14: PED/PEA-15 overexpression increases PLD1 activity. PLD1 activity analyzed by 
measuring the transphosphatidyl-butanol levels was increased either in basal state or upon TPA (100 nM) 
stimulation in Y1, compared to 293 cells (A). Each experiment was determined in triplicate and this was a 
representative of three experiments. The autoradiograph shows a representative experiment. The bar graph 
represents the densitometric quantitation of the spots in three experiments in triplicate ± SD (B). 
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The role of PED/PEA-15 phosphorylation 
Several reports indicate that PED/PEA-15 is phosphorylated at the level 
of Ser116 by calcium–calmodulin kinase II (CaMKII) and PKB/Akt, facilitating 
further phosphorylation by protein kinase C (PKC) at Ser104→Gly. Thus, 
PED/PEA-15 is present in the cell in both unphosphorylated and 
phosphorylated form.  
To clarify the role of the Ser104 and Ser116 phosphorylation on the 
association of PED/PEA-15 with PLD1, I transiently transfected the wild type 
form (Y1) or Ser104→Gly and Ser116→Gly mutants of PED/PEA-15 (generated 
in our laboratory as described in Trencia et al. 2003; see below attached 
publications) in 293 cells. 
No significant differences in the activation of PKCα were observed 
both in PEDS104 and PEDS116 293 cells, as compared with wild type cells 
(Figure 15). The co-immunoprecipitation experiments using anti-PLD1 
antibody also showed that the mutation of both Ser104 and Ser116 did not 
significantly affect PED/PEA-15/PLD1 association. 
These data demonstrated that the phosphorylation of PED/PEA-15 
protein did not control the binding with phospholipase D1. 
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Figure 15: PED/PEA-15 phosphorylation defective mutants and PLD1 function. Lysates from 
293 cells transfected with PED/PEA-15 (Y1) and Ser104→Gly (S104), Ser116→Gly (S116) mutants have been 
analyzed for PKCα activation levels and immunoprecipitated using anti-PLD1 antibody. The second panel 
shows that PKCα activity is up-regulated in all transfected cells. Co-immunoprecipitation experiments (lower 
panel) show that PED/PEA-15 and its S104, S116 mutants were equally capable to associate with PLD1. 
 
 
 
Generation of D4 fragment: its effects in vitro 
A previous study (Condorelli et al. 2001) has demonstrated that the 
activation of PKCα prevented insulin induction of PKCζ activity in L6 cells. 
The use of PKCζ constitutively active mutants in these same cells rescued the 
activity of the kinase and the insulin effect on glucose uptake. 
Thus, increased PED/PEA-15/PLD1 interaction caused insulin-
resistance by dysregulating the PKC signaling system.  
With this background, I wanted to prove the concept that, limiting this 
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interaction may improve insulin-sensitivity in vitro and in vivo. To this aim, I 
generated the minimum PLD1 fragment (D4) conserving the ability to bind 
PED/PEA-15 (Zhang et al. 2000). Following RT-PCR amplification of D4, 
DNA sequencing was performed to confirm the correct sequence. 
Furthermore, the D4 fragment was inserted into the pcDNA3 vector in 
frame with the HA epitope. Indeed, the D4 fragment has been cloned between 
Hind III and Xba I sites. I transfected the construct pcDNA3-HA-D4 in 293 
and in Y1 cells. Lysates obtained have been analyzed by Western blot with HA 
antibody to verify the expression of the fragment. The HA-tagged D4 fragment 
was expressed at comparable levels both in 293 and Y1 cells (Figure 16). 
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Figure 16: Effect of D4 transfection.  D4 fragment has been transfected in 293 and Y1 cells and 
the presence of the construct (pcDNA3-HA-D4) has been analyzed using anti-HA antibody. 
 
 
 
 
 
D4 cDNA was also cloned into a pEGFP vector. The GFP-D4 fusion 
protein, generated as described in Matherials and Methods, has been 
transfected in 293 and Y1 cells. After 48 hours the cells were lysed and 
analyzed by western blot with anti-GFP antibody (Figure 17). A specific band 
was detected in the cells which have been transfected with the construct, 
indicating that the chimerical protein was expressed in both 293 and Y1 cells.  
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Figure 17: Expression of pEGFP-D4. The pEGFP-D4 construct has been transiently transfected 
in 293 and Y1 cells. The effect of this transfection has been detected with anti-GFP antibody. 
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Next, I performed co-immunoprecipitation experiments following 
transfection of pcDNA3-HA-D4 and pEGFP-D4 constructs, to verify the effect 
of D4 expression on PED/PEA-15 and PLD1 association. 
In particular, lysates from 293, Y1 and Y1 transfected with pcDNA3-
HA-D4 and pEGFP-D4 respectively, have been immunoprecipitated with 
PED/PEA-15 antibody and subjected to Western blot analysis, using PLD1 
antibody (Figure 18). The expression of D4 was able to significantly reduce the 
PED/PEA-15/PLD1 interaction in Y1 transfected with either pcDNA3-HA-D4 
or pEGFP-D4 constructs. 
 
 
 
 
 
 
 
 
 
 
Figure 18: Effect of D4 on the PED/PEA-15/PLD1 association. Aliquots (300 µg) of cells 
transfected with pcDNA3-HA, pcDNA3-HA-D4, pEGFP and pEGFP-D4 have been immunoprecipitated with 
anti-PED/PEA-15 and probed with anti-PLD1 antibody. The D4 fragment significantly reduce the association 
between PED/PEA-15/PLD1 in Y1 cells compared to cells transfected with empty vectors. 
 
 
 
 
Once confirmed that the expression of D4 fragment reduced the 
association of PED/PEA-15 with PLD1 in cells overexpressing PED/PEA-15, I 
evaluated the effects of D4 on basal and insulin-induced activation of the 
PKCs. Insulin activated PKCα in 293 cells, as shown by determination of the 
phosphorylated form of the protein with specific anti-phospho-PKCα antibody. 
By contrast, in Y1 cells PKCα was constitutively activated in basal condition 
and no further stimulated by insulin. In Y1 cells, the expression of D4 fragment 
reduced the basal activity of PKCα to levels comparable to 293 control cells. 
Moreover, the D4 construct was able to almost completely rescue the normal 
kinase activation of PKC α, in response to insulin stimulation (Figure 19 A).  
Insulin activated PKCζ in 293 cells transfected with the empty 
pcDNA3-HA vector, while in Y1 cells, the overexpression of PED/PEA-15 
prevented the insulin-stimulated activation of PKCζ. In these cells, D4 
expression rescued the normal activation of PKCζ in response to insulin 
(Figure 19 B).  
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Figure 19: Insulin-stimulates activation of PKCs upon D4 transfection. 293 and Y1 cells 
have been stimulated with insulin (100 nM) to measure PKCα activation. Transfections have been analyzed 
with anti-HA antibody. Densitometric quantitation from western blotting analysis showed that in Y1 cells 
transfected with pcDNA3-HA, PKCα is constitutively activated and does not respond to insulin, compared to 
control cells (A). No significant change occurred in PKCζ activation. In the same cells, the expression of 
pcDNA3-HA-D4 construct reduces PKCα activation and restores its responsiveness to insulin (A). The 
same is shown for PKCζ (B). Bars represent the means ± SD of triplicate determinations in four 
independent experiments. Asterisks denote statistically significant differences (***, P< 0,001). 
 
 
 
 
Similar results were also obtained in Y1 cells transfected with pEGFP 
and pEGFP-D4 (not shown). 
In conclusion, these findings indicated that the inhibition of PED/PEA-
15 and PLD1 interaction rescues insulin action on PKC signaling pathways, 
supporting the hypothesis of a key role of phospholipase D1 in the negative 
effect of PED/PEA-15 on glucose transport.  
 
 
 
 
Generation of PED/PEA-15 derived peptides 
In order to test PED/PEA-15 molecular determinants involved in PLD1 
binding, peptides corresponding to aminoacids 1-53, 53-79 and 79-112 of 
PED/PEA-15 protein were generated (collaboration with the IBB-CNR). To 
analyze the entry of PED/PEA-15 peptides in our cellular system, 293 and Y1 
cells were incubated with the fluorescein isothiocyanate-conjugated peptides 
(FITC) PED/PEA-151-53, PED/PEA-1553-79, PED/PEA-1579-112 peptides. 
Intracellular loading of the synthetic peptides was achieved by means of 
cationic lipid mixture. As revealed by fluorescence microscopy, FITC-PED79-
112 was efficiently transduced in both 293 and Y1 cells (∼90%) (Figure 20). 
Similar results were obtained with the other peptides (not shown). 
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Figure 20: PED/PEA-1579-112 peptide location by fluorescence microscopy. 293 and Y1 cells 
have been transiently transfected with FITC-PED/PEA-1579-112 peptide and after 24 hours the cells have 
been fixed and visualized with fluorescence microscopy. In both cells (A-C panels) DAPI staining showed 
the presence of peptide compared with untransfected cells (B-D panels). 
 
 
 
 
Next, I performed co-immunoprecipitation experiments in Y1 cells to 
evaluate the effect of these peptides on PED/PEA-15/PLD1 association. As 
shown in figure 21, only the peptide PED79-112 was able to decrease PED/PEA-
15/PLD1 association compared to control cells. 
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Figure 21: Co-immunoprecipitation experiments with peptides. Lysates (500 µg) from Y1 
cells have been co-immunoprecipitated in presence of PED/PEA-15 peptides (1-53, 53-79, 79-112). The 
experiment showed a decrease in PLD1 protein levels in presence of PED/PEA-1579-112 peptide. 
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To test the potential role of PED/PEA-1579-112 peptide in the rescue of 
PKC signaling, 293 and Y1 cells were stimulated with insulin in the absence or 
in the presence of the transduced peptide and analyzed by western blotting with 
anti-phospho-PKCα antibody. The activation of PKCα in 293 cells was not 
significantly modified by FITC-PED/PEA-1579-112 peptide. In the Y1 cells, 
however, the PED/PEA-1579-112 peptide was able to reduce the PKCα 
activation and to partially rescue the response to insulin. 
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Figure 22: Effect of PED/PEA-1579-112 peptide on PKCα activation. Lysates from 293 and Y1 
cells loaded with FITC-PED/PEA-1579-112 peptide and stimulated with insulin (100 nM for 30 minutes) have 
been analyzed using anti-phospho-PKCα antibody. PKCα activation was not modified in 293 cells loaded 
with FITC-PED/PEA-1579-112 peptide compared to untransfected cells. In Y1 cells, FITC-PED/PEA-1579-112 
peptide decreased basal PKCα activation and significantly rescued the response to insulin compared to 
untransfected Y1 cells. The graph represents mean ± SD of three different experiments in triplicate. 
Asterisks denote statistically significant differences (***, P< 0,001). 
 
 
 
 
 
The interaction between PED/PEA-15 and PLD1 in vivo 
As described in Vigliotta et al. 2003 (see below attached publications), 
Ped/Pea-15 transgenic mice feature a two-fold increase of PLD1 protein levels 
in muscle and adipose tissues. To confirm that PED/PEA-15 was able to bind 
PLD1 also in vivo, I performed co-immunoprecipitation experiments in cellular 
extracts from brain and skeletal muscle tissues of transgenic and control mice. 
The brain tissue has been used as positive control because it is enriched of both 
proteins.  
These experiments demonstrated that PED/PEA-15 binds PLD1 in 
skeletal muscle and in brain tissues. This association is further accompanied by 
increased PKCα activation in transgenics compared to controls (Figure 23).  
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Figure 23: PED/PEA-15/PLD1 interaction in vivo. The lysates from muscle and brain tissues 
have been immunoprecipitated with anti-PED/PEA-15 antibody. The immunoprecipitated proteins have 
been subjected to 7% SDS-PAGE and immunoblotted with anti-PLD1 antibody. Data were representative 
results from three experiments and showed that the interaction between proteins was increased in lysates 
prepared from brain and muscle of transgenic mice (lanes 2-4) compared with their controls (lanes1-3).  
 
 
 
 
Based on these results, I performed a PLD assay in vitro using extracts 
from skeletal muscle of transgenic mice and their nontransgenic littermates. As 
revealed by thin-layer chromatography analysis, PLD1 activity from Ped/Pea-
15 transgenic mice was increased two-fold versus control mice. Similar results 
were also obtained with brain extracts. 
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Figure 24: PLD1 activity in vivo. The lysates of brain and muscle tissues have been prepared 
and assayed for PLD1 activity in fasting condition. Results have been expressed as the mean ± SD of the 
duplicate assays and each bar represents a preparation from a single mouse, with two determinations for 
each preparation. The level of PLD1 activity was up-regulated in the brains and muscles of transgenic mice 
(bars 3-4 and 7-8) compared with their controls (bars 1-2 and 5-6). Bars represent the mean ± SD of the 
spots in three experiments in triplicate. 
 
 
 
 
In vitro and in vivo modulation of adenovirus 
Recently, there has been considerable interest in developing 
adenoviruses as defective vectors to carry and express foreign genes for 
therapeutic purposes. One reason for this is that the adenovirus is a versatile 
system and its genome can be easily manipulated in vitro and in vivo. 
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Furthermore, in most recombinant vectors, the gene of interest is introduced by 
replacing E1 early region. The E1 deletion makes the viruses defective for 
replication and incapable of producing infectious viral particles in the target 
cells. Thus, I considered the hypothesis of generating an adenoviral construct 
bearing the D4 fragment, to block PED/PEA-15/PLD1 interaction both in vitro 
and in vivo. I performed several experiments to test the feasibility of the 
adenoviral systems, for this purpose.  
To this aim, I used an adenovirus containing the Green Fluorescent 
Protein (AdGFP) and an adenovirus containing β-Galactosidase gene (AdβGal) 
as adenoviral vectors, respectively, incorporated into the adenoviral backbone, 
that can allow direct observation of the infection efficiency.  
First of all, I infected L6 cells with raising concentration of AdGFP (0, 
100, 200, 400 pfu) for 24 hours. After incubation, the viral entry has been 
analyzed measuring the GFP fluorescence by flow cytometry. The results 
obtained showed that the infection with AdGFP was achieved in both cellular 
types and the increase of fluorescence was dose-dependent (Figure 25). 
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Figure 25: AdGFP infection in vitro. L6 and L6PED have been infected with AdGFP (0, 100, 200, 
400 pfu for 24 hours) and analyzed by flow cytometry. The figure shows a dose-dependent increase in 
cellular fluorescence in both cell types. The bar graph represents mean ± s d of three different experiments 
in triplicate. 
 
 
 
In a second series of experiments, I used the AdβGal adenovirus. The 
protocol of infection with this adenovirus was identical to the previous one, 
and I evaluated viral entry in individual intact cells with in situ X-
Galactosidase staining. In infected cells, β-Galactosidase cleaves 5-bromo-4-
chloro-3-indoyl-β-galactopyranoside (X-Gal) to produce a blue stain. The viral 
entry has been determined by showing stained and unstained cells with a 
microscope in the total population. The blue cells, indeed, have been infected 
by AdβGal as compared to control cells (Figure 26). 
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L6 L6-Adβgal  
Figure 26: X-Galactosidase staining in vitro. X-Gal staining has been performed at 24 hours 
after infection with Adβgal (400 pfu). The positive cells (L6) were stained after infection and compared with 
uninfected cells. As shown in the figure X-Gal staining showed the viral entry. 
 
 
 
This data indicated that L6 cells were significantly infected by both 
adenoviruses AdGFP and AdβGal. Once obtained the results in vitro, I also 
performed the infection in vivo. In particular, I anesthetized six mice and then 
introduced the AdGFP (2 x 107 pfu in 200 µl) by intramuscular direct (i.m.) 
injection in quadriceps and tibialis muscles of both mouse’s paws. 
Subsequently, mice have been killed with 2,2,2-tribromoethanol overdose, the 
quadriceps and tibialis muscles have been quickly taken and keeped in dry-ice. 
The infection has been prolonged for several times to evaluate the time-course 
of AdGFP expression. The injected tissues have been processed as described in 
Matherials and Methods. Western blotting analysis demonstrated a time-
dependent increase in GFP expression after injection in the quadriceps and 
tibialis muscles compared with non infected tissues (Figure 27). The GFP 
protein, indeed, was increased in the muscle after 4 hours, and started to 
decrease after 8-12 hours. This expression was completely switched off after 
24-72 hours. These results were obtained in both Ped/Pea-15 transgenic mice 
and in their nontransgenic littermates (WT). 
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Figure 27: AdGFP infection in vivo. Western blotting analysis with anti-GFP antibody at 
different times after direct intramuscular injection of AdGFP (2 x 107 pfu in 200 µl) in the right and left hind 
legs of three months-old wild type and transgenic mice. 
 
 
 
Similar experiments were performed by using AdβGal. After direct 
intramuscular injection, mice have been killed at different times (0, 4, 8, 12, 
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24, 72 hours) and muscles have been homogenized and β-Galactosidase 
activity has been evaluated in the lysates. As shown in figure 28, the infection 
was time-dependent compared with control muscle infected with the vehicle 
alone.  
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Figure 28: AdβGal infection in vivo. The lysates of muscles from mice have been prepared and 
assayed for β-Galactosidase activity at different times as described in Matherials and Methods. The graph 
represents mean ± SD of three different experiments in triplicate. 
 
 
 
 
The expression of the AdGFP and the AdβGal adenoviruses 
demonstrated that infection with adenoviral constructs might represent a 
feasible strategy to express the gene of our interest both in cultured cells and in 
vivo. 
 
 
 
Generation of an adenovirus containing D4 fragment 
Next, I cloned D4 cDNA in the polylinker of the pAdTrack-CMV 
vector to generate the AdTrack-CMV-D4 adenovirus. I selected candidate 
colonies by their resistance to kanamycin provided by the shuttle vector and 
obtained the DNA from them. Furthermore, I digested DNA using Hind III-
Kpn I restriction enzymes to verify the presence of D4 fragment (Figure 29). 
The plasmid DNA preparation containing the GFP-D4 construct has 
been linearized with a restriction endonuclease and transformed together with a 
supercoiled adenoviral vector (pAdEasy-E1) into E.coli strain BJ5183. 
Recombinants have been selected with kanamycin and screened by restriction 
endonuclease digestion.  
The positive recombinant adenoviral construct has been linearized and 
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transfected in packaging cell lines (HEK293) to visualize the GFP reporter that 
was incorporated into the viral backbone. After 7-10 days viruses have been 
harvested and used directly for infection experiments either in vitro or in vivo. 
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Figure 29: Cloning D4 fragment in pAdTrack-CMV shuttle vector. Numbers indicates: λDNA-
HindIII marker (1), pUC Mix marker (2), pAdTrack-CMV vector (3), pAdTrack-CMV digested Hind III - Kpn I 
(4), PCR-derived D4 fragment (5), pAdTrack-CMV-D4 construct (6), pAdTrack-CMV and D4 fragment 
digested Hind III - Kpn I (7). 
 
 
 
To assess viral effect of AdTrack-CMV-D4 (Ad-D4) in the cells, L6 
and L6PED were infected with 100 pfu of adenovirus and glucose uptake was 
measured upon insulin (100 nM) stimulation. The Figure 30 shows that the 
AdTrack-CMV-D4 infection rescued insulin-stimulated glucose uptake in L6 
cells overexpressing PED/PEA-15 compared to their controls infected with 
AdGFP alone. By contrast, no difference was observed by infecting 
untransfected L6 cells. 
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Figure 30: Glucose uptake upon AdTrack-CMV-D4 infection. L6 and L6PED cells were infected 
with pAdTrack-CMV-D4 adenovirus (100 pfu). Then, the cells were exposed to 100 nM insulin and assayed 
for 2-DG uptake. Infection completely rescued the low levels of basal glucose uptake of the L6PED cells and 
restored maximal levels of insulin-stimulated uptake. Bars represent mean ± SD of three different 
experiments in triplicate. 
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CONCLUSIONS 
 
 
The generation of a cellular model overexpressing PED/PEA-15 protein 
has brought new insights in the study of the physiopathology of insulin-
sensitivity. 
The PED/PEA-15 overexpressing cells, indeed, feature an increase in 
stability and activity of PLD1, with subsequent activation of classical PKCs. 
The increase of PKCα, in turn, inhibits insulin-induced PKCζ activation and 
impairs GLUT4 translocation to the plasma membrane and glucose-uptake. 
Moreover, the Tg-ped/pea-15 mice ubiquitously, feature insulin-
resistance, accompanied by increased PLD1/PKCα signaling. The Tg-ped/pea-
15 mice, therefore, show a reduced glucose tolerance, which progress to overt 
diabetes under appropriate environmental conditions. 
Based on these observations, I tested the possibility that limiting 
PED/PEA-15/PLD1 interaction may improve insulin-sensitivity in vivo, and 
ameliorate glucose tolerance. 
Thus, the generation of a peptide able to block PED/PEA-15/PLD1 
interaction may represent a therapeutic tool to ameliorate insulin-sensitivity 
caused by PED/PEA-15 overexpression. 
Zhang et al. 2000, have previously identified in a yeast two-hybrid 
system a portion of phospholipase D1 interacting with PED/PEA-15 protein. 
This fragment, indeed, named D4 constitutes the minimal fragment of 
interaction between the two proteins.  
Here, I show that the expression of D4 fragment in HEK293 and L6 
cells decrease PED/PEA-15/PLD1 association, thereby reducing PKCα 
activation and restoring insulin-stimulated glucose uptake in cells 
overexpressing PED/PEA-15. 
This suggests that reduction of PED/PEA-15 interaction with PLD1 
represent a novel strategy to improve glucose tolerance in individuals with type 
2 diabetes. 
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293 kidney embryonic cells feature very low levels of
the anti-apoptotic protein PED. In these cells, expres-
sion of PED to levels comparable with those occurring in
normal adult cells inhibits apoptosis induced by growth
factor deprivation and by exposure to H2O2 or anisomy-
cin. In PED-expressing 293 cells (293PED), inhibition of
apoptosis upon growth factor deprivation was paral-
leled by decreased phosphorylation of JNK1/2. In 293PED
cells, decreased apoptosis induced by anisomycin and
H2O2 was also accompanied by block of JNK1/2 and p38
phosphorylations, respectively. Impaired activity of
these stress kinases by PED correlated with inhibition
of stress-induced Cdc-42, MKK4, and MKK6 activation.
At variance with JNK1/2 and p38, PED expression in-
creased basal and growth factor-stimulated Ras-Raf-1
co-precipitation and MAPK phosphorylation and activ-
ity. Treatment of 293PED cells with the MEK inhibitor
PD98059 blocked ERK1/2 phosphorylations with no ef-
fect on inhibition of JNK1/2 and p38 activities. Complete
rescue of JNK and p38 functions in 293PED cells by over-
expressing JNK1 or p38, respectively, enabled only par-
tial recovery of apoptotic response to growth factor dep-
rivation and anisomycin. However, simultaneous rescue
of JNK and p38 activities accompanied by block of
ERK1/2 fully restored these responses. Thus, PED con-
trols activity of the ERK, JNK, and p38 subfamilies of
MAPKs. PED anti-apoptotic function in the 293 cells
requires PED simultaneous activation of ERK1/2 and
inhibition of the JNK/p38 signaling systems by PED.
PED is a 15-kDa protein with almost ubiquitous expression
(1, 2). cDNA sequencing led to the identification of a canonical
death effector domain (DED)1 at PED N terminus (3, 4). More
recently, we and others (3, 5) demonstrated that the DED of
PED binds the DED of both FAS-associated death domain
(FADD) and caspase 8 (FLICE). Through this mechanism, PED
inhibits FLICE activation by tumor necrosis factor- and FasL,
thereby blocking the apoptotic effects of these cytokines. It has
subsequently been shown that PED potentiates phosphoryla-
tion of the ERKs through a Ras-dependent mechanism (6). PED
also anchors the ERKs in the cytoplasm, preventing phospho-
rylation of their nuclear susbstrates and restraining cell pro-
liferation (7). These findings suggest that PED may feature a
broad function in control of cell survival. However, the molec-
ular mechanisms involved in PED action have only partially
been elucidated.
Mitogen-activated protein kinases (MAPKs) play a major
role in mediating cellular responses to a variety of extracellular
stimuli, including death and survival signals (8, 9). MAPKs
include at least three main subgroups: the extracellular signal-
regulated kinases (ERK1/2 or p42/44MAPK), the c-Jun N-termi-
nal kinases (p46/54JNK), and p38MAPK. While structurally re-
lated, MAPK families undergo activation in response to
extracellular stimuli through distinct upstream dual specificity
kinases, thereby functioning in separate MAPK cascades (10,
11). The Raf/ERK kinase1/2/ERK1/2 cascade is stimulated by
mitogenic and survival stimuli, largely through the Ras-Raf-1-
dependent pathway (12, 13). At variance, p46/54JNK and
p38MAPK are primarily activated by cellular stresses including
oxidative agents, UV irradiation, hypoxia, proinflamatory cy-
tokines, and anisomycin (14, 15). Exposure to these agents
often results in cell apoptosis (16). Dual specificity kinases
activating p46/54JNK are MAPK kinases 4 and 7 (MKK4 and
MKK7), while MKK3 and MKK6 were proved to activate
p38MAPK. MAPKs phosphorylate and activate a variety of cy-
toplasmic and nuclear substrates, including transcription
factors.
Despite the dicotomy in the main action of ERKs and stress
kinases, current evidence indicates that ERKs and p46/54JNK-
p38MAPK cooperate in inducing cells to survive or to die. Acti-
vation of the stress kinase cascade, alone, may not be sufficient
to induce apoptosis under all circumstances (17). Also, concom-
itant inactivation of survival signals appears to be necessary
for enabling p46/54JNK and p38MAPK induction to cause cell
death (17–21). It appears therefore that the balance between
the ERK and the p46/54JNK-p38MAPK signaling systems is crit-
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ical for inducing the cell to die or survive. However, the molec-
ular mechanisms responsible for tuning the ratio of activities in
these cascades are largely elusive. For instance, there is little
information on whether checkpoint proteins exist in the cell
that foster survival signal transduction through the ERK path-
way while inhibiting p46/54JNK-p38MAPK signaling or vice
versa. Answering this question will greatly help in the under-
standing how the cells control their own survival.
In the present report we show that PED inhibits p46/54JNK
and p38MAPK signaling and protects cells from stress-induced
apoptosis. More importantly, we report that full PED anti-
apoptotic action requires both ERK activation and inhibition of
p46/54JNK-p38MAPK function, indicating that PED represents a
major MAPK regulatory protein, which gathers antiapoptotic
signals toward the cell machinery.
EXPERIMENTAL PROCEDURES
Materials—Media, sera, antibiotics for cell culture, and the Lipo-
fectAMINE reagent were from Invitrogen. Rabbit polyclonal antibodies
toward ERK1/2, p38, and JNK/SAPK were purchased from Santa Cruz,
Inc. (Santa Cruz, CA). All phosphokinase antibodies were from New
England Biolabs Inc. (Beverly, MA), and PED antibodies have been
described previously (2). The HA-tagged JNK-1 and GST-tagged MKK6
cDNA plasmids were generously donated by Dr. S. Gutkind (National
Institutes of Health, Bethesda, MD) and the GST-CRIB cDNA by Dr. P.
Di Fiore (Istituto Europeo di Oncologia, Milan, Italy). The c-Jun cDNA
has been reported previously (22). SDS-PAGE reagents were purchased
from Bio-Rad, and radiochemicals, Western blotting, and ECL reagents
were from Amersham Biosciences. All other chemicals were from
Sigma.
Cell Culture and Transfection and Cell Death Assays—The 293
human kidney embryonic cells were grown in DMEM supplemented
with 10% fetal calf serum, 100 IU/ml penicillin, 100 IU/ml streptomy-
cin, and 2% L-glutamine in a humidified CO2 incubator. A pcDNA3
expression vector containing the Myc-tagged PED cDNA was generated
by first amplifying PED wild-type cDNA with the following two prim-
ers: PED5 (5-GGCCGGTACCGCCAGAGCGCGCGGGGCAGTGTG-
3) and 3MycPEDB (5-CGCGGATCCTCACAGATCCTCTTCTGAGAT-
GAGTTTTTGTTCGGCCTTCTTCTTCGGTGGGGGAGCCAATTTGAT-
GATCTCTT-3), carrying the KpnI and the BamHI restriction sites,
respectively. The amplification product was then cloned in the pcDNA3
plasmid and sequence verified using the T7Sequencing Kit by
Amersham Biosciences. The construct was stably transfected in 293
cells using the lipofectamine method as in Ref. 2. Selection was ac-
complished using G418 at the effective dose of 0.8 mg/ml. Transient
transfections of JNK-1, MKK6, and c-Jun cDNAs were accomplished by
the LipofectAMINE method according to the manufacturer’s instruc-
tions. Briefly, cells were cultured in p60 dishes up to 80% confluence
and incubated for 24 h with 3 g of cDNA and 15 l of LipofectAMINE
in serum-free DMEM. An equal volume of DMEM supplemented with
20% fetal calf serum was added for 5 h. The medium was then replaced
with DMEM supplemeted with 10% serum and cells further incubated
for 24 additional hours before being assayed.
For detecting apoptosis, the cells were kept in the presence or the
absence of serum or incubated with 50 M anisomycin (18 h) or 500 nM
H2O2 (1 h) or 100 M PD98059 (18 h), as indicated in the description of
the individual experiments. Apoptosis was then assayed by DNA lad-
dering detection according to Ref. 23 or quantitated using the Apoptosis
ELISA Plus kit (Roche Diagnostics GmbH, Mannheim, Germany), ac-
cording to the manufacturer’s instructions.
Western Blot Analysis—For these assays, the cells were solubilized in
lysis buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 4 mM EDTA, 10 mM
Na4PO7, 2 mM Na3VO4, 100 mM NaF, 10% glycerol, 1% Triton, 1 mM
phenylmethylsulfonyl fluoride, 100 g/ml aprotinin, 1 mM leupeptin) for
30 min at 4 °C. Lysates were centrifuged at 5,000  g for 15 min.
Solubilized proteins were separated by SDS-PAGE and transferred on
0.45 m Immobilion-P membranes (Millipore, Bedford, MA). Upon in-
cubation with the primary and secondary antibodies, immunoreactive
bands were detected by ECL according to the manufacturer’s
instructions.
MAPK Activity and Cdc-42 GTP Loading—MAPK activity was as-
sayed in vitro as reported previously (24). Briefly, cells were solubilized
in lysis buffer and lysates clarified by centrifugation at 5,000  g for 20
min. Equal aliquots of the lysates (200 g) were immunoprecipitated
with MAPK antibodies, and phosphorylation reactions were initiated by
adding 2 g of the myelin basic protein substrate, the phosphorylation
mixture (20 mM Hepes, pH 7.2, 10 mM MgCl2, 10 mM MnCl2, 1 mM
dithiothreitol, 5 mM ATP, 0.2 mM EGTA, 1 mM PKA inhibitor, final
concentrations) and 10 Ci/reaction [-32P]ATP. Phosphorylation reac-
tions were prolonged for 30 min at 22 °C, stopped by rapid cooling on
ice, and spotted on phosphocellulose disc papers. Discs were washed
twice with 1% H3PO4, followed by additional washes in water, and the
disc-bound radioactivity was quantified by liquid scintillation counting.
For estimating GTP loading of Cdc-42, cells were incubated in the
presence or the absence of cytotoxic necrotizing factor 1 (CNF1) (30
ng/ml) for 6 h and solubilized in 1% Nonidet P-40, 25 mM Tris, pH 7.5,
5 mM MgCl2, 100 mM NaCl, 5% glycerol, 1 mM phenylmethylsulfonyl
fluoride, 1 g/ml leupeptin, and 2 mM Na3VO4. Protein lysates (1 mg)
were then incubated for 20 min at 4 °C in the presence of 10 g of
agarose-bound GST CRIB in 2 volumes of binding buffer (0.5% Nonidet
P-40, 25 mM Tris, pH 7.5, 30 mM MgCl2, 40 mM NaCl, 1 mM dithiothre-
itol). Complexes were washed four times with lysis buffer and then
resuspended in Laemli buffer followed by boiling for 4 min and centrif-
ugation at 25,000  g for 3 min. Supernatants were analyzed by
SDS-PAGE and blotting with Cdc-42 antibodies.
RESULTS
Reduced Apoptosis in PED-overexpressing 293 Cells—293
human embryonic kidney cells were stably transfected with a
Myc-tagged PED cDNA. Several clones of PED-overexpressing
cells were obtained and three of them, termed 293PEDCl1,
293PEDCl2, and 293PEDCl3, were studied in detail. Immunoblot-
ting with either Myc or PED antibodies indicated that the
expression of PED in these transfected cells was increased by
100-fold compared with control cells, either those transfected
with the resistance plasmid alone (293PC) or the 293 untrans-
fected cells (293WT) (Fig. 1A). The 293WT cells feature very low
levels of endogenous PED. On a per milligram protein bases,
the levels of PED expression achieved in the transfectants were
comparable with those in mouse brain and fat tissues (data not
shown). Based on DNA laddering, serum deprivation of paren-
tal cells induced a time-dependent increase in DNA fragmen-
tation (Fig. 1B). In these cells, fragmentation was well detect-
able upon 24 h of serum deprivation, further increasing upon
48 and 72 h. At variance, no DNA fragmentation was observed
in PED-transfected cells up to 48 h after serum deprivation. In
these cells, apoptosis became detectable only by 72 h. The same
delay in the onset of DNA laddering in response to serum
starvation was observed in the two other transfected clones
(data not shown). To further investigate PED apoptosis-protec-
tive action, we compared the effects of the stress kinase acti-
vators anisomycin and hydrogen peroxyde in 293PEDCl1 and
control cells. As shown in Fig. 1C, treatment with anisomycin
for 18 h increased apoptosis by 3-fold in parental 293WT and
293PC cells, same as 48-h serum deprivation. In these same
cells, 1-h incubation with hydrogen peroxyde induced a 5-fold
increase in apoptosis. In 293PEDCl1 cells there was a 2-fold
inhibition in the apoptotic responses to all of these agents,
compared with the control cells (p  0.001). Almost identical
inhibition of apoptosis was observed in the other two clones of
PED-overexpressing cells.
JNK and p38 Function in PED-overexpressing 293 Cells—In
different cell types, the MAPK-related enzymes JNK and p38
play a major role in signaling apoptosis and undergo phospho-
rylation and activation in responses to growth factor with-
drawl, anisomycin, and oxidative stress (19–21). In control 293
cells, anisomycin also induced a 10-fold increase in phospho-
rylation of the key activation sites of JNK (Thr183 and Tyr185;
Fig. 2A). Anisomycin-induced phosphorylation was reduced by
3-fold in PED-transfected compared with the control cells with
no change in JNK expression levels. Similar to anisomycin,
serum deprivation increased JNK phosphorylation in 293WT
cells. This effect peaked at 10–16 h after serum starvation and
was 2.5-fold less evident in the 293PEDCl1 cells (Fig. 2B). The
decrease in JNK phosphorylation upon anisomycin treatment
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or serum starvation was paralleled by a 2.5-fold decreased
phosphorylation of the JNK substrate c-Jun in the PED-over-
expressing compared with control cells (Fig. 2C). Based on
Western blotting with specific phospho-p38 antibodies, hydro-
gen peroxide and serum deprivation treatments of control cells
also increased phosphorylation of p38 key activation sites
(Thr180, Thr182) by 6- and 2.5-fold, respectively (Fig. 3, A and
B). Phosphorylation of p38 by hydrogen peroxide and serum
deprivation were 2- and 4-fold inhibited in PED-transfected
cells. Control experiments with the 293PEDCl2 and 293PEDCl3
cells revealed very similar results (data not shown).
In Chinese hamster ovary cells, PED overexpression induces
ERK1/2 signaling through the Ras pathway (6). We therefore
hypothetized that increased ERK1/2 activity may be responsi-
ble for inhibiting JNK and p38 function in 293 PED-transfected
cells. As in PED-overexpressing Chinese hamster ovary cells,
extracts from 293 PED-expressing cells featured a 2.5-fold in-
creased Raf-1 co-precipitation with active Ras (Fig. 4A). In
addition, the 293 PED-transfected cells showed a constitutive
increase in ERK1/2 phosphorylation and activity (Fig. 4, B and
C). Further increase in ERK phosphorylation and activity in
response to serum were reduced in these cells, with no signif-
icant change in ERK1/2 expression.
In both the PED-transfected and the control cells, inhibition
of the ERK upstream kinase MEK with PD98059 blocked basal
and serum-stimulated ERK activities (Fig. 5A). Interestingly,
however, PD98059 had no effect on the impaired activation of
JNK by anisomycin in 293PEDCl1 cells (Fig. 5B). Similarly,
PD98059 treatment did not allow any recovery of p38 phospho-
rylation by hydrogen peroxide in PED-expressing as compared
with wild-type cells (Fig. 5C) and to cells transfected with the
empty plasmid (not shown). Thus, ERK activation, alone, did
not account for the inhibition of JNK and p38 functions in
PED-overexpressing cells.
Cdc-42 Signaling in PED-overexpressing 293 Cells—JNK
and p38 have been reported to be induced by the Cdc-42/PAK-1
signaling cascade in response to different stress-inducing
agents (25). In 293 cells, CNF1 (26) increased the pull-down of
the CRIB interaction domain of PAK-1 kinase with Cdc-42 by
4-fold (Fig. 6A). These effects did not occur in PED-expressing
293 cells, however. Phosphorylation of the key activation sites
on PAK-1 downstream kinases MKK4 and MKK6 (Thr223 and
Ser189/Ser207, respectively) were also increased by 8- and 2.5-
fold by anisomycin and hydrogen peroxide (Fig. 6B). As was the
case for the CRIB-Cdc-42 interaction, these effects were abol-
ished in the 293PEDCl1 cells, suggesting that PED may inhibit
JNK and p38 activation by blocking signaling through the
FIG. 1. PED action on stress-induced apoptosis in 293 cells. A,
293 human embryonic kidney cells were stably transfected with a
Myc-tagged PED cDNA as indicated. PED-overexpressing cell clones
(293PEDCl1, 293PEDCl2, 293PEDCl3) and control cells (untransfected cells,
293WT; cells transfected with the empty plasmid, 293PC) were solubi-
lized and immunoblotted with Myc, PED, or actin antibodies, as indi-
cated. Blotted proteins were revealed by ECL and autoradiography. B,
alternatively, the cells were incubated in the absence or the presence of
10% serum for the indicated times. Cytoplasmic DNA was extracted
and analyzed by 1.2% agarose gel electrophoresis and ethidium bromide
staining. Representative experiments are shown in A and B. C, the cells
were incubated in the absence or the presence of 10% serum (48 h), 50
M anisomycin (18 h), or 500 nM H2O2 (1 h), as indicated. Apoptosis was
quantitated by the ELISA Plus detection kit as described under “Ex-
perimental Procedures.” Bars represent the mean  S.D. of four inde-
pendent experiments in duplicate.
FIG. 2. PED action on JNK activity in 293 cells. A, 293PEDCl1 and
control cells were incubated with 50 M anisomycin for 30 min. The cells
were solubilized, and 50 g of cell proteins were blotted with phospho-
JNK (pJNK1/2) or JNK (JNK1/2) antibodies. Filters were revealed by
ECL according to the manufacturer’s instructions. Alternatively (B),
the cells were incubated in the presene or the absence of serum for the
indicated times, solubilized, and blotted with pJNK1/2 antibodies as
above. C, to test JNK activity, cells were first transfected with c-Jun
cDNA as reported under “Experimental Procedures.” The cells were
then exposed to anisomycin for 30 min. Phospho-c-Jun was identified by
Western blotting equal amounts of cell lysates with phospho-c-Jun
antibodies. The autoradiographs shown are representative of four (A)
and three (B) representative experiments.
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Cdc-42/PAK-1 pathway at an upstream step. There were no
changes in the expression levels of Cdc-42, MKK4, and MKK6
(Fig. 6, A and B) in PED-overexpressing compared with the
control cells.
ERK and JNK/p38 Function in PED Anti-apoptotic Ef-
fect—To further investigate the hypothesis that abrogation of
JNK and p38 activation is responsible for PED anti-apoptotic
effect, we sought to force JNK and p38 function in PED-ex-
pressing 293 cells. We transfected the cells with the HA-tagged
JNK-1, GST-tagged MKK6, or with both cDNAs. Western blot
analysis with phospho-JNK and phospho-p38 antibodies re-
vealed that these overexpressions activated JNK and p38 ki-
nases to almost identical extents in 293PEDCl1 and in control
cells (Fig. 7A), indicating that kinase overexpression succeeded
in overcoming their inhibition by PED. Consistently, co-trans-
fection of JNK-1 with the c-Jun substrate cDNA resulted in a
4-fold increase in c-Jun phosphorylation compared with the
cells transfected with c-Jun alone, both in 293PEDCl1 and in
control cells (Fig. 7B). In the control cells, overexpression of
JNK-1 or MKK6 increased apoptosis in response to serum
deprivation by 2.2-fold (Fig. 7C). Simultaneous overexpression
of these two kinases showed no additive effect. In the PED-
transfected cells, overexpression of JNK-1, MKK6, or both
cDNAs caused a 70% increase in cell apoptosis, bypassing PED
inhibition (difference with the 293WT cells significant at the p
0.01 level). Thus, despite full activation of JNK and p38 func-
tion in these cells, apoptosis remained significantly lower than
that in the 293WT cells. This finding suggested that the inhibi-
tion of JNK and p38 by PED overexpression in 293 cells does
not fully account for PED anti-apoptotic effect.
We therefore tested whether induction of ERK1/2 in PED-
overexpressing cells may also contribute to protection from
apoptosis, while not accounting for the inhibition of JNK and
p38. To this end, we blocked ERK activity with the PD98059
inhibitor. Treatment of serum-deprived cells with PD98059,
alone, caused no change in apoptosis, either in control or in
PED-expressing cells. In control cells overexpressing JNK-1
and/or MKK6, however, PD98059 enhanced apoptotic response
by 50%. Interestingly, in PED-transfected cells overexpressing
JNK-1 and/or MKK6, PD98059 treatment increased apoptosis
to levels identical to the control cells. Similar data were ob-
tained when cell apoptosis was induced by actinomycin rather
than serum depletion. Thus, PED protection from stress-in-
duced apoptosis in 293 cells appeared to depend on the simul-
taneous induction of ERK activity and inhibition of JNK and
p38 function.
DISCUSSION
We have recently identified PED as a DED-containing pro-
tein, which blocks FasL- and tumor necrosis factor--induced
apoptosis through its DED. In the present report, we show that
PED features a broader biological function, forwarding mutu-
FIG. 3. PED action on p38 phosphorylation. A, 293PEDCl1 and
control cells were exposed to 500 nM H2O2 for 30 min. The cells were
solubilized, and 50 g of cell proteins were blotted with phospho-p38
(P-p38) or with p38 antibodies as indicated. Alternatively (B), the cells
were incubated in the presence or the absence of serum for the indicated
times, and cell proteins were immunoblotted with P-p38 antibodies as
outlined above. Filters were revealed by ECL and autoradiography. The
autoradiographs shown are representative of four (A) and three (B)
independent experiments.
FIG. 4. PED effect on Ras-Raf-1 co-precipitation and MAPK
activation. A, 293PEDCl1 and control cells were solubilized as described
under “Experimental Procedures” and lysates (200 g of protein/sam-
ple) immunoprecipitated with either pan-Ras (Ras) or nonspecific IgG
(C), as indicated. Precipitated proteins were Western blotted with Raf-1
antibodies. For control, whole cell lysates were also blotted with Raf-1
antibodies (Raf-1) or Ras antibodies (Ras). B, 293PEDCl1 and control cells
were exposed to 10% serum for 20 min as described under “Experimen-
tal Procedures.” The cells were then solubilized and cell proteins (50 g)
blotted with phospho-ERK (P-ERK1/2) or ERK antibodies. Filters were
revealed by ECL and autoradiography. The autoradiographs shown are
representative of three (A) and four (B) independent experiments. C,
cell lysates from control and serum-stimulated cells (200 g of protein)
were precipitated with MAPK antibodies. Precipitates were assayed for
MAPK activity using MBP as substrate as described under “Experi-
mental Procedures.” Bars represent the mean  S.D. from four dupli-
cate experiments.
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ally reinforcing survival and anti-apoptotic signals to the cell
machinery through the ERK and the JNK-p38 pathways.
We found that PED overexpression in 293 kidney cells
strongly inhibits apoptosis caused by serum deprivation, oxi-
dative stress, and anisomycin treatment. Simultaneously, PED
blocks phosphorylation and activation of JNK and p38 by these
agents, indicating an important role of decreased signaling
through the JNK-p38 system in PED protection from stress-
induced apoptosis. Consistent with this mechanism, forced ex-
pression of JNK and p38 activities rescues the sensitivity to
stress-induced apoptosis in PED-overexpressing 293 cells. In
parallel with the block of stress-induced activation of JNK and
p38, their upstream activating kinases MKK4 and MKK6 were
also blocked in PED-overexpressing cells. In addition, in these
cells, PED inhibits Cdc-42 co-precipitation with the crib inter-
action domain of PAK-1, suggesting that high levels of PED
may inhibit Cdc-42 signaling. Collectively, these data indicate
that PED may prevent induction of JNK and p38 stress kinases
by acting at a very early step in their activation pathways. It is
possible that PED binds PAK-1 and inhibits its interaction
with Cdc-42. However, we could not detect co-precipitation of
PED with PAK-1 (data not shown). Alternatively, PED may
inhibit Cdc-42 activation, either by interacting with Cdc-42 or
with a protein upstream Cdc-42 in the signaling cascade. Un-
derstanding the mechanism of PED activation of JNK and p38
stress kinases will require the identification of PED-binding
proteins, which is presently in progress in our laboratory.
Studies by Ramos et al. (6) showed that, in Chinese hamster
ovary cells, PED activates ERK1/2 in a Ras-dependent manner.
ERK activation by PED also occurs in 293 cells, accompanied
by that of early mechanisms in the Ras signaling cascade.
Activation of the ERKs was not responsible for the inhibition of
JNK and p38 function in cells expressing high levels of PED.
Hence, block of ERK activity with the PD98059 inhibitor
caused no change in JNK-p38 inactivation in the 293PED cells.
PD98059 treatment does not affect apoptosis caused by serum
deprivation either in wild-type 293 cells (expressing almost no
endogenous PED) or in PED-overexpressing cells. Thus, ERK
activity, alone, is unable to prevent stress-induced apoptosis in
these cells. Rescue of JNK-p38 activities in PED-overexpress-
ing 293 cells is not sufficient either, since it did not allow
complete recovery of sensitivity to stress apoptosis. Interest-
ingly, the full apoptotic effect of serum deprivation and aniso-
mycin in PED-overexpressing 293 cells were restored by simul-
taneous block of ERK activation and reintegration of JNK-p38
function. This finding led us to propose that (i) in 293 cells,
PED operates as a major survival protein, which simulta-
neously controls the major mitogen-activated protein kinases;
and (ii) in these cells, stress-induced activation of apoptotic
programs depends on the concomitant inhibition of ERK sur-
vival pathway and on activation of death signaling through the
JNK-p38 routes.
Triggering of stress-activated kinases in concomitance with
the inhibition of the ERK pathway has been observed in a
number of cell systems undergoing programmed cell death
(17–21). Activation of the stress kinase cascade may not always
be sufficient to induce apoptosis in the cell (17). In fact, con-
comitant inactivation of survival signals has been proposed to
be a prerequisite for the JNK-p38 kinases to induce cell death
(17–21). Thus, the balance between the ERK and the JNK-p38
signaling systems seems critical for enabling the cell to die or
survive. How the cells control this balance has been less exten-
sively investigated. The pathways leading to activation of
FIG. 5. Effect of MAPK inhibition on JNK and p38 activation.
A, 293PEDCl1 and control cells were preincubated in serum-free medium
for 18 h, exposed to 50 M PD98059 for further 45 min, and then to 10%
serum for 10 min as indicated. Cells were solubilized, and lysates (50 g
of protein) were Western blotted with phospho-ERK antibodes (P-
ERK1/2). B, the cells were preincubated in serum-free culture medium
for 18 h in the presence or the absence of PD98059 and further incu-
bated for 30 min with either 50 M anisomycin or 500 nM H2O2, as
indicated. Cells were then solubilized and cell protein (50 g) immuno-
blotted with either phospho-JNK (P-JNK) or phospho-p38 (P-p38) an-
tibodies. Filters were revealed by ECL and autoradiography. The auto-
radiographs shown are representative of three (A and C) and four (B)
independent experiments.
FIG. 6. PED action on Cdc-42, MKK4, and MKK6 activation. A,
293PEDCl1, untransfected 293 cells (293WT), and cells transfected with
the empty plasmid (293PC) were exposed to CNF1 (30 ng/ml) for 6 h as
indicated. The cells were solubilized, and lysates (500 g of cell protein)
were incubated with 10 g of agarose-bound GST-CRIB. The complex
was then analyzed by SDS-PAGE followed by Western blotting with
Cdc-42 antibodies. B, the cells were exposed for 30 min to 50 M
anisomycin or 500 nM H2O2, as indicated. The cells were solubilized,
and cell lysates (50 g of protein) were blotted with phospho-MKK6
(P-MKK6), MKK6, phospho-MKK4 (P-MKK4), or MKK4 antibodies, as
indicated. Filters were revealed by ECL and autoradiography. The
autoradiographs shown are representative of four (A and B, left panels)
and three (A and B, right panels) independent experiments.
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ERKs and of JNK-p38 consist of multiple signaling compo-
nents, most of which are regulated by protein phosphorylation.
Cross-talk may occur between these pathways and contribute
to regulate ERK/JNK-p38 activity balance. Consistent with
this possibility, simple inhibition of ERK basal activity in HeLa
cells has been recently reported to be sufficient to trigger p38
activation in a caspase-dependent manner (27). It has also been
proposed that ERK and JNK-p38 pathways may down-regulate
each other by turning on the expression of phosphatases, which
act on the other (28). In the present report, we show that
increasing the PED expression level in cells simultaneously
fosters ERK survival function and inhibits JNK-p38 apoptotic
signaling in 293 cells. Thus, changing PED expression may
represent a third mechanism for the cell to control the balance
between ERK and JNK-p38 activities and to foster cell
survival.
Most recently, PED has been shown to possess a nuclear
export sequence (7). Through this sequence, PED was reported
to restrict ERKs to the cytoplasm in cultured astrocytes (7).
The cytoplasmic anchoring of ERKs does not affect phosphoryl-
ation of their cytosolic substrates, but inhibits ERK-dependent
c-Fos transcription and cell proliferation. Inhibition of cell pro-
liferation also occurs in 293 cells overexpressing PED (data not
shown). Thus, PED is a multifunctional protein. Increasing its
level may allow the cells to become quiescent and resistant to
different kinds of apoptotic stimuli.
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FIG. 7. Effect of JNK-1 and MKK6 overexpression on apoptosis
in 293PED cells. A, 293PEDCl1 and control cells were transiently trans-
fected with HA-tagged c-JNK-1 and/or GST-tagged MKK6 cDNAs. For
control, lysates from the transfected cells (100 g of protein) were
separated by SDS-PAGE followed by blotting with HA, GST, phospho-
JNK (P-JNK), or phospho-p38 (P-p38) antibodies, as indicated. B, to
control the activity of the transfected JNK-1 cDNA, the cells were
further transfected with HA-tagged c-JNK-1 and/or c-Jun cDNAs, as
indicated and cell proteins blotted with phospho c-Jun antibodies (P-c-
Jun). Filters were revealed by ECL and autoradiography. Representa-
tive autoradiographs are shown. C, the cells were subsequently exposed
to 50 M PD98058 for 18 h, as indicated, and apoptosis was quantified
by the ELISA plus apoptosis detection kit as described under “Experi-
mental Procedures.” Bars represent the mean  S.D. of four independ-
ent experiments in duplicate.
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Protein Kinase B/Akt Binds and Phosphorylates PED/PEA-15,
Stabilizing Its Antiapoptotic Action
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The antiapoptotic protein PED/PEA-15 features an Akt phosphorylation motif upstream from Ser116. In
vitro, recombinant PED/PEA-15 was phosphorylated by Akt with a stoichiometry close to 1. Based on Western
blotting with specific phospho-Ser116 PED/PEA-15 antibodies, Akt phosphorylation of PED/PEA-15 occurred
mainly at Ser116. In addition, a mutant of PED/PEA-15 featuring the substitution of Ser1163Gly (PEDS1163G)
showed 10-fold-decreased phosphorylation by Akt. In intact 293 cells, Akt also induced phosphorylation of
PED/PEA-15 at Ser116. Based on pull-down and coprecipitation assays, PED/PEA-15 specifically bound Akt,
independently of Akt activity. Serum activation of Akt as well as BAD phosphorylation by Akt showed no
difference in 293 cells transfected with PED/PEA-15 and in untransfected cells (which express no endogenous
PED/PEA-15). However, the antiapoptotic action of PED/PEA-15 was almost twofold reduced in PEDS1163G
compared to that in PED/PEA-15WT cells. PED/PEA-15 stability closely paralleled Akt activation by serum in
293 cells. In these cells, the nonphosphorylatable PEDS1163G mutant exhibited a degradation rate threefold
greater than that observed with wild-type PED/PEA-15. In the U373MG glioma cells, blocking Akt also reduced
PED/PEA-15 levels and induced sensitivity to tumor necrosis factor-related apoptosis-inducing ligand apo-
ptosis. Thus, phosphorylation by Akt regulates the antiapoptotic function of PED/PEA-15 at least in part by
controlling the stability of PED/PEA-15. In part, Akt survival signaling may be mediated by PED/PEA-15.
PED/PEA-15 is a recently identified cytosolic protein fea-
turing ubiquitous expression (8, 6). PED/PEA-15 has been
shown to exert antiapoptotic action through distinct mecha-
nisms. First, PED/PEA-15 inhibits formation of the death-
inducing signaling complex (DISC) and caspase 3 activation by
different apoptotic cytokines including FASL, tumor necrosis
factor alpha, and tumor necrosis factor-related apoptosis-in-
ducing ligand (TRAIL) (7, 16, 22). At least in part, this action
is accomplished through the death-effector-domain of PED/
PEA-15 upon PED/PEA-15 recruitment to the DISC (7, 16,
22). Secondly, PED/PEA-15 inhibits the induction of different
stress-activated protein kinases (SAPKs) triggered by growth
factor deprivation, hydrogen peroxide, and anisomycin (5).
This action of PED/PEA-15 is exerted by the blocking of an
upstream event in the SAPK activation cascade (5) and re-
quires the interaction of PED with ERK1/2 (14, 17).
PED/PEA-15 is phosphorylated at Ser116 by calcium-calmod-
ulin kinase II (CaMKII) (2) facilitating further phosphoryla-
tion by protein kinase C (PKC) at Ser104 (23). Thus, PED/
PEA-15 is present in the cell in the unphosphorylated (N),
singly phosphorylated (Pa), and doubly phosphorylated (Pb)
forms. Previous studies have shown that only the Pb form of
PED/PEA-15 can be recruited to the DISC and inhibit TRAIL
apoptotic signaling (31). In addition, the antiapoptotic action
of PED/PEA-15 requires PKC activity (7, 16, 22), indicating
that, in the cell, PED/PEA-15 function is regulated by phos-
phorylation. However, whether kinases different from PKC
and CaMKII may trigger survival or antiapoptotic signals by
regulating PED/PEA-15 function is currently unknown.
Akt/PKB is a serine/threonine kinase that plays a major role
in transducing proliferative and survival signals intracellularly
(15, 21, 25). Akt/PKB has been demonstrated to phosphorylate
a number of proteins involved in apoptotic signaling cascades,
including the BCL2 family member BAD (12), the protease
caspase 9 (4), the Forkhead transcription factor FRLH (3),
and p21CipWAF1 (24). Phosphorylation of these proteins pre-
vents apoptosis through several different mechanisms. For in-
stance, unphosphorylated BAD induces cell death by forming
heterodimers with BCL-XL and generating BAX homodimers
(12). Upon activation of Akt/PKB, phosphorylated BAD pro-
motes cell survival by binding the 14-3-3 protein, which pre-
vents BAD association to BCL-XL (12). At variance, in the
case of p21CipWAF1, phosphorylation by Akt/PKB results in
increased stability, promoting cell survival (24).
The finding that PED/PEA-15 possesses a low-stringency
Akt/PKB phosphorylation consensus led us to analyze the pos-
sibility that PED/PEA-15 may also represent a relevant Akt/
PKB substrate and that PED/PEA-15 phosphorylation by this
kinase may regulate the antiapoptotic function of PED/PEA-
15. In the present work we demonstrate that Akt, in addition to
CaMKII, phosphorylates PED at Ser116 in vitro and in vivo,
regulating PED/PEA-15 function on cellular apoptosis. In part,
Akt survival signaling may be mediated by PED/PEA-15.
* Corresponding author. Mailing address: Dipartimento di Biologia
e Patologia Cellulare e Molecolare, Universita` di Napoli Federico II,
Via S. Pansini, 5, 80131 Naples, Italy. Phone: 39 081 7463248. Fax: 39
081 7463235. E-mail: beguino@unina.it.
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MATERIALS AND METHODS
Materials. Media, sera, and antibiotics for cell culture and the Lipofectamine
reagent were purchased from Invitrogen Ltd. (Paisley, United Kingdom). Rabbit
polyclonal Akt antibodies were from Santa Cruz Biotechnology (Santa Cruz,
Calif.), and phosphokinase antibodies were from New England Biolabs Inc.
(Beverly, Mass.). PED/PEA-15 antibodies have been previously reported (6).
The HA-Akt, HA-Aktm4-129, and HA-AktK179M plasmids were donated by G. L.
Condorelli (La Sapienza University of Rome) and have been previously reported
(13), while recombinant Akt (rAkt) was purchased from Upstate Biotechnology
Inc. (Lake Placid, N.Y.). Antisera against phospho-Serine116 PED/PEA-15
(pSer116 PED Ab) were prepared in rabbits by PRIMM (Milan, Italy) by using
the PED/PEA-15 KLH-conjugated phosphopeptide NH2-CKDIIRQP(Sp)EEEI
IKLAP-COOH. The specificity of this antiserum is shown in Fig. 2 in the present
paper. The S70 (HIFEISRRPDLL), S104 (LTRIPSAKKYKD), and S116 (IIRQP
SEEIIK) PED/PEA-15 dodecapeptides were also synthesized by PRIMM. So-
dium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) reagents
were purchased from Bio-Rad (Richmond, Va.). Western blotting and ECL
reagents and radiochemicals were from Amersham (Arlington Heights, Ill.). All
other reagents were from Sigma (St. Louis, Mo.).
Plasmid preparation, cell culture, and transfection and apoptosis assays.
The PEDS1163G and PEDS1043G mutant cDNAs were prepared by using a
pcDNA3PED/PEA-15 cDNA and the site-directed mutagenesis kit by Strat-
agene (Heidelberg, Germany) according to the kit manufacturer’s instructions.
Sequences were confirmed by the Sanger method with the T7 sequencing kit
(Pharmacia-LKB, Milan, Italy). Stable expression of the mutant cDNAs in 293
cells was achieved as reported in reference 5. The 293 cells expressing the
wild-type PED/PEA-15 cDNA have been described in reference 16. The cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum, 100 IU of penicillin/ml, 100 IU of streptomycin/ml,
and 2% L-glutamine in a humidified CO2 incubator as reported in reference 5.
Transient transfection of wild-type or mutant Akt cDNAs in these cells was
accomplished by using the Lipofectamine method according to the manufactur-
er’s instructions. Briefly, the cells were cultured in 60-mm-diameter dishes and
incubated for 24 h in serum-free DMEM supplemented with 3 g of cDNA and
15 l of Lipofectamine reagent. An equal volume of DMEM supplemented with
20% fetal calf serum was then added for 5 h, followed by replacement with
DMEM supplemented with 10% serum for 24 h before the assays. The U373MG
human glioma cells were generously provided by C. Hao (University of Alberta,
Edmonton, Canada). These cells were cultured and transfected as described in
reference 16.
Apoptosis was quantitated by using the Apoptosis ELISA Plus kit (Roche
Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s in-
structions.
Western blot analysis, PED/PEA-15 phosphorylation, and determination of
Akt activity. For Western blotting, the cells were solubilized in lysis buffer (50
mM HEPES [pH 7.5], 150 mM NaCl, 4 mM EDTA, 10 mM Na4PO7, 2 mM
Na3VO4, 100 mM NaF, 10% glycerol, 1% Triton X-100, 1 mM phenylmethyl-
sulfonyl fluoride, 100 mg of aprotinin/ml, 1 mM leupeptin) for 60 min at 4°C. Cell
lysates were clarified at 5,000  g for 15 min. Solubilized proteins were then
separated by SDS-PAGE and transferred onto 0.45-m-pore-size Immobilon-P
membranes (Millipore, Bedford, Mass.). Upon incubation with the primary and
secondary antibodies, immunoreactive bands were detected by ECL according to
the manufacturer’s instructions.
For studying phosphorylation of PED/PEA-15 in intact cells, 293 cells were
transiently transfected with the different Akt constructs as indicated. After 24 h,
the cells were rinsed with 150 mM NaCl, incubated in phosphate- and serum-free
culture medium for 16 h at 37°C, and then further incubated for 8 h in this same
medium supplemented with 200 Ci of [32P]orthophosphate/ml. Insulin (final
concentration, 100 nM) was then added, and the cells were rapidly rinsed with
ice-cold saline followed by solubilization with 0.5 ml of lysis buffer per dish for 1 h
at 4°C. Lysates were centrifuged at 5,000  g for 20 min, and solubilized proteins
were precipitated with PED/PEA-15 antibodies, separated by SDS-PAGE, and
revealed by autoradiography. In these assays, insulin action on PED phosphor-
ylation was dose dependent, with half-maximal effect at 3 nM and maximal effect
at 100 nM.
Akt activity was assayed in vitro as previously reported (11). Briefly, 293 cells
expressing either the wild-type or the mutant PED/PEA-15 cDNAs were solu-
bilized in lysis buffer and lysates were clarified by centrifugation at 5,000  g for
20 min. Two hundred micrograms of the lysates were immunoprecipitated with
Myc antibodies. The precipitates (or 2 g of recombinant PED) were incubated
in a kinase reaction mixture containing 20 mM HEPES [pH 7.2], 10 mM MgCl2,
10 mM MnCl2, 1 mM dithiothreitol, 5 mM ATP, 0.2 mM EGTA, 1 mM protein
kinase inhibitor, 10 Ci of [-32P]ATP, and 0.4 g of rAkt or Akt or CaMKII
immunoprecipitates, as indicated. Alternatively, rAkt was incubated in the kinase
reaction mixture in the presence of 1 mM concentration of the S70, S104, or S116
PED/PEA-15 dodecapeptides. Phosphorylation reactions were prolonged for 10
min, stopped by cooling on ice, and spotted on phosphocellulose disk papers.
Disks were washed with 1% H3PO4, and disk-bound radioactivity was quantified
by liquid scintillation counting. Alternatively, phosphorylated proteins were sep-
arated by SDS-PAGE and analyzed by autoradiography. The stoichiometry of
PED phosphorylation by Akt and CaMKII was determined by allowing the
reactions to proceed for 1 h at 30°C in the presence of excess kinase to saturate
the reaction mixture. The number of moles of phosphate transferred per mole of
recombinant PED was calculated based on a [-32P]ATP standard curve.
PED/PEA-15–Akt interaction. To investigate the interaction of PED/PEA-15
with Akt, PED/PEA-15–glutathione S-transferase (GST) fusion protein was gen-
erated. To this end, wild-type PED/PEA-15 cDNA was amplified by using the
following two sets of primers: PED/PEA-15 5EcoRI (5-CCGGAATTCATGG
TTGAGTACGGGACCCTC-3) and PED/PEA-15 3SalI (5-GTCGACTCAG
GCCTTCTTCGGTGGGGGGACC-3). PED/PEA-15 cDNA was then cloned
in the pGEX 4T1plasmid, and the sequence was confirmed by using the T7
sequencing kit. Lysates from Akt-transfected cells (500 g) or 0.4 g of recom-
binant Akt were incubated in the presence of 50 l of Sepharose-bound GST–
PED/PEA-15 (approximately 2 g) for 2 h at 4°C. Beads were washed four times
with TNT buffer (0.5% NP-40, 25 mM TRIS [pH 7.5], 30 mM MgCl2, 40 mM
NaCl, 1 mM dithiothreitol) and then resuspended in Laemmli buffer followed by
boiling for 4 min and centrifugation at 25,000  g for 3 min. Supernatants were
analyzed by SDS-PAGE and blotting with Akt antibodies.
RESULTS
In vitro phosphorylation of PED/PEA-15 by Akt. PED/PEA-
15 sequence analysis revealed the presence of a low-stringency
Akt phosphorylation motif including the Ser116 residue of
PED/PEA-15 (Fig. 1A). To verify the hypothesis that PED/
PEA-15 is an Akt substrate, we first expressed the hemagglu-
tinin (HA)-tagged wild-type Akt (AktWT), the constitutively
active HA-Aktm4-129 (AktD), and the inactive HA-AktK179
M mutant cDNAs (AktD-) in 293 human embryonic kidney
cells, because these cells express no detectable levels of endog-
enous PED/PEA-15. HA antibody-precipitated Akt from these
cells was then tested for its ability to phosphorylate His-tagged
recombinant PED/PEA-15 in vitro. SDS-PAGE analysis of the
phosphorylation mixtures revealed that wild-type Akt induced
PED/PEA-15 phosphorylation (Fig. 1B). The constitutively ac-
tive Akt induced fourfold-greater phosphorylation of PED/
PEA-15 than did wild-type Akt. In contrast, precipitated inac-
tive Akt or HA precipitates from cells transfected with the
empty vector (PC) did not. Blotting with PED/PEA-15 and HA
antibodies revealed that these variations were not due to dif-
ferences in the amounts of either PED/PEA-15 or Akt in the
assays. In addition, blotting with specific antibodies toward the
key Akt Serine activation site (serine473; P-Akt) showed that
the different phosphorylation levels of PED/PEA-15 closely
paralleled the Akt activation state in each assay. Endogenous
Akt precipitated from 293 cells upon stimulation with 100 nM
insulin also induced a fivefold increase in PED/PEA-15 phos-
phorylation over the level observed with unstimulated cells
(Fig. 1C). Again, blotting with PED/PEA-15, Akt-1, and phos-
pho-Akt antibodies indicated that the changes in PED/PEA-15
phosphorylation reflected differences in the activation state of
Akt rather than different amounts of Akt or PED/PEA-15 in
the assays. PED was indeed phosphorylated by Akt with a
stoichiometry of 0.82 mol of phosphate/mol of recombinant
PED, a value close to that observed in the case of CaMKII
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phosphorylation (0.87 mol of phosphate/mol of PED; the dif-
ference is not statistically significant).
Identification of PED/PEA-15 phosphorylation site by Akt.
To prove that the Ser116 of PED/PEA-15 is phosphorylated by
Akt, we generated a cDNA mutant of PED/PEA-15 featuring
the Ser1163Gly substitution. We then stably expressed the
PED/PEA-15 Ser1163Gly cDNA and the wild-type PED/PEA-
15 cDNA in 293 cells (293S1163G and 293PEDWT cells; three
independent clones of cells expressing the mutant and four
expressing the wild-type PED were selected and characterized
in detail). For control, three independent clones of cells ex-
pressing a second mutant cDNA of PED/PEA-15, featuring
the Ser1043 Gly substitution, were also selected and used
(PEDS1043G cells; the Ser1043Gly mutation abolishes PED/
PEA-15 phosphorylation by PKC [23]). Precipitates of these
cells with PED/PEA-15 antibodies were phosphorylated by
using HA precipitates from insulin-exposed cells expressing
wild-type HA-Akt. In these assays, the Ser1163G mutant of
PED/PEA-15 showed a fourfold-decreased phosphorylation by
Akt compared to that of wild-type PED/PEA-15 (Fig. 2A).
Phosphorylation of the Ser1043Gly mutant showed no signif-
icant difference from that of wild-type PED/PEA-15. In addi-
tion, blotting with antisera raised against a specific phospho-
Serine116 PED/PEA-15 peptide showed a 15-fold-decreased
phosphorylation of the Ser1163G compared to that of the
Ser1043G PED mutant or the wild-type PED. Also, incubation
of recombinant active Akt with same amounts of PED/PEA-15
precipitated from cells expressing either the wild-type or the
S1163G mutant PED/PEA-15 cDNAs showed 10-fold-de-
creased phosphorylation of the PED/PEA-15 mutant com-
pared to that of the wild-type (Fig. 2B). In this same assay,
however, the active Akt phosphorylated the Ser1043Gly mu-
tant of PED/PEA-15 at a level similar to that observed with
wild-type PED/PEA-15. In vitro, the active Akt also phosphor-
ylated twofold more effectively a synthetic dodecapeptide fea-
turing the sequence of PED/PEA-15 surrounding Ser116 (S116
peptide) than a PED/PEA-15 dodecapeptide including Ser70
(S70 peptide; Fig. 2C). An additional PED/PEA-15 dodecapep-
tide including Ser104 (S104 peptide) was phosphorylated to a
level similar to that of the S70 peptide. Thus, in vitro, Akt
phosphorylates PED/PEA-15 on Ser116.
In vivo phosphorylation of PED by Akt. We also examined
the phosphorylation of PED/PEA-15 by Akt in intact 293PEDWT
cells upon metabolic labeling with [32P]orthophosphate. Incu-
bation of 293PEDWT cells with 100 nM insulin for 10 min
stimulated PED/PEA-15 phosphorylation twofold above the
basal level (Fig. 3A). Overexpression of similar levels of wild-
type or active Akt cDNAs also increased phosphorylation of
PED/PEA-15 1.8- and 3.2-fold, respectively. The same re-
sults were obtained with two further independent clones of
293PEDWT cells (not shown), indicating that, at least in part,
insulin may induce PED/PEA-15 phosphorylation through Akt
activation. Consistent with the role of Akt in insulin- and
serum-stimulated phosphorylation of PED, preincubation of
293 cells with the phosphatidylinositol (PI) 3-kinase blockers
Wortmannin or LY294002 inhibited insulin- as well as serum-
stimulated phosphorylation of PED/PEA-15 by 70% (Fig.
3B). These decreases in phosphorylation of PED were accom-
panied by a decrease of similar size in phosphorylation of the
key site of BAD by Akt.
Since Akt phosphorylates PED/PEA-15 at Ser116 in vitro, we
asked whether Ser116 is also phosphorylated in intact cells. To
answer this question, we compared PED/PEA-15 phosphory-
lation in the 293PEDWT, the 293S1163G, and the 293S1043G
FIG. 1. In vitro phosphorylation of PED/PEA-15 by Akt (A) Par-
tial amino acid sequence alignment of serine phosphorylation sites in
Akt substrates. hBAD (29); hCREB (18, 30); h14.3.3. (19, 27); hPED/
PEA-15 (2). Sequences have been aligned to maximize the homology
in the region upstream from the Ser116 of PED/PEA-15. The single-
letter amino acid code is used. (B) The HA-tagged wild-type Akt
(AktWT), constitutively active HA-Aktm4-129 (AktD), inactive HA-
AktK179 M (AktD-) mutant cDNAs, or the PcDNA3 empty vector (PC)
was transfected in 293 cells. Cells maintained in the presence of 10%
serum were solubilized, and cell lysates were precipitated with HA
antibodies. Precipitated Akt was incubated with 2 g of His-tagged
recombinant PED/PEA-15 in the presence of 10 Ci of [-32P]ATP.
The phosphorylation reaction was terminated with Laemmli buffer,
and samples were subjected to SDS-PAGE and autoradiography. For
control, the gels were also blotted with PED/PEA-15, HA, and Akt
phosphoserine473 antibodies (P-Akt), as indicated. (C) 293 cells were
stimulated with 100 nM insulin for 10 min and solubilized as described
in Materials and Methods, and lysates were immunoprecipitated with
Akt1 antibodies. Precipitated Akt was incubated with recombinant
PED/PEA-15, and PED/PEA-15 phosphorylation was assayed as de-
scribed above. For control, the gels were blotted with PED/PEA-15,
Akt-1, and P-Akt antibodies. The autoradiographs shown are repre-
sentative of three (B) and four (C) independent experiments.
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cells upon expression of the constitutively active HA-Akt or
insulin stimulation. As shown in Fig. 3C, PED/PEA-15 phos-
phorylation by active Akt was evident in the 293PEDWT and
293S1043G (3.2-fold increase) but not the 293S1163G cells. In-
sulin also increased PED/PEA-15 phosphorylation twofold and
40% in the 293PEDWT and the 293S1043G cells, respectively,
but elicited only a slight 20% increase in the 293PEDS1163G
cells. In addition, Wortmannin preincubation of the cells al-
most completely inhibited insulin-stimulated phosphorylations
of wild-type PED/PEA-15 and of the Ser1043Gly mutant but
showed no effect on that of the Ser1163Gly mutant, indicating
that the latter phosphorylation is independent of Akt. Blotting
with phospho-Ser116 PED antibodies revealed that wild-type
PED underwent phosphorylation in cells transfected with wild-
type Akt (upon insulin exposure) or with the active, but not the
inactive, Akt (Fig. 3D). Importantly, insulin-induced phos-
phorylation of PED at Ser116 was unaffected by cell preincu-
bation with KN-93 and bisindolylmaleimide (BDM), which
inhibit CaMKII and PKC, respectively. It appears therefore
that Ser116 represents the major Akt phoshorylation site of
PED/PEA-15 in intact cells as well as in vitro.
Action of Akt on PED function in 293 cells. To further
investigate the functional significance of Akt–PED/PEA-15 in-
teraction, we first analyzed whether Akt directly binds PED/
PEA-15. To this end, we incubated PED/PEA-15–GST fusion
protein with either recombinant active Akt or lysates from cells
expressing the constitutively active cDNA of Akt. Bound pro-
teins were then pulled down and blotted with Akt antibodies.
As shown in Fig. 4A, PED/PEA-15–GST bound both recom-
binant and transfected Akt. No Akt binding was evident upon
incubation with GST alone. PED/PEA-15–GST did not bind to
HA precipitates from cells expressing an HA-JNK-1 cDNA
either, indicating specificity of the PED/PEA-15–Akt interac-
tion (Fig. 4B). Based on overlay binding studies, PED/PEA-15
bound Akt and ERK1 with similar affinities (data not shown).
Importantly, precipitation of 293PEDWT lysates with PED/
PEA-15 antibodies followed by blotting with Akt antibodies, or
vice versa, also revealed coprecipitation of PED/PEA-15 with
Akt, indicating that Akt–PED/PEA-15 binding may occur in
intact cells as well as in vitro (Fig. 4C). PED/PEA-15–GST
incubation of extracts from cells expressing constitutively ac-
tive, kinase-defective, and wild-type HA-Akt cDNAs followed
by Akt blotting revealed that the mutant, the wild-type, and the
endogenous Akt equally bound to PED/PEA-15 (Fig. 4D).
Direct blotting of the cell extract with HA antibodies showed
similar levels of transfected Akt in the cells. It appeared there-
fore that the formation of the PED/PEA-15–Akt complex is
independent of Akt activity.
PED exerts a broad antiapoptotic action (5, 7, 16, 22). The
finding that PED/PEA-15 binds and is phosphorylated by Akt
led us to hypothesize that the antiapoptotic action of PED/
PEA-15 may be contributed by activation of Akt signaling, or
it may be regulated by phosphorylation by Akt, or both. To
answer these questions, we compared the serum activation of
Akt in the 293PEDWT cells with that in cells transfected with the
empty plasmid (293PC). As shown in Fig. 5A, there was no
difference between the phosphorylation levels of the key Akt
serine activation sites in these two cell types. Also, BAD phos-
phorylation by Akt featured no difference in the 293PEDWT and
the 293PC cells (Fig. 5B), indicating that Akt activity is not
FIG. 2. Identification of the in vitro Akt phosphorylation site of
PED/PEA-15. (A) 293 cells expressing the wild-type (WT), the
Ser1043Gly or the Ser1163Gly PED/PEA-15 cDNAs were solubilized
and precipitated with PED/PEA-15 antibodies. PED/PEA-15 precipi-
tates were phosphorylated with AktWT as outlined in the legend to Fig.
1, and samples were subjected to SDS-PAGE and autoradiography.
For control, aliquots of the phosphorylation mixtures were also blotted
with Akt, pSer116 PED/PEA-15, or PED/PEA-15 antibodies as indi-
cated. (B) Constitutively active AktD (recombinant; 0.5 g) was in-
cubated with PED/PEA-15 antibody precipitates from 293PEDWT,
PEDS104-G, and 293S1163G cells. Phosphorylation reactions were per-
formed as outlined above, and samples were subjected to SDS-PAGE
and autoradiography. To ensure equal amounts of Akt and PED/PEA-
15 in each assay, aliquots of the samples were also blotted with Akt or
PED/PEA-15 antibodies. The autoradiographs shown are representa-
tive of three (A) and four (B) independent experiments. (C) Synthetic
dodecapeptides matching the sequence of PED/PEA-15 surrounding
Ser70, Ser104, or Ser116 (PEP70, PEP104, or PEP116, respectively) were
incubated with recombinant AktD (0.5 g). Phosphorylation reac-
tions were initiated by addition of 10 Ci of [-32P]ATP and prolonged
for 30 min. Peptide phosphorylation was then quantitated as described
in Materials and Methods. Each bar represents the mean 	 standard
deviation of five independent experiments. Based on t test analysis, the
difference in phosphorylation of the PEP116 and those of the other
peptides was significant at P values of 
0.002.
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FIG. 3. PED/PEA-15 phosphorylation by Akt in intact cells. (A) The HA-tagged wild-type and constitutively active Akt (AktWT and AktD,
respectively) were transiently transfected in 293PEDWT cells. The cells were then labeled with [
32P]orthophosphate and, when indicated, exposed
to 100 nM insulin for 10 min. Cells were lysed and precipitated with PED/PEA-15 antibodies, and precipitated proteins were analyzed by
SDS-PAGE and autoradiography. For control, aliquots of the samples were also blotted with PED/PEA-15 or HA antibodies. (B) 293PEDWT cells
were labeled with [32P]orthophosphate, preincubated with 50 nM Wortmannin or 110 M LY294002 for 30 min, and stimulated with either 100
nM insulin (left panel) or 10% serum (right panel) for a further 10 min. The cells were solubilized and immunoprecipitated with PED/PEA-15
antibodies, and precipitates were subjected to SDS-PAGE and autoradiography. For control, the gels were subsequently blotted with either PED/
PEA-15 or phosphoBAD antibodies. (C) 293PEDWT, 293S1163G, and 293S1043G cells were transiently transfected with the active AktD cDNA (HA
tagged) and labeled with [32P]orthophosphate. The cells were then incubated with 50 nM Wortmannin and further stimulated with insulin as
indicated. Cell lysates were precipitated with PED/PEA-15 antibodies and analyzed by SDS-PAGE and autoradiography. For control, aliquots of
the cell lysates were also blotted with PED/PEA-15 or HA antibodies. (D) 293PEDWT cells were transfected with the wild-type (WT), the con-
stitutively active (D) or inactive (D) Akt, incubated with 50 M KN-93 or 100 nM BDM, and then stimulated with 100 M insulin as indicated.
Cell lysates were blotted with pSer116 PED/PEA-15 antibodies and, for control, reblotted with PED/PEA-15 antibodies. Filters were revealed by
ECL and autoradiography. The autoradiographs shown are representative of three (A, B, and D) and four (C) independent experiments.
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affected by cellular levels of PED/PEA-15. We therefore in-
vestigated whether phosphorylation by Akt regulates the anti-
apoptotic function of PED/PEA-15. To this end, we compared
the apoptosis induced by growth factor deprivation in untrans-
fected 293 cells with the apoptosis induced in cells expressing
comparable levels of wild-type or mutant PED/PEA-15. Con-
sistent with previous findings (6), the expression of wild-type
PED/PEA-15 resulted in a 2-fold decrease in apoptosis fol-
lowing serum deprivation compared to that observed for the
293 cells transfected with the empty vector (293PC cells; Fig.
5C). But this protective effect was 60% less evident in cells
expressing the nonphosphorylatable S1163G mutant of PED/
PEA-15. In comparison, substitution of Ser1043Gly reduced
PED/PEA-15 antiapoptotic function by only 35%. The levels
of ERK activation by serum in cells expressing wild-type PED/
PEA-15, in cells expressing mutant PED/PEA-15, and in un-
transfected 293 cells were not different (data not shown).
293PEDWT cells featured very low levels of apoptosis when
maintained in the presence of serum. However, exposure of
these cells to Wortmannin and BDM increased apoptosis nine-
FIG. 4. In vitro interaction of PED/PEA-15 and Akt. (A) Lysates from 293PEDWT cells expressing the AktD mutant (500 g of cell protein)
and recombinant AktD (rAkt; 0.4 g) were incubated with agarose-bound GST–PED/PEA-15 or, for control, agarose-bound GST, as indicated.
Pulled-down complexes were then analyzed by SDS-PAGE followed by Western blotting with Akt antibodies. Filters were revealed by ECL and
autoradiography. (B) In parallel experiments, 293PEDWT cells were transiently transfected with HA-tagged JNK-1 cDNA. Cell lysates (500 g of
protein) were incubated with agarose-bound GST–PED/PEA-15 or GST, as indicated, pulled-down, and analyzed by blotting with HA antibodies
and autoradiography. (C) 293PEDWT cells were solubilized, and cell lysates were immunoprecipitated with either PED/PEA-15 or preimmune
antisera followed by blotting with Akt antibodies (left panel). Alternatively, the lysates were precipitated with Akt or nonimmune antibodies
followed by blotting with PED/PEA-15 antibodies. Filters were revealed by ECL and autoradiography. (D) 293PEDWT cells were transiently
transfected with the HA-tagged active AktD, inactiveAktD, or AktWT cDNAs as indicated. Cell lysates were analyzed by GST–PED/PEA-15
pull-down assays as outlined above. For control, aliquots of the cell extracts were also blotted with HA antibodies followed by ECL and
autoradiography. The autoradiographs shown are representative of four (A) and three (B, C, and D) independent experiments.
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FIG. 5. Effects of phosphorylation by Akt on the antiapoptotic action of PED/PEA-15. (A) 293PEDWT and 293PC control cells were deprived
of serum overnight, followed by 10% serum stimulation as indicated. The cells were solubilized, and cell lysates were subjected to SDS-PAGE
followed by immunoblotting with Akt phosphoserine473 antibodies (P-Akt). For control, aliquots of the lysates were also blotted with Akt1/2
antibodies. (B) Further aliquots of the cell lysates were blotted with phospho-BAD (P-BAD). Filters were revealed by ECL and autoradiography.
The autoradiographs shown are representative of three (A) and four (B) independent experiments. (C) 293PC, 293PEDWT, 293S1163G, and
293S1043G cells were incubated in the presence or the absence of serum for 48 h. Cells were further incubated with 50 nM Wortmannin, 50 M
PD98059, or 100 nM BDM, as indicated. Apoptosis was quantitated by the ELISA Plus detection kit as described in Materials and Methods. Bars
represent the means 	 standard deviations from four duplicate experiments. Based on t test analysis, the difference in apoptosis following serum
deprivation between the 293S1163G and 293PEDWT cells is significant at P values of 
0.01. O.D.405, optical density at 405 nm.
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and fivefold, respectively. According to previous observations
in 293 cells (5), cell treatment with the MEK inhibitor
PD98059 also induced an increase in apoptosis of almost four-
fold. The effects of Wortmannin, PD98059, and BDM were
more pronounced than in untransfected cells (P 
 0.001 by t
test analysis), indicating an important role of PED/PEA-15 in
their elicitation. The 293S1163G and 293S1043G cells exhibited,
respectively, nine- and fivefold-higher basal rates of apoptosis
compared to the 293PEDWT cells (P 
 0.001). Wortmannin had
no further effect on apoptosis in the 293S1163G cells, whereas
it increased the apoptosis in the 293S1043G cells threefold. In
contrast, BDM slightly increased apoptosis in the 293S1163G
cells (40%; P 
 0.05) but had no effect at all in those express-
ing the Ser1043G mutant. PD98059 increased apoptosis by 40%
and twofold, respectively, in the 293S1163G and the 293S1043G
cells. Thus, Akt as well as PKC phosphorylations exerted an
important role in regulating PED function.
Akt action on PED stability in 293 cells. To elucidate the
significance of phosphorylation by Akt for PED/PEA-15 func-
tion, we tested the possibility that Akt phosphorylation affects
the half-life of PED/PEA-15 in the cells. We first compared the
expression levels of wild-type PED/PEA-15 in cells maintained
in the presence and in the absence of serum, when phosphor-
ylation of the key Akt activation site is maximal and undetect-
able, respectively. As shown in Fig. 6A, PED/PEA-15 levels
were fivefold higher in the cells exposed to serum than in the
starved cells. Also, the effect of serum on the expression level
of PED/PEA-15 was reduced threefold by Wortmannin, in
parallel with the effect of serum on Akt phosphorylation. Very
similar results were obtained in the presence of 100 nM insulin
instead of serum (data not shown). More compelling, in the
serum-starved cells, expression of the constitutively active Akt
mutant resulted in PED/PEA-15 expression levels comparable
to those measured in cells maintained in the presence of se-
rum. In addition, both the effect of serum and that of the active
Akt on PED/PEA-15 levels were absent in the 293S1163G cells,
demonstrating the role of Akt phosphorylation in determining
the intracellular levels of PED/PEA-15.
Next, we directly examined whether Akt phosphorylation
may increase the stability of PED/PEA-15. We incubated
293PEDWT and 293S1163G cells with the protein synthesis in-
hibitor cycloheximide. We then compared the degradation
rates of PED/PEA-15 in the two cell types. As shown in Fig.
6B, in the 293PEDWT cells, almost 50% of the initial levels of
PED/PEA-15 were still present after 6 h of incubation with
cycloheximide. The disappearance of PED/PEA-15 was much
faster in the 293S1163G cells, since in these cells 50% of PED/
PEA-15 levels became undetectable within only 1 h. Again, the
difference in PED stability in the 293PEDWT and the 293S1163G
cells was confirmed in two other clones of each cell line (data
not shown). Earlier reports showed that PKC phosphorylation
at Ser104 depends on previous phosphorylation at Ser116 (23).
Thus, phosphoserine104 might also contribute to PED stability.
Accordingly, wild-type PED stability also decreased when PKC
activity was blocked by BDM, although less evidently than with
the Ser1163Gly mutant. Hence, upon treatment with BDM,
50% of the initial levels of wild-type PED were present after
3 h of incubation with cycloheximide. Consistent with the per-
missive role of Ser116 phosphorylation on that of Ser104 (23),
treatment with BDM caused only a slight further increase in
the degradation rate of PEDS1163G.
Action of Akt on PED stability and function in human
glioma cells. To further address the significance of PED
phosphorylation by Akt, we have blocked Akt activity in the
U373MG human glioma cell line. These cells feature high
levels of PED determining resistance to the apoptotic cytokine
TRAIL (16, 31). Similar to what was observed with the 293
cells, in the U373MG glioma cells preincubation with either
Wortmannin or LY294002 caused an 80% increase in apopto-
sis (P 
 0.001; Fig. 7). This induction of apoptosis was accom-
panied by a 3-fold decrease in PED phosphorylation at
Ser116 and in the cellular levels of PED (Fig. 7, top). Interest-
ingly, both treatment with Wortmannin and treatment with
LY294002 rescued sensitivity to TRAIL apoptosis. Wortman-
nin and LY294002 also reduced Akt activity as well as PED re-
cruitment to TRAIL-induced DISC by 80% (data not
shown), supporting the major role of this kinase in controlling
the cellular function of PED in the glioma as well as in other
cells.
DISCUSSION
PED/PEA-15 is a recently identified protein featuring a
broad antiapoptotic function (5, 7, 16, 22). PED/PEA-15 in-
hibits the apoptotic signal of FasL, tumor necrosis factor alpha,
and TRAIL (7, 16, 22) and also blocks apoptosis following the
activation of several SAPKs (6). Previous work in our own as
well as in other laboratories has shown that phosphorylation by
PKC plays an important role in enabling the antiapoptotic
function of PED/PEA-15 (7, 16, 22). In the present paper we
demonstrate that PED/PEA-15 phosphorylation by Akt also
regulates PED/PEA-15 control of cell apoptosis.
We have shown that Akt phosphorylates PED/PEA-15 in
vitro as well as in intact cells. PED/PEA-15 sequence analysis
revealed a low-stringency Akt phosphorylation site, Ser116.
Hence, in vitro, Akt phosphorylates the wild-type PED/PEA-
15 but not a mutant PED/PEA-15 featuring the Ser1163Gly
substitution. Akt also phosphorylates twofold more effectively
a synthetic peptide featuring the sequence of PED/PEA-15
surrounding Ser116 than two other equally sized PED/PEA-15
peptides including either Ser104 or Ser70. In addition, active
Akt does not phosphorylate the PEDS1163G mutant when ex-
pressed in 293 cells, whereas it does phosphorylate wild-type
PED/PEA-15. Finally, Western blotting studies with a specific
phospho-Ser116 PED/PEA-15 antiserum identified Ser116 as
the major Akt phosphorylation site of PED/PEA-15 in vivo
and in vitro. Akt substrate serines are usually embedded in
RXRXXS consensus sequences (1). In contrast, the 5-amino-
acid region of PED/PEA-15 upstream from Ser116 exhibits only
a single Arg residue. The same structural feature has been
reported for the Akt Ser substrates of CREB (10) and of the
14-3-3 scaffold protein (27). In the case of PED/PEA-15, we
showed that PED/PEA-15 directly binds to Akt. The binding is
independent of Akt activity, as it effectively occurs to both
constitutively active and inactive Akt mutants as well as to
wild-type Akt. In addition, PED/PEA-15 binds Akt with an
affinity similar to that exhibited for ERK1, a known PED/PEA-
15 ligand (14, 17) (data not shown). It is possible, therefore,
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that in the cell PED/PEA-15 recruits Akt and that this facili-
tates PED/PEA-15 phosphorylation by the kinase.
When expressed in 293 cells, the S1163G mutant PED/PEA-
15 showed an almost twofold decrease in antiapoptotic func-
tion compared to wild-type PED/PEA-15. In 293 cells, PED
inhibition of apoptosis requires PED activation of ERKs (5).
However, reduced antiapoptotic function of the Ser1163G
mutant did not appear to depend on changes in its interaction
with ERKs, as ERK activation levels were not different in cells
expressing the mutant and in wild-type cells (data not shown).
Interestingly, a pharmacological blocking of wild-type PED/
PEA-15 phosphorylation at Ser116 was accompanied by a sig-
nificant increase in 293 cell apoptosis, even in the presence of
serum. These findings suggest that, at least in the 293 cells,
FIG. 6. Akt action on PED/PEA-15 stability in 293 cells. (A) 293PEDWT, and 293S1163G cells were transiently transfected with the active
HA-AktD mutant as indicated. The cells were maintained in the absence or the presence of serum for 16 h. During the last 3 h of incubation,
Wortmannin was added at a final concentration of 50 nM, as indicated. The cells were then solubilized and sequentially blotted with PED/PEA-
15, P-Akt, HA, and -tubulin antibodies. Filters were revealed by ECL and autoradiography. The autoradiograph shown is representative of three
independent experiments. (B) Alternatively, 293PEDWT and 293S1163G cells were deprived of serum for 14 h and then further incubated with 40
g of cycloheximide/ml for the indicated times in the absence or the presence of 100 nM BDM. Cells were then solubilized, and 100 g of cell
proteins were subjected to SDS-PAGE followed by blotting with PED/PEA-15 antibodies, ECL, and autoradiography. (C) Autoradiographs were
analyzed by laser densitometry. Each data point is the mean 	 standard deviation of four independent experiments, one of which is shown in panel B.
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PED may switch from an unphosphorylated proapoptotic form
to a phosphorylated antiapoptotic form. Hence, expression
of the Ser1163Gly mutant induces apoptosis, likely contribut-
ing to the reduced protection from apoptosis observed in
293PEDS1163G compared to the 293PEDWT cells. Kubes et al.
reported that endothelin-activated CaMKII also phosphory-
lates PED/PEA-15 at Ser116 (23). Consistent with our findings,
endothelin exerts antiapoptotic action in different cell types
(9). It is unlikely that CaMKII serves as a downstream medi-
ator of Akt action on PED/PEA-15 phosphorylation in the
intact cell, as blocking of CaMKII does not inhibit Akt phos-
phorylation of PED/PEA-15 at Ser116. More likely, therefore,
PED/PEA-15 represents a common target for multiple kinases
transducing survival signals triggered by growth factors and
cytokines, supporting an important role of PED/PEA-15 in the
cellular regulation of apoptotic programs.
Earlier works indicated that PED/PEA-15 phosphorylation
at Ser116 facilitates subsequent phosphorylation by PKC at
Ser104. In the present report, we show that the single substitu-
tion Ser1043G of PED/PEA-15 also reduced the antiapoptotic
activity of PED/PEA-15, but only by 30%. These findings in-
dicate that impaired phosphorylation at Ser104 may account, in
part, for reducing PED/PEA-15 antiapoptotic action when
phosphorylation of Ser116 is disabled. Consistent with this pos-
sibility, blocking of PKC only slightly increased apoptosis in
293S1163G cells.
Despite the relevance of phosphorylation at Ser116, other
factors seemed to be involved in regulating PED/PEA-15 anti-
apoptotic function in 293 cells. Hence, apoptosis induced by
serum starvation was less in cells expressing the S1163G mu-
tant than in cells expressing no PED/PEA-15 at all. Akt regu-
lation of PED function is not unique to the 293 cells, however.
In fact, we report that blocking of Akt in human glioma cells
expressing high levels of PED/PEA-15 simultaneously de-
creases PED/PEA-15 phosphorylation at Ser116 and rescues
sensitivity to the apoptotic cytokine TRAIL.
Akt regulates a number of cellular functions including cell
survival (25). Different substrates are phosphorylated by Akt
and converted into survival proteins (3, 4, 12, 24). This func-
tion, in turn, is accomplished by regulating protein-protein
interaction (12), by affecting protein localization (3) or protein
stability (24). In the present work, we show that Akt phosphor-
ylation increases the stability of PED/PEA-15 in the cell.
Hence, PED/PEA-15 levels are low in cells subjected to serum
starvation, when Akt activity is inhibited, and in cells subjected
to pharmacological blocking of the PI 3-K/Akt pathway. PED/
PEA-15 cellular levels increase upon expression of a consti-
tutively active Akt mutant. In addition, we report that the
S1163G PED/PEA-15 mutant features reduced stability com-
pared to that of wild-type PED/PEA-15. At variance with wild-
type PED/PEA-15, the S1163G mutant is unaffected by Akt.
Thus, at least in part, Akt regulates PED protein stability and
antiapoptotic function by phosphorylating PED/PEA-15 at
Ser116. PED/PEA-15 degradation is blocked by treatment of
the cells with the proteasome inhibitor lactacystin, suggesting
that PED/PEA-15 intracellular levels are regulated by the
ubiquitin pathway (data not shown). Whether this hypothesis
holds and whether PED/PEA-15 ubiquitination is, in turn,
inhibited by Akt phosphorylation is currently being investi-
gated in our laboratory.
The PED/PEA-15 gene is amplified in human breast cancer
(20) as well as in other tumors and PED/PEA-15 overexpres-
sion may have a role in skin carcinogenesis (S. Santopietro and
J. Portella, personal communication). Akt is also upregulated
in a number of human cancers (26, 28, 29). In this work, we
demonstrated that PED/PEA-15 is a substrate for Akt and
obtained evidence that Akt phosphorylation and stabilization
of PED/PEA-15 is a previously unrecognized mechanism in-
volved in Akt survival signaling. Simultaneous increases in
PED/PEA-15 cellular levels and Akt activity might function
cooperatively in tumorigenesis and/or tumor progression in
humans.
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Overexpression of the ped/pea-15 gene is a common feature of type 2 diabetes. In the present work, we show
that transgenic mice ubiquitously overexpressing ped/pea-15 exhibited mildly elevated random-fed blood glu-
cose levels and decreased glucose tolerance. Treatment with a 60% fat diet led ped/pea-15 transgenic mice to
develop diabetes. Consistent with insulin resistance in these mice, insulin administration reduced glucose
levels by only 35% after 45 min, compared to 70% in control mice. In vivo, insulin-stimulated glucose uptake
was decreased by almost 50% in fat and muscle tissues of the ped/pea-15 transgenic mice, accompanied by
protein kinase C activation and block of insulin induction of protein kinase C. These changes persisted in
isolated adipocytes from the transgenic mice and were rescued by the protein kinase C inhibitor bisindolyl-
maleimide. In addition to insulin resistance, ped/pea-15 transgenic mice showed a 70% reduction in insulin
response to glucose loading. Stable overexpression of ped/pea-15 in the glucose-responsive MIN6 beta-cell line
also caused protein kinase C activation and a marked decline in glucose-stimulated insulin secretion.
Antisense block of endogenous ped/pea-15 increased glucose sensitivity by 2.5-fold in these cells. Thus, in vivo,
overexpression of ped/pea-15 may lead to diabetes by impairing insulin secretion in addition to insulin action.
Type 2 diabetes is a genetically determined disorder, affect-
ing over 150 million people worldwide (35). The pathogenesis
of type 2 diabetes is characterized both by insulin resistance in
muscle, fat, and liver and by impaired insulin secretion (10, 16).
Whether a single genetic defect may simultaneously cause im-
paired insulin action and secretion in common forms of human
diabetes and by what mechanism are unknown.
PED/PEA-15 is a ubiquitously expressed multifunctional
protein. It controls mitogenic signaling by binding extracellular
signal-regulated kinases and anchoring them to the cytoplasm
(14). PED/PEA-15 also inhibits several apoptotic pathways
through a number of different mechanisms and plays an im-
portant role in tumor development and sensitivity to antineo-
plastic agents (5, 6, 11, 15, 30, 34). Recently, PED/PEA-15 was
reported to bind to and increase the cellular stability of phos-
pholipase D, enhancing its activity in the cell (8, 35). In addi-
tion, we showed that overexpression of the ped/pea-15 gene is
a common defect in type 2 diabetes (7). Overexpression of
PED/PEA-15 protein impairs insulin-stimulated GLUT4
translocation and glucose transport in cultured muscle and
adipose cells, suggesting that ped/pea-15 overexpression may
contribute to insulin resistance in type 2 diabetics (7).
Other studies have demonstrated that ped/pea-15-induced
resistance to insulin action on glucose disposal is accompanied
by activation of the classical protein kinase C (PKC) isoform
PKC (8). In turn, the induction of PKC by ped/pea-15 over-
expression prevents subsequent activation of atypical PKC/
by insulin (8). Rescue of PKC/ function in ped/pea-15-over-
expressing cells restores glucose transport to its normal sensi-
tivity to insulin. Thus, in cultured muscle and adipose cells,
ped/pea-15 generates resistance to insulin action on glucose
disposal by impairing normal regulation of PKC/ function by
PKC. Accumulating evidence now indicates that the atypical
PKCs  and  are major downstream effectors activating the
glucose transport machinery in response to insulin in both
skeletal muscle and adipose tissues (12). Activation of atypical
PKCs by insulin is defective in humans with type 2 diabetes as
well as in animal models of type 2 diabetes (12, 17, 18). It
therefore appears that atypical PKCs are key molecules in the
pathogenesis of type 2 diabetes and may represent important
drug targets as well.
Defective insulin secretion in response to secretogogues also
plays an important role in the pathogenesis of type 2 diabetes
(24). At least in part, this further abnormality appears to be
genetically determined (2, 33). However, metabolic abnormal-
ities determined by insulin resistance also contribute to beta-
cell failure in type 2 diabetes (2, 24, 33). In the present report,
we show that overexpression of ped/pea-15 to levels similar to
those found in many type 2 diabetics may lead to diabetes in
transgenic mice. This defect is accompanied by defective insu-
lin action on glucose transport and, additionally, by impaired
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glucose-stimulated insulin secretion. Thus, overexpression of
the ped/pea-15 gene may cause diabetes by impairing beta-cell
function in addition to insulin sensitivity.
MATERIALS AND METHODS
Generation of ped/pea-15 transgenic mice. ped/pea-15 cDNA (7) was cloned in
the BamHI sites of plasmid pBap2, containing the human beta-actin promoter.
To generate transgenic mice, the 5.2-kb ClaI fragment was excised, purified by
agarose gel electrophoresis, and injected into pronuclei of C57BL/6J  DBA/2J
mouse embryos. Three F0 founders were identified by Southern blot analysis of
genomic DNA by probing with the PstI fragment of the human -actin promoter.
To establish transgenic lines, founder mice were mated with BDF1 mice.
Heterozygous transgenic mice were subsequently identified by Southern blotting
with either the ClaI fragment or the PCR amplification product of the fragment
obtained with primers 5-CGCGGATCCATGGCTGAGTACGGGACCCTC-3
and 5-GGCCTTCTTCGGTGGGGGAGCCAATTTGATGATCTCTTCCTC
A-3; by Northern blotting with the ClaI fragment; and by Western blotting with
polyclonal rabbit antibodies against PED/PEA-15 protein (7). Three lines (L1,
L61, and L30) overexpressing PED/PEA-15 protein were established. Animals
were kept in a 12-h dark-light cycle and fed standard or chow with a 60 kcal% fat
content (Research Diets formulas D12328 and D12331, respectively; Research
Diets, Inc., New Brunswick, N.J.) ad libitum. All procedures described below
were approved by the Institutional Animal Care and Utilization Committee.
Phenotypic analysis. Blood glucose levels were measured with glucometers
(Accu-check; Boehringer Mannheim), plasma insulin was measured by enzyme
immunoassays (ultrasensitive mouse insulin enzyme-linked immunosorbent as-
say; Mercordia AB, Uppsala, Sweden), fasting plasma free fatty acids were
measured with the Wako NEFA C kit (Wako, Richmond, Va.), and triglycerides
were measured with the Infinity triglyceride reagent (Sigma, St. Louis, Mo.).
Insulin tolerance tests. Random-fed mice were subjected to intraperitoneal
injection with insulin (0.75 mU g of body weight1). Venous blood was subse-
quently drawn by tail clipping at 0, 15, 30, 45, 60, 90, and 120 min after insulin
injection to determine blood glucose levels.
Glucose tolerance tests and insulin secretion. Mice were fasted overnight and
then injected with glucose (2 g kg of body weight1) intraperitoneally. Venous
blood glucose was drawn by tail clipping at 0, 15, 30, 45, 60, 90, and 120 min
without reclipping of the tails. We also measured plasma insulin concentrations
at 2, 5, 15, and 30 min.
In vivo tissue glucose transport during glucose tolerance tests. 2-Deoxy-D-
[1,2-3H]glucose (Amersham) was mixed with 20% glucose and then injected
intraperitoneally (2 mg kg of body weight1; 10 	Ci/mouse) into weight-matched
mice. Blood samples were obtained from the tail veins at 0, 15, 30, 45, 60, 90, and
120 min, and glucose concentrations were determined. The glucose specific
activity was determined as described before (37). At 120 min, mice were killed
and tissues were snap frozen in liquid nitrogen. To determine tissue accumula-
tion of 2-deoxyglucose-6-phosphate, 100 to 500 mg of tissue was homogenized in
2 ml of distilled water, and 1.6 ml of the homogenate was transferred to 1.6 ml
of 7% ice-cold perchloric acid. The sample was centrifuged to remove precipi-
tated protein, and 2.5 ml of the supernatant was neutralized for 30 min with 625
	l of 2.2 M KHCO3. The precipitate was removed by centrifugation, and the
supernatant was divided into 800-	l aliquots. One aliquot was used to determine
total 3H radioactivity, and another was passed through an AG 1-X8 anion
exchange resin column (Bio-Rad, Hercules, Calif.) to remove labeled 2-deoxy-
glucose-phosphate. The column was washed with 3 ml of distilled water, and the
radioactivity in the eluted volume was measured in a scintillation counter. The
difference between total and eluted 3H radioactivity represents accumulated
2-deoxy-D-[1,2-3H]glucose-6-phosphate. The protein pellet was digested for 20
min at 55°C with 1 N KOH, and the protein concentration was determined by the
Bradford assay (Bio-Rad, Hercules, Calif.). To calculate 2-deoxyglucose uptake,
the radioactivity was divided by the integrated glucose specific activity area under
the curve and the sample protein content.
Tissue collection and immunoblotting. Tissue samples (tibialis and soleus
muscles and subcutaneous and perigonadal adipose tissues) were collected rap-
idly after mice were sacrificed by pentobarbitone overdose. Tissues were snap
frozen in liquid nitrogen and stored at 80°C for subsequent Western blotting,
biochemical assays of PKC activity, and diacylglycerol levels. Tissue samples were
homogenized in a Polytron (Brinkman Instruments, Westbury, N.Y.) in 100 mg
of buffer A per ml according to the method of Qu et al. (26). After centrifugation
at 3,000  g, the supernatant was centrifuged at 200,000  g for 90 min to pellet
the crude membrane and cytosolic fractions. Further purifications to obtain the
plasma membrane fractions were achieved as described by Uphues et al. (32).
Ouabain-sensitive Na/K ATPase was used as a marker enzyme for plasma
membranes, and activity was determined as described by Russ et al. (29).
Membranes recovered from the 0.72 M sucrose layer were 12-fold enriched in
the activity of the Na/K ATPase and considered to represent the plasma
membrane fraction. Preparation of total tissue lysates was achieved by homog-
enization in TAT buffer (4). Total homogenates and plasma membrane fractions
were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) with 10% gels, as described by Laemmli (21). Proteins separated
on the gels were electroblotted onto nitrocellulose filters as described before (8)
and probed with antibodies to GLUT4, PKC (Santa Cruz Biotech Inc., Santa
Cruz, Calif.), PLD (BioSource International, Camarillo, Calif.) phospho-Akt
(Ser473) (Cell Signaling Technology, Inc., Beverly, Mass.), or Akt (Upstate
Biotechnology, Lake Placid, N.Y.).
Determination of PKC and phosphatidylinositol 3-kinase activities. For de-
termination of PKC activity, tissues and cells were homogenized in TAT buffer,
followed by immunoprecipitation with specific PKC antibodies. PKC activity in
the immunoprecipitates was then assayed as described by Condorelli et al. (8).
Alternatively, for assaying phosphatidylinositol 3-kinase, tissue homogenates
were precipitated with phosphotyrosine antibodies coupled to protein A-Sepha-
rose, and phosphatidylinositol 3-kinase activity in the immunoprecipitates was
determined as described by Filippa et al. (13).
Lipid extraction and diacylglycerol measurement. Muscle and adipose tissues
and cells were powdered under liquid nitrogen and then extracted in 1:2 (vol/vol)
chloroform-methanol as described by Turinsky et al. (31). sn-1,2 Diacylglycerol
was determined with the diacylglycerol kinase assay of Preiss et al. (25).
[
-32P]phosphatidic acid was separated by thin-layer chromatography on Silica
Gel-60 plates (Merck) as described previously (31). The plates were developed in
chloroform-methanol-acetic acid (65:15:5, vol/vol/vol), and the positions of the
spots corresponding to [
-32P]phosphatidic acid were determined by autoradiog-
raphy. Radioactivity in the spots was determined by liquid scintillation counting.
Cell culture procedures and transfection. MIN6 cells were cultured in Dul-
becco’s modified Eagle’s medium (Life Technologies, Karlsruhe, Germany) con-
taining 25 mM glucose, 50 	M 2-mercaptoethanol, and 10% fetal calf serum
(Biochrom, Hamburg, Germany) at 37°C in a 5% CO2 atmosphere (23). For
insulin secretion experiments, cells were seeded into 96-well plates at a density of
3 104 cells per well. Three days after plating, the cells were washed with Earle’s
balanced salt solution containing 0.1% bovine serum albumin (Sigma). After
starvation for 1 h in the same salt solution, the cells were incubated with either
0.1 or 16.7 mM glucose, as indicated, for 1 additional hour. The cell supernatant
was filtered through Multiscreen MAVN filter plates (Millipore, Eschborn, Ger-
many) and stored at 20°C until the insulin determination was performed.
Ped/pea-15 antisense (5-TGACGCCTCCGGAGCTGAGA-3) and scram-
bled (5-GGCAATTTCGAGCGGCACGC-3) oligonucleotides were synthe-
sized by PRIMM (Milan, Italy). The ped/pea-15 expression vector has been
reported (7). Transfection of ped/pea-15 cDNA and antisense DNAs was per-
formed as described previously (15).
Adipocytes were isolated from epididymal fat pads by collagenase digestion, as
described previously (28). The number of adipocytes isolated was adjusted to 106
cells/ml of suspension, and 2-deoxyglucose uptake was measured as described
previously (6).
Immunohistochemical analysis. Pancreas from transgenic and control animals
were fixed in 4% paraformaldehyde–0.1 M sodium phosphate buffer at 4°C
overnight and placed in 30% sucrose at 4°C overnight. After being embedded in
Tissue-Tek OTC compound and frozen at 20°C, tissue sections were prepared.
Immunohistochemical analysis was carried out with the H38 rabbit insulin anti-
body (Santa Cruz Biotechnology, Inc.; 1:200 dilution), the N-17 goat glucagon
antibody (Santa Cruz Biotechnology, Inc.; 1:200 dilution), or PED/PEA-15 an-
tiserum (7) (1:20,000 dilution). Incubation with the primary antibody was fol-
lowed by incubation with biotinylated anti-rabbit or anti-goat immunoglobulin G
and peroxidase-labeled streptavidin. Analysis of serial consecutive islet sections
stained with either insulin or the PED/PEA-15 antibodies was used to confirm
ped/pea-15 expression in insulin-immunopositive beta cells.
Statistical procedures. Data were analyzed with Statview software (Abacus-
concepts) by one-factor analysis of variance. P values of less than 0.05 were
considered statistically significant. The total area under the curve for glucose
response during the insulin tolerance test was calculated by the trapezoidal
method.
RESULTS
Generation of transgenic mice overexpressing ped/pea-15.
To investigate the relevance of ped/pea-15 overexpression to
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glucose tolerance, we used the -actin promoter to generate
transgenic mice overexpressing human ped/pea-15 (hped/pea-
15) ubiquitously, as ped/pea-15 overexpression frequently oc-
curs in type 2 diabetes (7) (Fig. 1a). Three lines of mice (L1,
L61, and L30) were established in which ped/pea-15 RNA as
well as ped/pea-15 protein featured a 5 to 20-fold increased
expression in fat, in skeletal and in cardiac muscles, three
major targets of insulin action (Fig. 1b and c). Transgenic mice
were fertile and generated viable offspring showing no signif-
icant growth alterations compared to control mice or other
apparent abnormalities. L1 ped/pea-15 transgenic mice also
exhibited normal fasting glucose levels (Fig. 2a). However,
random-fed blood glucose levels were mildly elevated in the
transgenic (145  40 and 138  28 mg/dl in male and female
mice, respectively) versus the nontransgenic littermates (115 
37 and 103  18 mg/dl in males and females, respectively). The
difference between transgenic and control mice was significant
(P  0.01). In addition, glucose loading (2 mg kg1) rendered
the transgenic mice significantly hyperglycemic for the follow-
ing 120 min. (Fig. 2b and c), indicating decreased glucose
tolerance in ped/pea-15 transgenic mice. Almost identical ab-
normalities were observed in L61 and L30 transgenic mice
(data not shown). As shown in Fig. 2, gender had no effect on
the impairment in glucose tolerance caused by overexpression
of ped/pea-15. Aging (3 to 12 months) also determined no
FIG. 1. Generation of ped/pea-15 transgenic mice. a. Subcloning of
the ped/pea-15 cDNA in the BamHI sites of plasmid pBap2 containing
the -actin promoter. Tissues from ped/pea-15 transgenic mice (Tg)
and their nontransgenic littermates (C) were collected as described
under Materials and Methods and subjected to Northern (b) or West-
ern (c) blotting. Northern blots (25 	g of RNA/lane) were probed with
ped/pea-15 cDNA as reported (6). Loading of the same amount of
RNA in each lane was ensured by further blotting for -actin. Quan-
titation of the blots was performed by densitometric analysis. Data are
plotted as increase of ped/pea-15 mRNA expression in transgenic ver-
sus control mice. Bars represent the means  standard deviation of
comparisons in five transgenic and five nontransgenic animals. For
Western blotting, tissues from control and transgenic mice (L1, L30,
and L6 lines) were solubilized, and lysates (100 	g of protein/lane)
were blotted with PED/PEA-15 antiserum (6), followed by chemilu-
minescence and autoradiography. Three representative experiments
are shown.
FIG. 2. Glucose tolerance in ped/pea-15 transgenic mice. (a) ped/
pea-15 transgenic mice (Tg) and their nontransgenic littermates
(C) were either fasted for 12 h or fed ad libitum (random feeding).
Blood glucose levels were then determined as described under Mate-
rials and Methods. Bars represent the mean  standard deviation of
determinations in at least 10 mice in each group. The differences in
fasting glucose levels between transgenic and control mice were not
statistically significant. Alternatively (b), whole-blood glucose was de-
termined at 0 to 120 min after intraperitoneal glucose injection (2 mg
kg1) of age-matched male (top panel) and female (bottom panel)
transgenic and control mice after overnight fasting. Values are ex-
pressed as mean  standard deviation for at least 12 mice in each
group. Asterisks denote statistically significant differences (**, P 
0.01; ***, P  0.001).
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significant changes in ped/pea-15-induced decreases in glucose
tolerance (data not shown).
Feeding L1 ped/pea-15 transgenic mice and their nontrans-
genic littermates a 60% fat diet for 10 weeks led to a 25%
increased body weight compared to the standard 10% fat diet
(P  0.001; Fig. 3a). This increase in body weight caused only
slight elevations of both fasting and random-fed blood glucose
levels in nontransgenic animals (Fig. 3b). Glucose levels during
tolerance tests were only moderately increased in nontrans-
genic mice after high-fat diet feeding (Fig. 3c). In ped/pea-15
transgenic mice, increased body weight was accompanied by a
significant elevation in both fasting and random-fed blood glu-
cose levels (138  20 and 204  38, respectively, versus 68 
32 and 124  40, respectively, in control mice; P  0.001).
Moreover, as shown by glucose loading, the high-fat diet fur-
ther and severely deteriorated glucose tolerance in the ped/
pea-15 transgenic mice, indicating that, in vivo, overexpression
of ped/pea-15 in conjunction with environmental modifiers may
lead to diabetes. Gender had no significant effect on these
diet-induced abnormalities in ped/pea-15 transgenic mice (data
not shown).
Effect of ped/pea-15 overexpression on insulin sensitivity.
Female L1 ped/pea-15 transgenic mice featured a 10-fold in-
crease in fasting insulin levels compared to control animals
FIG. 3. Effect of high-fat feeding on glucose tolerance in ped/
pea-15 transgenic mice. Three-month-old female transgenic (Tg) and
control (C; nontransgenic littermates) mice were fed either standard
(10% fat) or 60% fat diets for 10 weeks. Animals were then weighed
(a), and blood glucose levels were determined (b) after overnight
fasting and in random-fed animals. Bars represent the mean  stan-
dard deviation of values from at least 10 mice in each group. The
differences in fasting blood glucose levels in control mice treated with
standard or high-fat diets were not statistically significant. Asterisks
denote statistically significant differences (*, P  0.05; ***, P  0.001).
Alternatively (c), glucose tolerance was compared in weight-matched
female transgenic and control animals (at least 10 animals/group)
subjected to the two different diets, as outlined in the legend to Fig. 2.
Differences in blood glucose levels after high-fat diet treatment were
significant at P  0.001 (transgenic mice) and P  0.06 (control mice).
FIG. 4. Insulin sensitivity in ped/pea-15 transgenic mice. Three-
month old female ped/pea-15 transgenic mice and age-matched non-
transgenic littermates (16 per group) were fasted for 12 h, followed by
determination of insulin (a), triglycerides (b), and free fatty acid (c)
levels in plasma as described under Materials and Methods. Bars
represent the mean  standard deviation of duplicate determinations
in each animal. Differences between transgenic and control mice were
significant at P  0.001 (serum insulin) and P  0.01 (serum free fatty
acids and triglycerides). Alternatively, random-fed male (d) or female
(e) mice (n  12/group) were injected intraperitoneally with insulin
(0.75 mU g1), followed by determinations of blood glucose levels at
the indicated times. Values are expressed as mean  standard devia-
tion of duplicate determinations in each animal. Asterisks denote
statistically significant differences (P  0.01).
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(Fig. 4a; P  0.001). Fasting nonesterified free fatty acid and
triglyceride blood concentrations in ped/pea-15 transgenic mice
were also increased by 47 and 65%, respectively, suggesting the
presence of insulin resistance in these animals (Fig. 4b and c;
P  0.01). Almost identical differences were present in male
mice (data not shown). To address the effect of ped/pea-15
overexpression on insulin sensitivity, we performed insulin tol-
erance tests. In control animals, intraperitoneal injection of
insulin (0.125 mU g1) caused a severe and sustained drop in
random-fed blood glucose levels (Fig. 4d and e). This decrease
achieved a maximum (70%; P  0.001) after 45 min and was
maintained for a further 45 min. At variance, insulin reduced
glucose levels by only 40% after 45 min in ped/pea-15 trans-
genic mice, whether male or female. This smaller reduction
was followed by a progressive rescue of the initial blood glu-
cose concentration over the next 45 min. The same differences
were observed in transgenic mice of the L30 and L61 lines and
in control animals (data not shown).
In cultured cells, ped/pea-15 overexpression causes resis-
tance to insulin action on glucose uptake (7). We therefore
asked whether ped/pea-15 overexpression also impairs insulin
stimulation of the glucose transport machinery in vivo. We
compared glucose uptake in perigonadal and subcutaneous fat
and in the tibialis and soleus muscles in L1 ped/pea-15 trans-
genic and in control mice. A 50% decrease in glucose uptake
was observed in perigonadal and subcutaneous fat (Fig. 5a; the
difference from control animals significant at the P 0.001 and
P  0.01 levels, respectively). Also, glucose uptake in the
tibialis and soleus muscles from transgenic animals was de-
creased by 43 and 37%, respectively, compared to the non-
transgenic mice (Fig. 5b; P  0.05). Glucose uptake was sim-
ilarly reduced in both female and male transgenic mice (data
not shown). Thus, insulin resistance in peripheral tissues might
provide an important contribution to the impaired glucose
tolerance of ped/pea-15 transgenic mice. In parallel with the
decreased glucose uptake, GLUT4 membrane translocation in
response to insulin and feeding was also significantly decreased
in tibialis muscles and perigonadal adipose tissues from ped/
pea-15 transgenic mice (Fig. 5c). This abnormality was accom-
panied by no significant change in the total GLUT4 levels in
transgenic muscle or adipose tissues.
PKC signaling in ped/pea-15 transgenic mice. To address the
molecular mechanism responsible for these abnormalities, we
measured PKC activity in immunoprecipitates from lysates of
transgenic and control tissues. PKC activity was constitutively
increased in adipose tissue from fasted transgenic mice (Fig.
6a). In addition, there was little further activation in the ran-
dom-fed state in these animals, even upon insulin injection. At
variance with the ped/pea-15 transgenic mice, PKC activity
increased by twofold in the fed state in the nontransgenic mice.
In addition, in these mice, insulin further increased PKC
activity up to 2.5-fold above fasting levels.
The differences in PKC activity between transgenic and
control mice were accompanied by parallel changes in phos-
phorylation of the Ser657 PKC key activation site, with no
change in the total levels of PKC in the tissues (Fig. 6b). In
the control mice, transition from the fasted to the fed state was
also accompanied by fourfold-increased phosphorylation of
the Thr410 key activation site of PKC/ (P 0.001), indicating
PKC/ activation. A similar induction of PKC/ was ob-
served after administration of insulin to those animals (data
not shown). The effect of feeding was decreased by 50% (P 
0.05) and 80% (P  0.01) in muscle and adipose tissues, re-
spectively, from the ped/pea-15 transgenic mice. Again, the
decrease in PKC/ activation was accompanied by no signif-
icant change in the total PKC/ levels in the tissues. The same
changes in PKC and / were observed in male and female
ped/pea-15 transgenic mice (data not shown).
PED/PEA-15 is a phospholipase D interactor and increases
phospholipase D cellular activity by enhancing its expression
level (34). We therefore compared the levels of the phospho-
lipase D product diacylglycerol in extracts from transgenic and
control tissues, as diacylglycerol is a major PKC activator. As
FIG. 5. Glucose transport in ped/pea-15 transgenic mice. (a)
Weight-matched female transgenic (Tg; n  6) and control (C; n  6)
mice were subjected to intraperitoneal injection of D-[1,2-3H]glucose
(2g kg of body weight1; 10 	Ci/mouse) and insulin (0.75 mU g of body
weight1) and killed, and tissues were snap-frozen in liquid nitrogen.
D-[1,2-3H]glucose-6-phosphate accumulated in muscle and fat tissues
was quantitated as described under Materials and Methods. Bars rep-
resent mean values  standard deviations. Differences between con-
trol and transgenic animals were significant at P  0.05 (tibialis and
soleus muscles), P  0.01 (subcutaneous fat), and P  0.001 (perigo-
nadal fat). (b) Alternatively, tissues from insulin-injected animals were
frozen in liquid nitrogen and harvested for plasma membrane prepa-
ration as described under Materials and Methods. Total homogenates
and plasma membrane lysates were then analyzed by Western blotting
with GLUT4 antibodies. Blots were revealed by enhanced chemilumi-
nescence and autoradiography. The autoradiographs shown are rep-
resentative of four independent experiments.
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revealed by thin-layer chromatography analysis, there diacyl-
glycerol levels in subcutaneous and perigonadal adipose tissues
from the ped/pea-15 transgenic mice were increased 2-fold
(Fig. 6d; P  0.01). In tibialis muscles from ped/pea-15 trans-
genic mice, diacylglycerol levels were also increased by 60% (P
 0.05) over that in the nontransgenic mice. Thus, diacylglyc-
erol levels in fat and skeletal muscle tissues correlated with
PED/PEA-15-induced PKC activity in these tissues. PLD1
expression was also two- and fivefold higher in muscle and
adipose tissues, respectively, from transgenic versus control
mice (Fig. 6c; P  0.001). This additional finding suggested
that increased phospholipase activity is at least one of the
mechanisms determining the high diacylglycerol levels in the
tissues of the transgenic mice.
The significance of these findings to the impaired insulin-
stimulated glucose uptake in tissues from ped/pea-15 trans-
genic mice was addressed further in adipocytes isolated from
the animals. Consistent with the fat tissue, isolated adipocytes
from the transgenic mice showed an almost fivefold decrease in
insulin-induced glucose uptake compared to control cells (P 
FIG. 6. PKC activation in ped/pea-15 transgenic mice. (a) Weight-
matched female mice were fasted overnight or fed ad libitum, followed
by intraperitoneal insulin injection (0.75 mU g1 body weight), as
indicated. The animals were killed, and perigonadal fat tissue was
collected, homogenized, and immunoprecipitated with PKC antibod-
ies. PKC activity was assayed in the immunoprecipitates as outlined
under Materials and Methods. Bars represent the mean  standard
deviation of data from at least seven mice per group. Asterisks denote
statistically significant differences (P  0.01). Alternatively, fat or mus-
cle tissues were solubilized, and lysates were Western blotted with
phospho-PKC (P-PKC), PKC (panel b), or phospholipase D 1(PLD1)
antibodies (panel c). Bands were revealed by enhanced chemilumines-
cence and autoradiography. The autoradiographs shown are represen-
tative of four (PKC and phospholipase D 1) and three (PKC) inde-
pendent experiments. (d) For determining diacylglycerol levels, tissues
were extracted in chloroform-methanol, and lipid extracts were as-
sayed by adding diacylglycerol kinase and [
-32P]ATP as described
under Materials and Methods. [32P]phosphatidic acid was separated by
thin-layer chromatography and quantitated by liquid scintillation
counting. Bars represent the mean  standard deviation of data from
at least six mice per group. Asterisks denote statistically significant
differences (*P  0.05, **P  0.01).
FIG. 7. Bisindolylmaleimide and propanolol effects on 2-deoxyglu-
cose uptake in epididymal fat adipocytes from ped/pea-15 transgenic
mice. Adipocytes from transgenic (Tg) and control (C) mice were
incubated with 100 nM bisindolylmaleimide (BDM) or 150 	M pro-
panolol for 30 min, as indicated; 100 nM insulin (final concentration)
was then added, and the cells were assayed for 2-deoxyglucose uptake
(a). Lysates of adipocytes from transgenic and control mice were im-
munoprecipitated with PKC antibodies, followed by determination of
PKC activity (b), as described under Materials and Methods. Alterna-
tively, the cells were extracted and diacylglycerol (DAG) levels were
determined as described under Materials and Methods (c). Bars rep-
resent the means  standard deviation of duplicate determinations in
four (2-deoxyglucose uptake), three (PKC activity), and five (diacyl-
glycerol levels) independent experiments with fat pads from five trans-
genic and five control mice. Asterisks denote statistically significant
differences (**, P  0.001).
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0.01; Fig. 7a). Bisindolylmaleimide incubation reduced PKC
activity by fourfold in both wild-type and transgenic mouse
adipocytes (P  0.01; Fig. 7b). Simultaneously, bisindolylma-
leimide almost completely rescued insulin-stimulated glucose
uptake in transgenic mouse adipocytes (Fig. 7a). Preincubation
with the phospholipase D inhibitor propanolol also caused a
50% reduction in diacylglycerol and PKC activity in adipo-
cytes from transgenic as well as control mice. As with bisin-
dolylmaleimide, these changes were accompanied by a signif-
icant recovery of insulin-stimulated glucose uptake, indicating
an important role of the phospholipase D/PKC pathway in
alteration of glucose uptake by ped/pea-15.
Activation of the phosphatidylinositol 3-kinase/Akt/protein
kinase B (PKB) pathway is a major event leading to stimula-
tion of GLUT4 translocation by insulin. However, insulin in-
jection caused a twofold activation of phosphatidylinositol
3-kinase in skeletal muscles from both transgenic and control
mice (Fig. 8a). Based on immunoblotting with specific phos-
pho-Ser473 Akt antibodies, Akt/PKB activity was also normally
induced by insulin in transgenic muscles (Fig. 8b), with no
gender-related difference (data not shown). It therefore ap-
peared that dysregulation of PKC signaling is a major mecha-
nism responsible for ped/pea-15-induced resistance to insulin
action in glucose uptake, independently of the phosphatidyl-
inositol 3-kinase/Akt/PKB pathway. The mechanism of ped/
pea-15 inhibition of insulin-stimulated glucose uptake is shown
schematically in Fig. 8c.
Glucose-regulated insulin secretion in ped/pea-15 transgenic
mice. Based on insulin tolerance tests, ped/pea-15 transgenic
mice developed only a further 20% increase in insulin resis-
tance after the high-fat diet (Fig. 9a; difference from animals
fed the standard diet was significant at the P  0.05 level). In
comparison, nontransgenic mice underwent a 60% reduction
in their sensitivity to insulin (P  0.01), and became as insulin
resistant as their transgenic littermates (difference from trans-
genic mice not significant). Nevertheless, nontransgenic mice
showed little change in glucose tolerance after the high-fat
diet, while ped/pea-15 transgenic mice developed diabetes (Fig.
3c). We therefore hypothesized that resistance to insulin action
alone is not sufficient to cause the alteration in glucose toler-
ance of the ped/pea-15 transgenic mice.
To address this possibility, we first analyzed the expression
of ped/pea-15 in beta cells of the transgenic mice. Staining of
pancreas sections with specific PED/PEA-15 antibodies re-
vealed a significant increase in the immunoreactivity of the
islet cores, where beta cells are localized, in L1 transgenic
compared to control mice (Fig. 9b). At variance, both insulin
and glucagon immunoreactivities were comparable in ped/
pea-15 transgenic mice and controls. We next compared insulin
secretion following a glucose load in L1 ped/pea-15 transgenic
mice and in their nontransgenic littermates. In control mice, a
five- to sixfold increase in insulin secretion was observed 2 min
after intraperitoneal glucose injection, and the levels remained
higher than baseline values for up to 30 min, indicating a
second-phase response (Fig. 9c). Based on insulin area under
the curve quantitation, the acute first-phase insulin secretory
response to glucose was reduced by almost 70% in transgenic
mice (P  0.001). The second-phase response was also signif-
icantly impaired in ped/pea-15 transgenic mice compared to
control mice (P  0.01). Almost identical decreases in early
and late insulin responses were observed in both male and
female transgenic mice. Again, defective insulin secretion was
also observed with the L30 and L61 mouse lines (data not
shown).
To test the further hypothesis that overexpression of ped/
pea-15 is sufficient to impair hyperglycemia-induced insulin
secretion, we generated MIN6 beta-cell lines stably overex-
pressing ped/pea-15 by 3- to 10-fold above endogenous levels
(Fig. 10a). We then compared insulin secretion in these cells
and in cells expressing only endogenous ped/pea-15. MIN6
control cells responded with a fivefold induction in insulin
FIG. 8. Activation of phosphatidylinositol 3-kinase and Akt in ped/
pea-15 transgenic mice. (a) Weight-matched female mice were fasted
overnight or fed ad libitum, followed by intraperitoneal insulin injec-
tion (0.75 mU g of body weight1), as indicated. Animals were sacri-
ficed, and the tibialis muscles were collected, homogenized, and as-
sayed for phosphatidylinositol (PI) 3-kinase activity as described under
Materials and Methods. Bars represent the mean standard deviation
of data from five mice per group. The difference in insulin-induced
PKB in transgenic versus control mice was not statistically significant.
(b) Alternatively, tissue lysates were Western blotted with either PKB
or phospho-PKB antibodies. Filters were revealed by enhanced chemi-
luminescence and autoradiography. The autoradiographs shown are
representative of four independent experiments. (c) Proposed mech-
anism of PED action on insulin-stimulated glucose transport (details in
the text). Asterisks denote statistically significant differences (*, P 
0.05; **, P  0.01).
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FIG. 9. Insulin secretion in ped/pea-15 transgenic mice. (a) Transgenic (Tg) and control (C) female mice were fed either a 10% fat standard
or a 60% high-fat diet for 10 weeks. Weight-matched animals were then subjected to intraperitoneal insulin tolerance tests as outlined in the legend
to Fig. 4. The effect of the high-fat diet on insulin tolerance is expressed as total areas under the curve (glucose AUC). Bars represent the mean
 standard deviation of data from seven mice per group. Asterisks denote statistically significant differences versus mice maintained on the
standard diet (*, P  0.05; **, P  0.01; ***, P  0.001). (b) Overexpression of ped/pea-15 in pancreas from ped/pea-15 transgenic mice. Pancreas
from ped/pea-15 male transgenic mice (Tg) and their nontransgenic littermates (C) were fixed and embedded in Tissue-Tek OTC, and sections were
prepared as described under Materials and Methods. Immunohistochemical analysis of the islets was carried out with PED/PEA-15, insulin, and
glucagon antibodies as indicated. Anti-rabbit or anti-goat immunoglobulin G was used as the second antibody. Immunoreactivity was revealed by
peroxidase-labeled streptavidin. The microphotographs shown are representative of images obtained from eight transgenic (four male and four
female) and seven nontransgenic mice (three male and four female). (c) Weight-matched transgenic and control mice were subjected to
intraperitoneal glucose loading as outlined in the legend to Fig. 2, followed by determination of plasma insulin levels at the indicated times. Data
points represent the mean  standard deviation of determinations in 14 transgenic (seven female and seven male) and 16 control mice (eight
female and eight male). Differences between control and transgenic mice were statistically significant, as indicated in the text.
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secretion when subjected to physiological increases in the glu-
cose concentration in the medium (Fig. 10b). In these same
cells, the overexpression of ped/pea-15 increased basal insulin
secretion (30 to 80%, P  0.01) and reduced that induced by
glucose by 50 to 90% (P  0.001). These changes closely
correlated with the expression levels of ped/pea-15 achieved in
the cells. Treatment with a specific antisense oligonucleotide
effectively blocked ped/pea-15 expression and almost com-
pletely rescued the abnormal insulin secretion in the ped/
pea-15 overexpressors (Fig. 10c and d). More importantly, an-
tisense transfection of cells expressing only the endogenous
ped/pea-15 enhanced glucose-induced insulin secretion by 2-
fold, indicating that this gene has a physiological role in con-
trolling beta-cell secretion in response to glucose.
As in other cell types, overexpression of ped/pea-15 in MIN6
cells also caused a twofold activation of PKC (Fig. 11a, P 
0.001). Moreover, phospholipase D 1 and diacylglycerol levels
in ped/pea-15 overexpressing MIN6 cells were increased com-
pared to those in control cells by 2.5- and 3-fold, respectively
(Fig. 11b and c, P  0.001). Thus, activation of the phospho-
FIG. 10. Insulin secretion in ped/pea-15-overexpressing MIN6 cells.
(a) MIN6 beta cells were stably transfected with ped/pea-15 cDNA.
Several clones overexpressing ped/pea-15 by 3-, 5-, and 10-fold were
selected. Three clones were further characterized (termed clones a, b,
and c). (b) Transfected cell clones, untransfected cells (NT), and cells
transfected with the empty plasmid (PC) were stimulated with either
0.1 mM glucose (open bars) or 16.7 mM glucose (dashed bars), and
insulin was assayed in the culture medium as described in the text. Bars
represent values  standard deviation of triplicate measurements in
five independent experiments. The differences between ped/pea-15-
overexpressing (all clones) and control cells (whether untransfected or
transfected with the empty plasmid) were significant at P  0.01 (basal
secretion) and P  0.001 (glucose-induced secretion). (c) Alterna-
tively, control cells transfected with the empty plasmid (PC) or clone c
(Cl.c) cells were transfected either with ped/pea-15 antisense (AS) or
with scrambled (SC) oligonucleotides. (d) Glucose-stimulated insulin
secretion was assayed as outlined above. Bars represent values 
standard deviation of triplicate measurements in four independent
experiments. Basal insulin secretion differences in the antisense versus
scrambled oligonucleotide-treated cells were significant at P  0.001
(empty plasmid-transfected cells) and P  0.01 (clone c cells). Glu-
cose-stimulated secretion differences in the antisense versus scrambled
oligonucleotide-treated cells were also significant at the P  0.001
(empty plasmid-transfected cells) and P  0.01 levels (clone c cells).
FIG. 11. PKC activity, phospholipase D1 expression, and diacyl-
glycerol levels in ped/pea-15-overexpressing MIN6 cells. MIN6 beta
cells stably transfected with ped/pea-15 cDNA (clone c) or the empty
vector (empty plasmid-transfected cells [PC]) and untransfected cells
(NT) were assayed for PKC activity (a), phospholipase D1 (PLD1)
expression (b), and diacylglycerol (DAG) (c) levels as outlined in the
legend to Fig. 6. Western-blotted phospholipase D1 bands were re-
vealed by enhanced chemiluminescence and autoradiography and
quantitated by laser densitometry. Bars represent the means  stan-
dard deviation of four (PKC and phospholipase D1), and five (diac-
ylglycerol) independent determinations. Based on t test analysis, the
differences between ped/pea-15-overexpressing and control cells were
significant at the P  0.001 level.
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lipase D/PKC pathway also occurs in beta cells overexpressing
ped/pea-15.
DISCUSSION
Analysis of the gene expression profile revealed increased
expression of the ped/pea-15 gene in skeletal muscle and adi-
pose tissues from individuals with type 2 diabetes (7). More
recently, 5- to 20-fold overexpression of ped/pea-15 has been
demonstrated to occur in almost 30% of the type 2 diabetics in
a large Italian cohort, indicating that increased expression of
the ped/pea-15 gene is a common abnormality in this form of
diabetes (R. Valentino and F. Beguinot, unpublished data). In
other studies, we reported that overexpression of ped/pea-15 in
cultured skeletal muscle cells and adipocytes impairs insulin
action on glucose transport and cell surface recruitment of
GLUT4 (7, 8). However, whether the ped/pea-15 defect alone
impairs glucose tolerance in vivo remains unknown.
In the present work, we report that transgenic mice overex-
pressing ped/pea-15 to levels comparable to those occurring in
human type 2 diabetes exhibit mildly elevated random-fed
blood glucose levels and become hyperglycemic after glucose
loading, indicating that increased expression of this gene is
sufficient to impair glucose tolerance. Moreover, ped/pea-15
transgenic mice become diabetic when body weight increases
through administration of high-fat diets. This additional find-
ing suggests an important interaction of environmental modi-
fiers with ped/pea-15 gene function, leading to a further de-
rangement in glucose tolerance. Based on the insulin tolerance
tests, ped/pea-15 transgenic mice are much more insulin resis-
tant than their nontransgenic littermates. The transgenic mice
were consistently markedly hyperinsulinemic in the basal state
and exhibited increased free fatty acid levels in blood. The
transgenic mice also show reduced insulin response to a glu-
cose challenge, indicating that the overexpression of ped/
pea-15 impairs insulin secretion in addition to insulin action. In
addition, we found that, when fed high-fat diets, these animals
become as insulin resistant as their nontransgenic littermates.
Nevertheless, ped/pea-15 transgenic mice develop random hy-
perglycemia while control animals remain euglycemic. It there-
fore appears that both decreased glucose-stimulated insulin
secretion and impaired insulin action contribute to the abnor-
mal glucose tolerance determined by ped/pea-15 gene overex-
pression.
Decreased insulin sensitivity in ped/pea-15 transgenic mice
might have been determined by the increased free fatty acids
(1, 3, 27). However, it is unlikely that higher free fatty acid
levels in ped/pea-15 transgenic mice could completely account
for insulin resistance, as ped/pea-15 overexpression also im-
pairs insulin action on glucose uptake in cultured cells (7, 8).
Previous studies in yeasts as well as in eukaryotic cells showed
that ped/pea-15 gene encodes a phospholipase D interactor
(35). Importantly, in cultured cells, binding to PED/PEA-15
protein stabilizes the phospholipase, leading to enhanced
phospholipase activity (35). In L6 skeletal muscle cells stably
overexpressing ped/pea-15, inhibition of phospholipase D ac-
tivity rescues insulin action on glucose transport (our unpub-
lished observations), underlining the importance of proper
phospholipase D function for normal insulin sensitivity of the
insulin-regulated glucose transport system. In addition, our
previous work has shown that L6 cells overexpressing ped/
pea-15 feature constitutive activation of the classical PKC iso-
form PKC (8). Activation of PKC by ped/pea-15, in turn,
determines almost complete loss of PKC/ sensitivity to insu-
lin and of insulin action on glucose transport in these cells (8).
We now show that muscle and fat tissues from ped/pea-15
transgenic mice also feature reduced insulin action on glucose
transport and PKC/ activation and, simultaneously, in-
creased PKC activity and phospholipase D levels. Transgenic
tissues also exhibit increased levels of diacylglycerol, a major
activator of PKC. The same abnormalities persist in epidid-
ymal fat pad adipocytes from ped/pea-15 transgenic mice. In
these cells, as in L6 muscle cells overexpressing ped/pea-15 (8),
pharmacological block of PKC or phospholipase D activities
rescues insulin-stimulated glucose transport. Thus, the overex-
pression of ped/pea-15 in tissues from the transgenic mice
seems to determine insulin resistance in glucose disposal by
inhibiting PKC/ function through the induction of PKC
(Fig. 7). Consistent with this mechanism, Leitges et al. have
recently shown that elimination of the PKC gene by homol-
ogous recombination enhances insulin signaling and action on
glucose transport in mice (22).
Insulin-induced activation of atypical PKCs is markedly im-
paired in tissues of type 2 diabetic individuals as well as in
those from animal models of type 2 diabetes (12, 17, 18, 19).
This abnormality has been proposed to account for the de-
creased insulin-stimulated glucose disposal observed during
hyperinsulinemic-euglycemic clamps in type 2 diabetic humans
and monkeys (12). The defective activation of atypical PKCs in
skeletal muscle from type 2 diabetic individuals was also shown
to be independent of PKC protein levels and accompanied by
normal activation of phosphatidylinositol 3-kinase and Akt by
insulin (12, 19, 20). Based on those studies, however, the mech-
anism responsible remains unclear. The finding that ped/pea-15
gene overexpression impairs glucose disposal in major insulin
target tissues by inhibiting insulin activation of PKC/ indi-
cates that, at least in part, the impaired glucose utilization in
type 2 diabetics can be accounted for by increased levels of
ped/pea-15. In fact overexpression of ped/pea-15 was found to
represent a common abnormality in type 2 diabetes (7), and
this defect does not determine changes in phosphatidylinositol
3-kinase or Akt activation by insulin in either cultured skeletal
muscle cells (7, 8) or muscle tissue from ped/pea-15 transgenic
mice.
The abnormal beta-cell function in ped/pea-15 transgenic
mice might have been caused by the metabolic consequences
of insulin resistance. More likely, ped/pea-15 overexpression
directly impairs beta-cell function. In fact, we have shown that
ped/pea-15 overexpression in cultured beta cells causes a two-
fold increase in basal insulin secretion and inhibits that in-
duced by glucose. Thus, beta-cell overexpression may contrib-
ute to the basal hyperinsulinemia found in ped/pea-15
transgenic mice while rendering them unable to compensate
for hyperglycemia by further increasing plasma insulin levels.
Similar to other tissues from the transgenic mice, overexpres-
sion of ped/pea-15 in cultured beta cells led to activation of the
phospholipase D/PKC pathway. At variance with insulin-reg-
ulated glucose transport, however, PKC inhibition allowed
only partial reversal of the insulin secretion defect in ped/pea-
15-overexpressing beta cells (data not shown). Thus, abnormal
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PKC signaling might contribute to the secretion abnormali-
ties in these cells. Whether different mechanisms play a major
role and the identity of these mechanisms remain to be defined
and are presently under investigation in our laboratory.
The control of glucose-regulated insulin secretion appears to
represent a physiological function of ped/pea-15 in beta cells.
Hence, transfection of a specific antisense oligonucleotide into
MIN6 cells expressing only endogenous ped/pea-15 enhanced
glucose-induced insulin secretion by almost threefold. This
additional finding identifies ped/pea-15 as a novel gene con-
trolling insulin secretion in addition to insulin action. Under
appropriate environmental conditions, ped/pea-15 overexpres-
sion leads to diabetes by impairing both of these functions and
may contribute to genetic susceptibility to type 2 diabetes in
humans.
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PED/PEA-15 Regulates Glucose-Induced Insulin
Secretion by Restraining Potassium Channel Expression
in Pancreatic -Cells
Claudia Miele,1 Gregory Alexander Raciti,1 Angela Cassese,1 Chiara Romano,1 Ferdinando Giacco,1
Francesco Oriente,1 Flora Paturzo,1 Francesco Andreozzi,2 Assunta Zabatta,3 Giancarlo Troncone,3
Fatima Bosch,4 Anna Pujol,4 Herve´ Chneiweiss,5 Pietro Formisano,1 and Francesco Beguinot1
The phosphoprotein enriched in diabetes/phosphoprotein
enriched in astrocytes (ped/pea-15) gene is overexpressed
in human diabetes and causes this abnormality in mice.
Transgenic mice with -cell–specific overexpression of ped/
pea-15 (-tg) exhibited decreased glucose tolerance but
were not insulin resistant. However, they showed impaired
insulin response to hyperglycemia. Islets from the -tg also
exhibited little response to glucose. mRNAs encoding the
Sur1 and Kir6.2 potassium channel subunits and their
upstream regulator Foxa2 were specifically reduced in
these islets. Overexpression of PED/PEA-15 inhibited the
induction of the atypical protein kinase C (PKC)- by
glucose in mouse islets and in -cells of the MIN-6 and
INS-1 lines. Rescue of PKC- activity elicited recovery of
the expression of the Sur1, Kir6.2, and Foxa2 genes and of
glucose-induced insulin secretion in PED/PEA-15–overex-
pressing -cells. Islets from ped/pea-15–null mice exhib-
ited a twofold increased activation of PKC- by glucose;
increased abundance of the Sur1, Kir6.2, and Foxa2
mRNAs; and enhanced glucose effect on insulin secretion.
In conclusion, PED/PEA-15 is an endogenous regulator of
glucose-induced insulin secretion, which restrains potas-
sium channel expression in pancreatic -cells. Overexpres-
sion of PED/PEA-15 dysregulates -cell function and is
sufficient to impair glucose tolerance in mice. Diabetes 56:
622–633, 2007
Type 2 diabetes is a genetically determined disor-der for which the pathogenesis is characterizedby development of impaired secretogogue-regu-lated insulin secretion and insulin resistance
(1,2). Metabolic abnormalities caused by insulin resistance
contribute to -cell dysfunction in type 2 diabetes (3–5).
Deranged -cell function is also determined by genetic
factors, but their identity remains elusive (3,5).
Phosphoprotein enriched in diabetes/phosphoprotein
enriched in astrocytes (PED/PEA-15) was originally iden-
tified as a major astrocyte phosphoprotein (6,7) and found
to be widely expressed in different tissues (8) and highly
conserved among mammals (7). It is a highly regulated
protein (6,9,10) whose gene maps on human chromosome
1q21-22 (8). Several studies in cultured cells and rodent
tissues have revealed that PED/PEA-15 is a cytosolic
scaffold protein, as it regulates multiple cellular functions
by binding to distinct components of major intracellular
transduction pathways (10–14). These include extracellu-
lar signal–related kinase-1/2, Akt, and ribosomal protein
S6kinase2. PED/PEA-15 is a death effector domain–con-
taining protein (15). In part through this interaction do-
main, it inhibits a number of molecules conveying
apoptotic signals to the nucleus (10–12). PED/PEA-15 also
binds to and increases the stability of phospholipase D,
enhancing its activity and controlling important mecha-
nisms in cell metabolism (14).
Gene profile studies evidenced that ped/pea-15 is com-
monly overexpressed in individuals with type 2 diabetes
(8,16). In cultured muscle and adipose cells and in periph-
eral tissues from transgenic mice, high levels of PED/
PEA-15 impair insulin-stimulated GLUT4 translocation and
glucose transport, suggesting that PED/PEA-15 overex-
pression may contribute to insulin resistance in type 2
diabetes (13,17). Indeed, more recent studies revealed that
in offspring of type 2 diabetic subjects, PED/PEA-15 levels
negatively correlate to insulin sensitivity (16). Other stud-
ies have demonstrated that PED/PEA-15–induced resis-
tance to insulin action on glucose disposal is accompanied
by phospholipase D–dependent activation of the classical
protein kinase C (PKC) isoform PKC- (13). In turn, the
induction of PKC- by PED/PEA-15 prevents subsequent
activation of the atypical PKC- by insulin (13,17). Rescue
of PKC- activity in cells overexpressing PED/PEA-15
restores normal sensitivity to insulin of the glucose trans-
port machinery (17). Thus, in muscle and adipose cells,
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PED/PEA-15 generates resistance to insulin action on
glucose disposal by impairing normal regulation of PKC-
(17). Characterization of transgenic mice overexpressing
PED/PEA-15 ubiquitously evidenced that, in addition to
generating insulin resistance and altered glucose toler-
ance, high levels of PED/PEA-15 impair glucose-regulated
insulin secretion (13). Whether this effect is directly
caused by the action of PED/PEA-15 in the -cell and
through which mechanism was not conclusively estab-
lished in these studies. Whether PED/PEA-15–determined
-cell abnormalities are sufficient to impair glucose toler-
ance in these mice is also unknown.
RESEARCH DESIGN AND METHODS
Generation of transgenic mice. The rip-I/ped/pea-15 chimeric gene was
obtained by introducing a 2.3-Kb EcoRI fragment containing the entire human
ped/pea-15 cDNA at the EcoRI site in a pB5-RIP--globin expression vector
(kindly provided by Prof. D. Accili, Columbia University, NY). This chimeric
gene was microinjected into fertilized C57BL6/SJL mouse eggs. The general
procedures used for microinjection and animal selection have been previously
described (18). Six F0 founders were identified by PCR as in reference 13. Mice
were fed ad libitum with a standard diet (Research Diets formulas D12328;
Research Diets, New Brunswick, NJ) and kept under a 12-h light/12-h dark
cycle. Tissue samples were collected rapidly after mice were killed by
pentobarbitone overdose. Tissues were snap frozen in liquid nitrogen and
stored at 80°C. All procedures described below were approved by the
institutional animal care and utilization committee. Blood glucose levels were
measured with glucometers (A. Menarini Diagnostics, Florence, Italy); insulin
was measured by radioimmunoassay (RIA) with rat insulin as standard
(Insulin Rat RIA kit; Linco Research, St. Louis, MO). Fasting plasma free fatty
acids were measured with the Wako NEFA C kit (Wako Chemicals, Richmond,
VA), and triglycerides were measured with the Infinity triglyceride reagent
(Sigma-Aldrich, St. Louis, MO).
Determination of glucose and insulin tolerance and assessment of
insulin secretion and glucose utilization. Glucose tolerance tests, insulin
tolerance tests, and insulin secretion were measured as previously described
(19,20). For analyzing glucose utilization by skeletal muscle, an intravenous
injection of 1 Ci of the nonmetabolizable glucose analog 2-[1-3H]deoxy-D-
glucose (2-DG) (Amersham Pharmacia Biotech, Piscataway, NJ) and an
intraperitoneal injection of insulin (0.75 mU/g body wt) were administered to
random fed mice. The specific blood 2-DG clearance was determined with
25-l blood samples (tail vein) obtained 1, 15, and 30 min after injection as
previously reported (21). Skeletal muscles were removed 30 min after the
injections. Glucose utilization index was determined by measuring the accu-
mulation of radiolabeled compound (22). The amount of 2-DG-6 phosphate
per milligram of protein was then divided by the integral of the concentration
ratio of 2-DG to the measured unlabeled glucose. Glucose utilization indexes
were expressed as picomoles per milligram of protein per minute.
Immunoistochemistry and morphometric analysis. Generation of PED/
PEA-15 antibody has been previously reported (8). Immunoistochemical
detection of PED/PEA-15, insulin, and glucagon in pancreases from control
and transgenic mice were analyzed as described (13). Analysis of serial
consecutive islet sections stained with either insulin or PED/PEA-15 antibod-
ies was used to confirm PED/PEA-15 expression in insulin-immunopositive
-cells. Sections were also stained with hematoxylin and eosin. For morphom-
etry, pancreases were obtained from 6-month-old control and transgenic mice,
and immunohistochemical detection of insulin was performed in three sec-
tions (2–3 m) separated by 200 m as in reference 18.
Islet isolation, ex vivo insulin secretion assessment, and estimation of
pancreatic insulin content. Islets were isolated from 6-month-old mice by
collagenase digestion and subsequent centrifugation on a Histopaque (Sigma-
Aldrich) gradient as in reference 23. A total of 20 islets were manually selected
and preincubated in Dulbecco’s modified Eagle’s medium (Life Technologies) at
37°C in a 5% CO2 atmosphere for 24 h. Islets were then further incubated in
Krebs-Ringer buffer (120 mmol/l NaCl, 1.2 mmol/l MgSO4, 5 mmol/l KCl, 10 mmol/l
NaHCO3, 1.3 mmol/l CaCl2, and 1.2 mmol/l KH2PO4) for 30 min and then
stimulated at 37°C with various concentrations of either glucose for 1 h, KCl for
30 min, or glyburide (Sigma-Aldrich) for 1 h. Islets were subsequently collected by
centrifugation and supernatants assayed for insulin content by RIA. For measur-
ing total pancreatic insulin content, pancreases were solubilized in acid-ethanol
solution (75% ethanol, 1.5% HCl) overnight at 4°C and centrifuged for 15 min at
800g. Insulin was measured in the supernatants by RIA.
Cell culture procedures and transfection. MIN-6 cells were cultured in
Dulbecco’s modified Eagle’s medium containing 25 mmol/l glucose, 50 mol/l
2-mercaptoethanol, and 10% FCS (Biochrom) at 37°C in a 5% CO2 atmosphere
(24). INS-1 cells were cultured in RPMI-1640 medium (Life Technologies)
containing 11 mmol/l glucose, 50 mol/l 2-mercaptoethanol, and 10% fetal
bovine serum (Biochrom) at 37°C in a 5% CO2 atmosphere (25). Stable
transfection of the ped/pea-15 cDNA was performed with the lipofectamine
method (13) according to the manufacturer’s instructions. Transient transfec-
tion of the PKC- cDNA was also performed with the lipofectamine method.
By using PCAGGS--Gal as a reporter, transfection efficiency was between 65
and 85%, staining with the chromogenic substrate 5-bromo-4-chloro-3-indolyl
b-D-galactopyranoside.
Northern blot and real-time RT-PCR analysis. Total cellular RNA was
isolated from pancreatic islets and tissue samples by using the RNeasy kit
(Qiagen Sciences) according to the manufacturer’s instructions. Northern blot
analysis was performed as in reference 18. For real-time RT-PCR analysis, 1
g islet or cell RNA was reverse transcribed using Superscript II Reverse
Transcriptase (Invitrogen, Carlsbad, CA). PCR were analyzed using SYBR
Green mix (Invitrogen). Reactions were performed using Platinum SYBR
Green qPCR Super-UDG using an iCycler IQ multicolor Real Time PCR
Detection System (Biorad, Hercules, CA). All reactions were performed in
triplicate, and -actin was used as an internal standard. Primer sequences
used were as follows: PED/PEA-15 forward 5-TTCCCGCTGTTCCCTTAGG-3,
PED/PEA-15 reverse 5-TCTGGCTCATCCGCATCC-3; Kir6.2 forward 5-TC
CACCAGGTAGACATCCC-3, inwardly rectifying K channel 6.2 (Kir6.2)
reverse 5-TAGGAGCCAGGTCGTAGAG-3; sulfonylurea receptor 1 (SUR1)
forward 5-GCATCAACTTGTCTGGTG-3, SUR1 reverse 5-ACTGTCCTCTT
GTCATCC-3; forkhead box A2 (Foxa2) forward 5-CACCTGAGTCCGAGTCTG
3, Foxa2 reverse 5-CGAGTTCATGTTGGCGTAG-3; glucose transporter 2
(Glut2) forward 5-ACAGTCACACCAGCATAC-3, Glut2 reverse 5-ACCCA
CCAAAGAATGAGG3; glucokinase (GK) forward 5-GCTGTACGAAAAGAT
CATTGG-3, GK reverse 5-CTCCGTGGAACAGAAGATTC-3; hexokinase
(HK)1 forward 5-ACGACACCCCAGAGAACATC-3, HK1 reverse 5-AGTCTC
CGAGGCATTCAGC-3; HK2 forward 5-CTCAGGACACCACAGGCTAC-3,
HK2 reverse 5-TTCACTCACTGGGTCACTAAGG-3; and -actin forward
5-GCGTGACATCAAAGAGAAG-3, -actin reverse 5-ACTGTGTTGGCATA
GAGG-3.
Western blot analysis and PKC assay. Tissues homogenates and cell
lysates were separated by SDS-PAGE and analyzed by Western blot as
previously described (13,17,26). Membranes were probed with antibodies to
PED/PEA-15 (8), PKC- (Santa Cruz Biotechnology, Santa Cruz, CA), or
tubulin (Santa Cruz Biotechnology). For analyzing atypical PKC activity, cells
were incubated with Krebs-Ringer buffer for 30 min and then incubated with
either 2.8 or 16.7 mmol/l glucose containing medium for 1 h at 37°C in a 5%
CO2 atmosphere. Cells were solubilized in lysis buffer (25 mmol/l Tris-HCl, pH
7.4, 0.5 mmol/l EDTA, 0.5 mmol/l EGTA, 0.05% Triton X-100, 10 mmol/l
-mercaptoethanol, 1 g/ml leupeptin, and 1 g/ml aprotinin) for 1 h at 4°C.
Lysates were precipitated with a PKC- antibody (17), and PKC activity was
assayed using the SignaTECT PKC assay system (Promega, Madison, WI)
according to the manufacturer’s instructions. Determination of PKC activity
using the Ac-MBP (4–14) or the pseudosubstrate region of PKC- (specific for
atypical PKC) provided consistent results.
Statistical procedures. Data were analyzed with Statview software (Abacus
Concepts) by one-factor ANOVA. P values 	0.05 were considered statistically
significant. The total area under the curve for glucose response during the
insulin tolerance test was calculated by the trapezoidal method (13).
RESULTS
To investigate the relevance of PED/PEA-15–induced
-cell dysfunction to glucose tolerance, we used the
insulin promoter to generate transgenic mice featuring
selective overexpression of PED/PEA-15 in the -cells
(-tg; Fig. 1A). Three lines of -tg mice (L5, L8, and L9)
were established in which ped/pea-15 mRNA as well as
PED/PEA-15 protein showed a 10- to 20-fold increased
expression in the -cells but unchanged expression in
other tissues (Fig. 1B and C). Transgenic mice were fertile
and generated viable offsprings showing no significant
growth alterations compared with their nontransgenic
littermates (controls) or other apparent abnormalities. L8
ped/pea-15 transgenic mice, both male and female, exhib-
ited slightly reduced fasting blood glucose levels com-
pared with control mice (males 84 
 6 vs. 91 
 7 mg/dl;
females 82 
 8 vs. 92 
 6 mg/dl; significant at P 	 0.05).
Similarly reduced fasting blood glucose levels were mea-
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sured in the other transgenic lines (data not shown).
However, glucose loading (2 g/kg) rendered the -tg mice
significantly more hyperglycemic during the following 120
min compared with control mice (Fig. 2A and B). Very
similar abnormalities were observed in the L5 and L9 lines
(data not shown), indicating that -cell overexpression of
PED/PEA-15 is sufficient to impair glucose tolerance
in mice. As shown in Fig. 2, sex had no effect on the
impairment in glucose tolerance caused by -cell overex-
pression of PED/PEA-15. Aging (3–14 months) also deter-
mined no significant changes in PED/PEA-15–induced
decreases in glucose tolerance (data not shown).
L8 -tg mice featured no significant differences in fasting
nonesterified free fatty acid and triglyceride blood concen-
trations compared with their controls (free fatty acids
0.82 
 0.03 vs. 0.78 
 0.05 mmol/l; triglycerides 115 
 7 vs.
111 
 8 mg/dl). However, fasting insulin levels were 80%
increased in the transgenics (0.31 
 0.07 vs. 0.17 
 0.03;
P 	 0.001). The same results were obtained in the L5 and
the L9 lines, with no sex- or age-related variation (data not
FIG. 1. Generation of -tg (beta-tg) mice. A: Subcloning of the ped/pea-15 cDNA in the pB5-RIP--globin expression vector. Tissues are from three
lines of -tg mice (L5, L8, and L9) and from their nontransgenic littermates (C) and were subjected to Northern (B) or Western (C) blotting.
Northern blots (30 g RNA/lane) were probed with ped/pea-15 cDNA. Loading of the same amount of RNA in each lane was ensured by further
blotting the filters for -actin. Quantitation was performed by densitometric analysis. Data are plotted as increase of ped/pea-15 mRNA
expression in transgenic versus control mice. Each bar represents the means  SD of determinations in five transgenic and five nontransgenic
animals. For Western blotting, tissue lysates (100 g proteins/lane) were blotted with the PED/PEA-15 antiserum. The autoradiographs shown
are representative of five (top) and six (bottom) independent experiments.
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shown). To verify whether -cell overexpression of PED/
PEA-15 is accompanied by reduced insulin sensitivity, we
performed insulin tolerance tests. Intraperitoneal injection
of insulin (0.75 mU/g) evoked comparable hypoglicemic
responses in both -tg and control mice (Fig. 2C) with no
significant difference in glucose areas under the curve in
all of the transgenic lines (C 9,180 
 1,900 mg/dl per 120
min; L5 8,898 
 1,800 mg/dl per 120 min; L8 8,805 
 1,600
mg/dl per 120 min; L9 9,121 
 1,600 mg/dl per 120 min).
Furthermore, insulin-dependent glucose uptake in quadri-
ceps and tibialis muscles from -tg and control mice
exhibited no difference (Fig. 2D).
We then investigated how glucose tolerance is reduced
in the -tg and analyzed their islets by immunohistochem-
istry and morphometry. Islets from -tg mice immuno-
stained with PED/PEA-15 antibody significantly more
intensely than those from control mice (Fig. 3A). Impor-
tantly, islets from the -tg mice were larger and showed a
more elongated and irregular shape but feature normal
distribution of - and -cells compared with control islets
(Fig. 3B). Also, quantitative morphometry revealed two-
fold increased islet and -cell mass per unit of total
pancreatic area in the -tg mice (P 	 0.01) with no
significant difference in their pancreas weight (Table 1).
In control mice, a sevenfold increase in insulin secretion
was observed 3 min after intraperitoneal glucose injection,
and the levels remained higher than baseline values for up
to 30 min, indicating second-phase response (Fig. 3C).
Based on the area under the curve, the acute first-phase
insulin secretory response to glucose was reduced by
more than threefold in -tg mice (P 	 0.001). The second-
phase response was also significantly impaired in the -tg
compared with control mice (P 	 0.001). Again, almost
identical decreases in early and late insulin responses
were observed in both male and female -tg mice and in all
of the lines produced (data not shown). Thus, in vivo,
isolated -cell overexpression of PED/PEA-15 increases
fasting insulinemia but impairs further insulin secretion
response to hyperglycemia.
Similar as in intact mice, -tg mouse islets also exhib-
ited a twofold increased insulin release when incubated in
medium containing 2.8 mmol/l glucose (Fig. 4A; P 	
0.001). Raising glucose concentration did not further in-
crease the insulin release by these islets, while enhancing
that from control mice by 3.9-fold (P 	 0.001). Similarly,
islets from transgenic mice ubiquitously expressing PED/
PEA-15 (13) showed 2.4-fold increased insulin release
when exposed to 2.8 mmol/l glucose (P 	 0.001) and no
further release upon exposure to 16.7 mmol/l glucose (Fig.
4B). At variance with glucose, exposure to the membrane
depolarising agent potassium chloride (33 mmol/l) caused
a comparable release of insulin by the -tg and the control
islets, suggesting an effect of PED/PEA-15 on earlier
events of -cell response to glucose. Total insulin content
in pancreases was 25% increased in -tg mice (2.9 
 0.4
ng/mg in -tg vs. 2.3
 0.2 ng/mg in control mice; P	 0.05).
To gain further insight into the mechanisms leading to
dysfunction of -cells overexpressing PED/PEA-15, we
have profiled the expression of several genes relevant to
the glucose sensory apparatus by real-time RT-PCR anal-
ysis of total RNA isolated from islets of -tg mice (Fig. 4C).
FIG. 2. Glucose tolerance, insulin sensitivity, and glucose transport in
-tg mice. Three-month-old -tg male (A) and female (B) mice and
their nontransgenic littermates (C) were fasted for 16 h and subjected
to intraperitoneal glucose loading (2 g/kg body wt). Blood glucose
levels were determined before and at the indicated times following the
load. Values are expressed as means  SD of determinations in at least
12 (A) and 15 (B) mice per group. *Statistically significant differences
(*P < 0.05; **P < 0.01). C: Three-month-old random, fed -tg mice and
their nontransgenic littermates (C) (n  12/group; 6 males and 6
females) were injected intraperitoneally with insulin (0.75 mU/g body
wt), followed by determinations of blood glucose levels at the indi-
cated times. Values are expressed as means 
SD. D: Weight-matched, random, fed -tg mice and their nontransgenic
littermates were subjected to intravenous injection of 1 Ci of 2-DG
and intraperitoneal injection of insulin. Tibialis (T) and right (dx)
and left (sx) quadriceps (Q) muscles were removed 30 min after and
snap frozen in liquid nitrogen. 2-DG accumulated in muscle tissues was
quantitated as described in RESEARCH DESIGN AND METHODS. Bars repre-
sent mean values  SD of determinations in at least seven mice/group.
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The amounts of mRNAs for the Sur1 subunit of the
ATP-sensitive K channel was significantly reduced by
30% in these islets compared with those in control mice
(P 	 0.001). Consistently, islets from both the -tg and the
transgenic mice featuring ubiquitous overexpression of
PED/PEA-15 exhibited no secretory response to the K
channel locking agent glyburide (Fig. 4D). RNAs encoding
the Kir6.2 potassium channel subunit and the Sur1/Kir6.2
upstream regulator Foxa2 were also reduced, respectively,
by 30 and 35% in the islets from the ped/pea-15 -cell–
specific transgenics (P 	 0.01). Decreased expression of
Sur1, Kir6.2, and Foxa2 mRNAs was confirmed by North-
ern blot analysis (Fig. 4E). At variance, the abundance of
glucokinase, HK1, HK2, and GLUT2 mRNAs did not differ
between transgenic and control mice (Fig. 4C and E).
A 35% decrease in the abundance of the Sur1, Kir6.2,
and Foxa2 mRNAs has also been observed in the glucose-
responsive MIN-6 and INS-1 -cell lines upon transfection
with ped/pea-15 cDNA (Min-6
ped/pea-15
, INS-1ped/pea-15; Fig. 5A;
P 	 0.001). As in the mouse islets, these changes were
accompanied by a significantly greater release of insulin
when in low-glucose medium (2.8 mmol/l glucose) with no
further insulin secretion upon exposure to 16.7 mmol/l
glucose (Fig. 5B; P 	 0.001). This raise in glucose concen-
tration caused a 2.5- and 4-fold enhancement in insulin
secretion, respectively, by the untransfected INS-1 and
MIN-6 cells, however. In both the mouse islets and the
cultured -cell lines, the effect of glucose on insulin
release was paralleled by a twofold increase in immuno-
precipitated PKC- activity, with no measurable change in
its expression (Fig. 5C). Interestingly, however, the effect
of glucose was almost completely abolished in cells over-
expressing PED/PEA-15 whether the MIN-6 or the -tg
mouse islets. Similar data were obtained in the INS-1 cells
(data not shown), further suggesting an important role of
atypical PKCs in regulating genes of the insulin secretion
pathway. To further analyze this issue, we forced the
expression of PKC- in the MIN-6ped/pea-15 and the INS-1ped/
pea-15 cells. The overexpression largely rescued PKC-
activity in the precipitates from glucose-exposed MIN-6ped/
pea-15 cells (Fig. 6A). Importantly, this rescue was accom-
panied by recovery of the Sur1, Kir6.2, and Foxa2 gene
expression (Fig. 6B). In part, the changes in insulin release
caused by PED/PEA-15 were also reverted, determining
recovery of glucose-induced insulin secretion (Fig. 6C).
The same results were obtained using the INS-1 cells (data
not shown), indicating that the changes in atypical PKC
function caused by PED/PEA-15 overexpression represent
upstream abnormalities impairing the function of multiple
genes involved in regulating insulin secretion by the -cell.
To further address this issue, we used islets from
ped/pea-15–null mice. These animals have been previously
characterized and reported (27) and feature no PED/
PEA-15 expression in -cells (Fig. 7A). Importantly, islets
from these animals evidenced a twofold increased PKC-
activation following glucose exposure, as compared with
islets from control mice (P	 0.01; Fig. 7B). In parallel with
this enhanced response, islets from the ped/pea-15–null
mice exhibited a significant twofold increase in sensitivity
to glucose and glyburide effect on insulin secretion com-
pared with control islets, with unchanged response to
potassium chloride (P 	 0.001; Fig. 7C). Abundance of the
Sur1, Kir6.2, and Foxa2 mRNAs was also increased by
45% in these islets (P 	 0.001; Fig. 7D), indicating that
these genes represent major effectors through which PED/
PEA-15 physiologically controls insulin secretion.
FIG. 3. Immunohistochemical analysis and insulin secretion in -tg
mice. A and B: Pancreases from -tg and control (C) 6-month-old mice
were fixed and embedded in Tissue-Tek OTC, and sections were
prepared as described in RESEARCH DESIGN AND METHODS. Sections were
stained with hematoxylin and eosin (H&E). Immunoistochemical anal-
ysis of the islets was carried out using PED/PEA-15 (A) or insulin or
glucagon (B) antibodies, as indicated. Anti-goat or anti-rabbit immu-
noglobulin G was used as the second antibody. Immunoreactivity was
revealed by peroxidase-labeled streptavidin. The microphotographs
shown (H&E 200; glucagon and insulin 400) are representative of
images obtained from eight transgenic (male/female  1) and eight
nontransgenic (male/female  1) mice. Note that -tg mice show an
increased number of enlarged islets. C: -Tg and control mice (C) were
fasted overnight and then injected with glucose (3 g/kg body wt)
intraperitoneally. Serum insulin concentrations were measured at the
indicated times by RIA. Data points represent the means  SD of
determinations in 10 -tg and 12 control mice. *Statistically significant
differences (*P < 0.05; ***P < 0.001).
TABLE 1
Morphometric analysis of -tg pancreas
Control -Tg
% islet area/pancreatic area 0.52 
 0.06 1.04 
 0.11**
% -cells/islet 76.87 
 4.66 81.33 
 2.08*
% -cells/islet 17.23 
 1.92 14.54 
 1.85 NS
% other cells/islet 5.90 
 0.71 4.13 
 0.41 NS
Pancreas weight (mg) 182 
 16 188 
 12 NS
Islet cell mass (mg) 0.95 
 0.08 1.96 
 0.06**
-Cell mass (mg) 0.73 
 0.05 1.59 
 0.06**
Data are means 
 SD in six -tg and six control (nontransgenic
littermates) mice. Mice were analyzed as described in RESEARCH DESIGN
AND METHODS. * and ** denote statistically significant differences,
respectively, at the P 	 0.05 and 0.01 levels.
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FIG. 4. Insulin secretion and gene expression profile in isolated islets from PED/PEA-15–overexpressing mice. Islets were isolated from
6-month-old mice, either from the -tg and their nontransgenic littermates (C, open bars) (A) or from transgenic mice ubiquitously
overexpressing PED/PEA-15 (33) and their nontransgenic littermates (C1, open bars) (B). Insulin release was determined upon exposure to the
indicated concentrations of glucose or potassium chloride as described in RESEARCH DESIGN AND METHODS. Bars represent the means  SD of
determinations in 12 (A) and 11 (B) independent experiments in duplicate. C: The abundance of mRNAs for the indicated proteins was
determined by real-time RT-PCR analysis of total RNA isolated from islets of -tg mice and their nontransgenic littermates using -actin as
internal standard. The mRNA levels in -tg islets are relative to those in control animals (C). Each bar represents the mean  SD of four
independent experiments in each of whom reactions were performed in triplicate using the pooled total RNAs from six mice/genotype. D: Islets
were isolated from 6-month-old -tg and ubiquitously PED/PEA-15–overexpressing transgenic mice and their nontransgenic littermates
(respectively, C and C1). Insulin release was determined after exposure to 10 mol/l glyburide for 60 min, as described in RESEARCH DESIGN AND
METHODS. Bars represent the means SD of data from four independent experiments, each with at least three mice/group. *Statistically significant
differences (**P < 0.01; ***P < 0.001). E: Total RNA isolated from -tg and control (C) islets was analyzed by agarose-formaldehyde
electrophoresis and hybridized to the indicated cDNA probes. 28S and 18S ribosomal RNA is shown as a loading control.
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FIG. 5. Gene expression profile, glucose-stimulated insulin secretion and PKC- activity in -cell lines overexpressing PED/PEA-15. A: The
abundance of mRNAs for the indicated proteins was determined by real-time RT-PCR analysis of total RNA isolated from INS-1 and MIN-6
wild-type cells and from the same cells stably transfected with a ped/pea-15 cDNA (INS-1ped/pea-15 and MIN-6ped/pea-15). Bars represent the mRNA
levels in the transfected cells and are relative to those in wild-type (control) cells. Data are expressed as means  SD of triplicate reactions for
total RNAs from each cell type in five independent experiments. B: Insulin release was assayed by RIA in the culture medium of the wild-type and
the ped/pea-15–transfected -cells upon 60 min incubation with the indicated glucose concentrations. Bars represent mean values  SD from six
independent experiments each in duplicate. C: Islet from -tg and control mice (right) and wild-type MIN-6 cells and those stably expressing the
ped/pea-15 cDNA (MIN-6ped/pea-15; left) were exposed to 16.7 mmol/l glucose for 60 min and then solubilized. A total of 100 g proteins were then
precipitated with PKC- antibody, and PKC activity was assayed as described in RESEARCH DESIGN AND METHODS. PKC activity is expressed as fold
increase over basal activity (measured in the presence of 2.8 mmol/l glucose). Bars represent the mean  SD of data from four independent
experiments. For control, aliquots of the cell lysates were normalized for protein and directly blotted with PKC- antibodies. Blots were revealed
by enhanced chemiluminescence and autoradiography. The blot shown in the inset is representative of those in the other three experiments.
*Statistically significant differences (*P < 0.05; ***P < 0.001).
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FIG. 6. Rescue of PKC- activity, gene expression profile, and glucose-stimulated insulin secretion in MINped/pea-15 cells. A: MIN-6 and
MIN-6ped/pea-15 cells were transiently transfected with a PKC- cDNA, solubilized, and lysates immunoprecipitated with a PKC- antibody. PKC
activity was assayed in the immunoprecipitates. For control, aliquots of the lysates were blotted with the PKC- antibody (inset). Bars represent
the means  SD of five independent experiments in duplicate. The autoradiograph shown in the inset is representative of blots from the five
experiments. B: The abundance of mRNAs for the indicated proteins was determined by real-time RT-PCR analysis of total RNA isolated from
MIN-6 and MIN-6ped/pea-15 cells. Bars represent the mRNA levels in the MIN-6ped/pea-15 cells and are relative to those in the untransfected cells
(MIN-6). Data are expressed as means  SD of triplicate reactions for total RNAs from each cell type in four independent experiments. C: The
MIN-6 cells, either those transiently transfected with the PKC- cDNA and the untransfected cells, were exposed to 16.7 mmol/l glucose for 60
min, and insulin release in the culture medium was assayed by RIA as described in RESEARCH DESIGN AND METHODS. Bars represent the means  SD
of duplicate determinations in three independent experiments. *Statistically significant differences (*P < 0.05).
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FIG. 7. PKC- activity, insulin secretion, and gene expression profile in isolated islets from ped/pea-15–null mice. B: Islets were isolated from
6-month-old ped/pea-15–null mice (KO) and, for control, from their unmodified littermates (C2). The islets were exposed to glucose as indicated,
solubilized, and precipitated with PKC- antibodies. PKC activity was assayed in the immunoprecipitates as described in RESEARCH DESIGN AND
METHODS. PKC activity is expressed as fold increase over basal activity (measured in the presence of 2.8 mmol/l glucose). Bars represent the
means  SD of four independent experiments, each in which two mice/group were used. Aliquots of the lysates were blotted with PED/PEA-15
antibodies (A). For control, filters were reprobed with tubulin antibodies. The autoradiographs shown are representative of the blots performed
in each of the four experiments. C: Islets from knockout and control mice were exposed to glucose, potassium chloride, or glyburide as indicated,
and insulin was assayed in the culture medium by RIA. Insulin release is expressed as fold increase in medium insulin concentration over the basal
(measured with cells exposed to 2.8 mmol/l glucose alone). Bars represent mean values  SD of data with islets from at least six mice in each
group. D: The abundance of mRNAs for the indicated proteins was determined by real-time RT-PCR analysis of total RNA isolated from islets of
ped/pea-15–null mice and their unmodified littermates, using -actin as internal standard. The mRNA levels in knockout islets are relative to
those in islets from the unmodified littermates. Each bar represents the mean  SD of four independent experiments, each in which reactions
were performed in triplicate using the pooled total RNAs from six mice/genotype. *Statistically significant differences (**P< 0.01; ***P< 0.001).
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DISCUSSION
In the present study, we generated transgenic mice over-
expressing PED/PEA-15 selectively in -cells (-tg mice).
We found that PED/PEA-15 overexpression determines
islet hyperplasia with a specific increase in -cell mass.
This may result from a direct effect on -cell survival as
PED/PEA-15 exerts a broad antiapoptotic action in a
number of different cell types (10,15,27–30), including
-cells (C.M., unpublished observation). Increased -cell
mass is consistent with the increased fasting serum insulin
levels detected in the -tg mice. Indeed, these mice do not
feature resistance to insulin action. They do show grossly
impaired glucose tolerance and reduced insulin secretion
in response to hyperglycemia, however. This latter defect
is comparable with that occurring in mice with ubiquitous
overexpression (13), leading us to conclude that -cell
overexpression of PED/PEA-15 is sufficient to impair glu-
cose tolerance in mice. Previous studies in isolated cells
and in vivo evidenced that chronic insulin resistance may
impair -cell function, ultimately reducing glucose re-
sponse (2). Secondary impairment of -cell function may
also occur in the transgenic mice overexpressing PED/
PEA-15 ubiquitously. However, the findings in the present
study evidence that impaired response to glucose is a
direct consequence of PED/PEA-15 overexpression in the
-cells. Consistently, islets from -tg mice persistently
show similarly impaired glucose response in culture as
well as in the intact animal. Also, the expression of
ped/pea-15 cDNA in different -cell lines inhibits insulin
release following increased glucose concentration in the
culture medium.
The defective insulin secretion induced by -cell over-
expression of PED/PEA-15 affected both the early and the
late phases of insulin response to glucose, raising the
possibility that the overexpression of PED/PEA-15 impairs
the glucose-sensing machinery. Earlier reports evidenced
that the KIR6.2 and SUR1 potassium channel subunits
couple glucose metabolism to the electrical activity of
-cell membrane and insulin secretion by setting the
resting membrane potential below the activation threshold
for voltage-gated Ca2 channels (31). We found that the
membrane depolarizing agent potassium chloride causes a
similar release of insulin by both transgenic and control
mouse islets, indicating that the site of PED/PEA-15 action
on glucose-induced secretion is upstream the membrane
depolarization step. Indeed, -cell expression profiling
revealed that mRNA abundance of both the Kir6.2 and the
Sur1 transcripts are significantly depressed by the over-
expression of ped/pea-15. PED/PEA-15 action on the
Kir6.2 and Sur1 genes represents a specific abnormality,
as other genes encoding key components of the glucose-
sensitive insulin secretion machinery were unaffected by
PED/PEA-15. The latter include GLUT2, HK1, and HK2.
Consistent with the functional consequence of this defect,
glyburide showed impaired action on insulin secretion in
PED/PEA-15–overexpressing islets.
Previous studies in mice evidenced that ablation of
either the Sur1 or the Kir6.2 genes results in a phenotype
reminiscent of that characterizing the -tg mice (32–34).
Indeed, both the Sur1/ and the Kir6.2/ mice feature
blunted insulin secretion response to sulfanylureas. The
defective insulin response to the sulfanylurea glyburide
seems even more pronounced in the -tg mice as, in these
animals, 	30% decrease in Sur1 and Kir6.2 gene expres-
sion blocks glyburide action. The simultaneous impair-
ment in Sur1 and Kir6.2 gene function may result in an
additive effect on glyburide action in the -tg mice. Similar
to the -tg, fasted Sur1/ mice are more hyperinsuline-
mic than control animals due to persistent activation of
voltage-gated calcium channels (33,34). These mice are
also significantly more hypoglycemic than controls when
fasted. Furthermore, both the Sur1/ and the Kir6.2/
mice feature impaired glucose tolerance and glucose-
induced first- and second-phase insulin secretion. Thus, at
least in part, the loss of potassium channels caused by
-cell overexpression of PED/PEA-15 may account for the
abnormalities in basal and glucose-stimulated insulin se-
cretion and in glucose tolerance observed in the -tg mice.
Recent evidence in skeletal muscle and fat indicated
that high cellular levels of PED/PEA-15 impair the function
of the atypical PKC isoform PKC- through a phospho-
lipase D–mediated mechanism (13,17). Interestingly, the
activity of PKC- is also decreased in islets from the -tg
transgenics compared with those from control mice.
PKC- overexpression in -cells transfected with a ped/
pea-15 cDNA simultaneously rescues glucose-induced in-
sulin secretion and the expression of the Sur1 and Kir6.2
genes. These data evidence that PKC- activation is suffi-
cient to upregulate these genes, while not proving that the
loss of PKC- accompanying PED/PEA-15 overexpression
causes Sur1 and Kir6.2 downregulation. Another atypical
PKC isoform, PKC-, has recently been shown to play a
major role in regulating glucose-induced insulin secretion
by modulating the expression of a number of pancreatic
-cell genes (35). However, the latter report did not
exclude that, as we now show, the activation of PKC- may
also upregulate Sur1 and Kir6.2 gene function. Indeed,
while clearly distinct and involved in a number of special-
ized mechanisms, PKC- and - also feature structural
similarities and many common functions (36). Downregu-
lation of PKC- and/or - may cause impaired glucose-
induced insulin response in -tg mouse islets by reducing
Sur1 and Kir6.2 gene expression.
Atypical PKCs have been reported to control the func-
tion of a number of transcription factors (37,38). Very
recent data by Hashimoto et al. (35) evidenced that in
PKC-–null mice, the abundance of pancreatic -cells, the
expression of the Foxa2 mRNA in addition to that of Sur1
and Kir6.2, is significantly reduced. In addition, in pancre-
atic -cells, the expression of the Sur1 and Kir 6.2 genes
is dependent on Foxa2 activity (25,39,40). Similar to the
PKC/ mice, we now report that Foxa2 mRNA abun-
dance is also reduced in islets from -tg transgenics. Thus,
the impaired activity of PKC- in -cells overexpressing
PED/PEA-15 may also prevent normal potassium channel
generation and glucose-regulated secretion of insulin by
depressing Foxa2 expression. Supporting this conclusion,
we evidenced that forcing the expression of PKC- in
PED/PEA-15–overexpressing -cells rescued Foxa2 lev-
els, in addition to those of Kir6.2 and SUR1, and glucose-
induced insulin secretion. Importantly, islets from ped/
pea-15–null mice feature upregulated PKC- function. The
enhanced PKC- activity is accompanied by specific in-
creases in the abundance of Kir6.2, Sur1, and Foxa2
mRNAs and augmented insulin secretion in response to
glucose. Thus, Foxa2-mediated control of glucose sensi-
tivity represents a physiological function of PED/PEA-15
in the -cell. Dysregulation of this mechanism may be
relevant for type 2 diabetes in humans as well.
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